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The intravesical administration of Bacillus Calmette Guerin for the
treatment of transitional cell carcinoma of the bladder is the most
effective immunotherapy for any solid human malignancy. Despite this
awesome accolade relatively little is understood of its mechanisms of
action. This study details the in vitro interaction between IL-2 activated
lymphocytes and tumour cells, the effect of cytokines produced as a result
of immunotherapy on tumour cells and the relationship of these finding to
the situation in vivo.
Bladder cancer cells were not found to be susceptible to NK cell
activity but were found to be differentially susceptible to IL-2 activated
lymphocytes. No correlation was evident between the histopathological
grade of the tumour. The interaction between these cells was observed to
involve intimate contact and the tumour cells were found to constitutively
express either ICAM-1 or ICAM-2. The expression of these cell adhesion
molecules correlated significantly with the sensitivity of the tumour cells
to LAK mediated cytolysis.
Following BCG therapy a variety of cytokines including IFNy and
TNFa are detected in the urine. When bladder cancer cells were cultured
in the presence of recombinant IFNy and TNFa an increase in the levels of
ICAM-1 expression was observed. The optimal stimulation was found
after 24 hours culture with lOOUml1 IFNy, whilst TNFa stimulated to a
lesser extent. Culture in the presence of both cytokines was observed to
synergistically induce or augment ICAM-1 expression. Following culture
with IFNy, the tumour cells displayed increased susceptibility to LAK
activity, this was significantly correlated with increased ICAM-1
expression. The levels of tumour cell response to IFNy could not be
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correlated with either the abundance or affinity of specific receptors as
determined by Scatchard analysis. Thus investigations were initiated into
the events down-stream of the ligand-receptor interaction.
Monoclonal antibodies to ICAM-1, decreased the sensitivity of
tumour cells to LAK activity. However, monoclonal antibodies to LFA-1
(the ligand for ICAM-1) further blocked the action of LAK cells. The LFA-1
dependent, ICAM-1/2 independent activity was suggestive of a further
ligand for LFA-1. Using a sensitive flow-cytometric assay the conjugation
of effector to target cells was investigated. Conjugation was shown to be
energy dependent, requiring the presence of divalent cations. In the
absence of Ca2+, Mg2+ and Mn2+ were found to increase the percentage of
target cells which formed conjugates with LAK cells.
Finally the in vitro findings were applied to the in vivo situation.
Urine from patients receiving BCG therapy was found to augment the
expression ofMHC class II and ICAM-1 molecules on bladder tumour cells.
This urine was found to contain both TNFa and IFNy. Treatment with
neutralizing antibodies to IFNy, but not TNFa, abolished the biological
effects of urine. In addition to the presence of cytokines in urine, several
patients had detectable levels of soluble ICAM-1 within the first 12 hours
following instillation. The significance of this finding remains unclear as
ICAM-1 expression has been correlated with both a propensity to
metastasize and with increased susceptibility to leucocyte functions.
In conclusion, these investigations dissect some of the molecules
involved in the interaction between LAK and bladder tumour cells.
Furthermore, using an in vitro model ofbladder cancer, the control of these
molecules by relevant cytokines was delineated. Finally, reference was
made to the situation in vivo thereby demonstrating relevance to the




1.1.1 As a clinical problem
Bladder cancer is a common disease with over 10,000 new cases
presenting in the UK per annum. Over recent years there has been an
increase in the number of new cases of bladder cancer registered in the
UK. In 1975 there were 7611 new cases and in 1986 (the latest available
figures) there were 9591 (Office of population censuses and surveys.MB 1
no. 19 HMSO). The question as to whether this is a true increase in the
incidence of the disease, or whether it reflects better diagnosis and
documentation, continues to be debated. Regardless, bladder cancer is
indisputably a common disease and in 1986 accounted for 5% of all
reported malignancies in England and Wales. In Europe, the mean
bladder cancer incidence is estimated at 22.9 per 100,000 males and 5.2
per 100,000 females. The general trend at present is an increase in the
incidence of bladder cancer (Koroltchouk et al 1987). Today, bladder
cancer is the eighth most common cancer among males and the eleventh
among females, worldwide.
Bladder cancer is a disease of old age, being more common in males
than in females, in Caucasians than blacks or Asians, and in urban rather
than rural dwellers (Morrison et al 1976). This fact probably reflects the
increased exposure to industrial promoters and inducers. Incidence varies
between countries, and between regions within each country (Thompson
et al 1990). In Scotland between 1975 and 1980, incidences varied from
3.2/100,000 in Sutherland to 26.9/100,000 in Stirling (Waterhouse et al
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1982. Thompson et al 1990).
1.1.2 Pathological classification
In the UK at least 99% of bladder tumours are carcinomas, and
more than 90% of these are of the transitional cell type. The majority of
patients (>70%) presenting with transitional cell carcinomas have
superficial disease (Melicow et al 1974). Superficial bladder cancer is
defined as disease which does not involve the detrusor muscle, and
includes the stages Ta, T1 and carcinoma-in-situ (CIS) (see Figure 1)
(Chisholm et al 1980). Superficial bladder cancer is not a single disease
entity, but rather a spectrum of tumours with markedly different natural
histories and prognoses. Transitional cell carcinoma is a malignant
diathesis of the whole urothelial tract, a fact which is reflected by its
polychronotropic nature, which in turn dictates its management.
Histopathologically these tumours are classified into three stages of
disease: Cis (carcinoma in situ) - a flat, nonpapillary, high-grade
carcinoma of the epithelium; Ta - a papillary carcinoma confined to the
epithelium, T1 - a tumour invading, but confined to the lamina propria and
not involving the superficial muscle layer of the bladder.
A significant proportion (7-22%) of patients with superficial
tumours will eventually progress to develop invasive and therefore life
threatening bladder cancers (Barnes et al 1977. Heney et al 1983). Initial
incorrect staging will account for a few cases of this apparent disease
progression (Lutzeyer et al 1982), as problems of inadequate tumour
sampling and specimen orientation arise when the whole bladder is not
available for histopathological study. Four to twelve percent of patients
who present with a superficial bladder cancer will die of the disease
23
Figure 1. The classification of superficial bladder tumours
The TNM classification of superficial bladder tumours. CIS (carcinoma in situ)
-a flat nonpapillary, high grade carcinoma of the bladder epithelium; Ta-a papillarycarcinoma confined to the epithelium; Tl-a tumour invading, but confined to, thelamina propria and not involving the superficial muscle layer of the bladder.I - urothelium; II - basement membrane; III - lamina propria; IV - superficialmuscle layer; V - deep muscle layer of the bladder.
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(Pocock et al 1982).
The depth of infiltration at which a tumour is no longer considered to
be superficial is being reduced as criteria are revised. Originally any
tumour infiltrating up to halfway through the bladder wall was considered
superficial (Bl) (Jewett et al 1946). At present, superficial tumours are
restricted to those not associated with muscle invasion. More recently,
tumours which penetrate the lamina propria (Tl) are having their
superficiality called into question. Many workers have demonstrated the
less favourable outlook of Tl as compared with Ta tumours (Abel et al
1988a. Abel 1988b). Many Tl tumours are poorly differentiated (G3),
and true recurrence rates in patients with such tumours (Tl G3) may be
in the order of 60% (Jakse et al 1987) while progression has been
documented in up to 48% (Heney et al 1983). The need for a more
aggressive approach to the G3 pTl tumour is now recognised (Birch et al
1989). Of all patients presenting with invasive bladder tumours (T2-4),
50% will have regional and/or distant metastases (Prout et al 1979), but in
more than half of these the metastases are occult (Culter et al 1982).
There are several parameters which have clinical use as
prognosticators of disease recurrence and progression in superficial
cancer. The stage of a tumour at presentation has some predictive value
(Abel et al 1988a and b,). In Abel's study, only a low number of patients
with Ta tumours had progressed to Tl, and none had become invasive.
However, 9 of 27 Tl tumours had invaded the muscle layer. Furthermore,
the majority of Ta tumours had not developed recurrences at 3 years as
compared with 30% patients with Tl tumours. The incidence of
progression to invasive disease is greater in those tumours showing least
differentiation (Heney et al 1983). Such high-grade, poorly differentiated
tumours have a correspondingly poor prognosis.
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The presence of CIS in urothelial biopsies elsewhere in the bladder
at the time of presentation is a poor prognostic sign (Smith et al 1983).
This fact is perhaps not surprising as CIS is a high grade malignant
condition which has an aggressive natural course when it involves
significant proportions of the urothelium (Utz et al 1980). Other cellular
abnormalities in the mucosa adjacent to the primary bladder tumour are
of prognostic importance. Althausen observed that most of the patients
with superficial bladder cancer who went on to develop invasive disease
had had either cellular atypia or CIS surrounding the presenting tumour
(Althausen et al 1976).
The expression of a variety of receptors for growth factors has been
studied on bladder cancer cells. Normal urothelial cells do not express the
transferrin receptor other than in the basal layer. However, cancer cells
show an increase in the expression of this receptor which correlates with
stage and grade (Basar et al 1991). Epidermal growth factor (EGF) is
also of importance in the control and regulation of epidermal cell growth,
and its receptor expression has been studied in bladder cancer (Neal et al
1990). Expression of growth factor receptors may offer a means of
identifying tumours likely to progress. However, none of these factors
have proved to have additional and independent prognostic capabilities for
the behaviour of bladder cancer, and tumour stage and grade remain the
most important predictors of clinical outcome (Pauwels et al 1987).
1.1.3 The aetiology ofbladder cancer
The earliest known factor implicated in the development of bladder
cancer was the exposure of chemical industry workers to aniline dyes
(Rehn et al 1895). Since then, an ever increasing number of defined
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chemicals have been added to the list which now includes
dichlorobenzidine, a-naphthylamine, o-dianisidine and auramine. Workers
in the dye, rubber, petroleum and printing industries, where such
chemicals are either inhaled, ingested or absorbed through the skin, show
an increased risk of bladder tumours (Case et al 1954. Glashan et al
1981). The development of bladder cancer in patients exposed to industrial
carcinogens is a long-term problem, the most important part ofwhich is
long term follow-up as the latent period from exposure to onset of disease
can be several decades. Many studies from around the world have shown
that cigarette smoking increases the risk of developing cancers, including
bladder cancer (Miller etal 1977).
There is little evidence that any dietary agent, including coffee
(Morrison et al 1984) and saccharin (Kabat et al 1986), significantly
increases the likelihood of bladder cancer. Early work suggested
tryptophan and its metabolites as causative agents (Dunning etal 1950.
Rauschenbach et al 1963). However, controlled studies looking at urinary
tryptophan metabolites have not shown any correlation with bladder
cancer (Friedlander and Morrison 1981).
Oliver et al have proposed that human pappiloma virus (HPV) may
have a role in the induction of bladder cancer in a number of patients
(Oliver et al 1989). Syrjanen demonstrated a fragment of HPV 16 in 5 of
8 bladder tumours (Syrjanen 1989), but this observation needs to be
compared with the incidence of HPV in normal or at least non-neoplastic
epithelium to raise it beyond the merely speculative.
The molecular biology of urological tumours has been the subject of
considerable attention (Russell et al 1990). A number of genes termed
proto-oncogenes have been reported to have a central role in the
regulation of normal cell growth and differentiation (Buckley 1988). The
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products of such genes include nuclear transcription factors, molecules
involved in signal transduction of growth factor receptors and in growth
factor receptors themselves (Schalken et al 1988). It has been
demonstrated that, in malignant cells, certain proto-oncogenes can be
activated to become oncogenes. Several proto-oncogenes have been to be
found activated in human urological malignancies (Malone et al 1985).
One such proto-oncogene, termed c-erbB-1, encodes the epidermal growth
factor (EGF) receptor. EGF has been found to stimulate the growth of a
number of bladder cancer cell lines in a dose dependent manner (Messing
et al 1987). Immunohistochemical studies of EGF-recpetor expression in
TCC of the bladder have shown a correlation between expression and an
increase in the stage and grade of the tumours (Neal et al 1985. Berger
etal 1987).
1.1.4 Conventional management strategies for bladder cancer
Bladder cancer is an accessible tumour which lends itself to local
surveillance and excision. After simple cystoscopic resection of the
primary lesion there is a high rate of further bladder tumours developing.
Reported rates of recurrence vary between 30% when the presenting
tumour is small, single and of low grade, to more than 90% when multiple
and of high grade (Soloway et al 1988).
Superficial bladder cancer is theoretically curable if the local
tumour is completely removed. However, between 4-12% of patients
presenting with superficial disease eventually die of bladder cancer
(Pocock et al 1982). These figures represent those patients whose
tumours progress during follow-up. Progression is either defined as a
higher grade of recurrent tumour (becoming less differentiated), or as a
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more advanced stage of invasion. A drawback of treating patients with
sequential courses of intravesical chemotherapies or immunotherapies, is
that in patients who have tumours that are destined not to respond
valuable time may be lost before cystectomy. Bracken reported on a
group of patients who had required cystectomy for uncontrollable
superficial disease and found their survival to be comparable with age-
matched controls (Bracken et al 1981). If every patient with superficial
TCC underwent cystectomy, the few would possibly benefit at the
expense of the many, for whom cystectomy would represent gross over
treatment, and who would suffer the morbidity of cystectomy and urinary
diversion. The ideal situation is to be able to select those patients who will
progress to life threatening disease before it happens. Our current
understanding of bladder cancer is insufficient to predict patients who are
unlikely to respond to therapy.
Despite recent advances in the treatment of superficial cancer, the
prognosis of invasive bladder cancer remains poor. Patients who have no
apparent metastases are offered radical loco-regional treatment with
radiotherapy, surgery or a combination of the two. Such treatments will
cure approximately half ofpatients (Quilty et al 1986), the remainder will
have died at 5 years. This death rate corresponds to the percentage of
patients with metastatic disease at presentation (Prout, et al 1979).
Therefore, it is likely that metastasis occurs prior to radical local
treatment. As yet there is no good adjuvant treatment for invasive
bladder cancer. The possibilities for adjuvant treatment of
micrometastases include adoptive immunotherapy (discussed later). To
improve on these figures an effective systemic therapy is required. There
is some promise with the newer M-VAC (methotrexate, vinblastine,
adriamycin and cisplatin) combination chemotherapeutic regime
(Sternberg etal 1988).
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1.1.5 Immunotherapeutic strategies for the management ofbladder cancer
The success of immunotherapy depends upon the tumour bulk and
the immunocompetence of the host. The major potential for its use is as
adjuvant treatment for minimal residual or micrometastatic disease
which remains after surgery, chemotherapy or radiotherapy. Intravesical
therapies (chemotherapy and immunotherapy) allow a relatively large
amount of drug to come in contact with the abnormal urothelium, whilst
at the same time minimizing systemic toxicity.
Several chronic infective diseases have been noted for their
association with low cancer incidence, these include tuberculosis, leprosy
and syphilis (Fraenkel 1905. Levin 1910). It was presumably with these
observations in mind that therapeutic applications of the tubercle bacillus
were investigated in the 1920's by Centanni and Rezzeri (Centanni and
Rezzeri 1926). Whilst examining the effect of tubercle bacilli on murine
carcinomas they noted that it was important for the bacilli to be viable.
The importance of both the viability of the bacilli and the intimate contact
with the tumour cells has subsequently been confirmed (Zbar et al 1972).
Auguste Calmette and Claude Guerin first developed an avirulent
strain of Mycobacterium bovis. Bacillus Calmette Guerin (BCG) is an
attenuated live vaccine developed originally from this strain. It has been
in use as a prophylactic vaccine against tuberculosis for about sixty
years, and during the 1950s several immunologists, including Freund,
described the immunostimulatory effects it had on the mammalian
immune system (Freund 1956).
Local immunotherapy using intravesical bacillus Calmette Guerin
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now has a major role in the treatment and prophylaxis of superficial
bladder cancer (Morales et al 1976. Herr et al 1985. Badalament et al
1987). BCG immunotherapy is of clinical benefit in both the prophylaxis
(Martinez-Pineiro et al 1990) and treatment of superficial bladder cancer
including carcinoma-in-situ (Coplen et al 1990), and unlike intravesical
chemotherapeutic agents, it decreases the rate of progression to muscle-
invasive disease (Herr et al 1988). Its most important role would seem to
be in reducing the incidence of recurrence and the rate of progression to
invasive disease. The efficacy of BCG therapy for superficial bladder
cancer has been established throughout the world (Martinez-Pineiro et al
1990. Cumming et al 1989. DeKernion 1985. Steg 1989. Herr et al 1986.
Kavoussi et al 1988. Sarosdy et al 1989. Brosman 1985. Shinka 1990).
As with most therapies, BCG therapy is not without side effects.
Lamm et al have reviewed the complications of BCG administration in
over 2000 patients and described significant side effects in 8% (Lamm et
al 1992). High fevers (3%) and local irritative symptoms remain the most
common problems. Systemic BCG infection with pneumonitis and
hepatitis occur rarely (0.7%). Four patient deaths have now been reported
in association with the administration of BCG vaccine for superficial
bladder cancer (Rawls et al 1990. Deresiewicz et al 1990). At the present
time, it appears that the advantages of intravesical BCG for the
treatment and prophylaxis of superficial bladder tumours far outweigh the
known disadvantages.
The mechanisms of action of BCG have not been fully elucidated.
However, clinical and laboratory studies have provided evidence that the
local and systemic immune status is increased in response to BCG.
Following intravesical instillation of BCG, an infiltration of
immunologically active cells into the bladder wall has been observed
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(Prescott et al 1992). Detailed characterization of the chronic
inflammatory infiltrate using monoclonal antibody probes has been
undertaken (El-Demiry et al 1987. Prescott et al 1989. Bohle et al 1990).
The major infiltrating cell type in the submucosal tissues was found to be
the T-cell, the majority of which were of the CD4+ sub-type. These helper
T-cells were immunologically activated as judged by the expression the IL-
2 receptor. Macrophages and B cells, the latter occurring mainly in
lymphoid follicles, have also been identified; however natural killer (NK)
cells were rarely observed.
During the twelve hours following instillation, relatively high
concentrations of several cytokines (the relevance ofwhich is discussed in
chapter 1.3) are readily detected in the urine. Interleukin-2 (IL-2), a^
product of activated T-cells, was detected in the urine of patients treated
with intravesical BCG (Ratliff et al 1986) but not in the urine of either
healthy controls or patients with bacterial cystitis. Subsequently other
workers have confirmed this observation (Haaff et al 1986. Fleischmann
et al 1989). Interleukin-1 (IL-1) and tumour-necrosis factor-alpha
(TNFoc), have also been identified in the urine of patients following BCG
administration (Bohle et al 1990). Interferon-gamma (IFNy) has been
detected in the post-instillation urine of BCG-treated patients, but not in
patients receiving intravesical mitomycin C for superficial bladder cancer
(Prescott et al 1990). However, some controversy exists over the
presence of this cytokine in the urine (A. Bohle, personal communication).
The kinetics of cytokine secretion following BCG-treatment may be
characteristic of a successful response. Levels rise from undetectable
pre-instillation levels and peak values are observed between 2 and 6 hours
post instillation. Levels have fallen to pre-instillation values 12 hours
later. It would seem that with repeated instillation of BCG, peak levels of
32
cytokines increase.
Following repeated instillation of BCG into the bladder phenotypic
changes have been observed. The urothelium, which does not normally
express the products of the MHC class II genes, becomes strongly positive
for these antigens (Prescott et al 1989). Furthermore, an increase in the
level of MHC class I expression has also been reported. Circulating
antibodies to BCG are found in the serum of patients treated with
intravesical BCG vaccine for superficial bladder carcinoma (Winters et al
1981). Prescott (1989) proposed that the possible anti-tumour
mechanism of BCG therapy may be via enhanced recognition of the
tumour antigenicity through de novo HLA-class II expression. This is
substantiated by studies of animal models, where induction of HLA-class
II antigens on tumour cells enhances their eradication by the host
(Bateman et al 1991).
If the response against bladder cancer following BCG therapy is
specific in nature, then candidate antigens are required. Whether these
are BCG or tumour derived has not been determined, however, cross-
reactivity between BCG and tumour antigens may exist (Minden et al
1976). Repeated exposure to bacillus antigens could theoretically result in
sufficient numbers of the reactive T-cells to kill the tumour cells as well as
the inciting bacilli. Further evidence for the role of T-cells comes from
animal models of bladder cancer. When intravesical BCG is administered
to athymic mice hosting the transplantable MBT2 tumour, no anti-
tumour effects are observed (Ratliffet al 1987). However the anti-tumour
response can be restored by an intravenous injection of BCG-sensitised
splenocytes.
Following cessation of BCG treatment, the state of immunological
alertness in the bladder wall decreases, and by 6 months is virtually non-
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existent. Importantly, none of the above phenomena have been observed
in the bladders of patients treated with conventional intravesical
chemotherapy, thus indicating that intravesical BCG is indeed an
immunotherapy.
Other forms of immunotherapy have been investigated as possible
treatments for superficial bladder cancer, but have not had the same
success as BCG vaccine and have largely been abandoned in clinical
practice. Recently, a report has emerged using lymphokine activated
killer cells for the therapy of invasive bladder cancer, however no clinical
responses were observed (Hermann et al 1992). This data will be
discussed in chapter 1.4.
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1.2 The host/tumour relationship
1.2.1 Normal cellular control
The intimate relationship between the tumour and its host is
complex and varies between types of tumour, types of host and the
environmentwithin which the two co-exist. One may consider the tumour
cell to be an invading pathogen, a pathogen which is antigenically very
similar to the host. However, it is in the best interest of the host not to
allow a tumour to develop and to eradicate existing tumours.
Many tissue structures are in constant flux as they develop, adapt
to changes in their environment, or are repaired following injury. Under
such circumstances, the carefully regulated process of resorption,
remodelling and repair are important. It is vital for cells to be correctly
orientated in order to maintain the function of a tissue system (Fleming
1991). Furthermore, when tissue repair is complete, there must be
adequate control signals to cause cessation of the growth. The abnormal
growth behaviour of malignant tumours are the reflection of complex
abnormalities in physiology which result from expression of mutated or
viral genes and/or deregulated expression of normal genes. When cells are
subjected to chemical carcinogens and to various forms of radiation,
structural damage may occur to the chromosomal DNA. Point mutations
and chromosomal breaks result which have the potential to cause a loss of
normal control if not repaired by the host cells enzyme system. Any
breakdown in these mechanisms could lead the cell into a state of
disregulation and eventually neoplasia.
1.2.2 The concept of immune surveillance
35
The theory of immune surveillance against cancer postulates that
the immune system plays a pivotal role in resistance to the development
of tumours. Initially, immune surveillance was thought to be exclusively
associated with T-cell mediated responses. However, further work has
clearly shown that these responses are mainly concerned with virally
induced tumours and not with tumours which may arise spontaneously or
as a result of chemical carcinogenesis (Allison et al 1967). In transplant
patients receiving Cyclosporin A (an inhibitor ofT-cell response) there is a
high incidence of EBV associated lymphoma (Calne 1979). EBV infected
B cells from such patients can be propagated in vitro indefinitely, as
cyclosporin A serves to inactivate the T cells (Hanto et al 1985).
One of the main lines of evidence for immune surveillance lies in
observations that individuals which are immunosuppressed (naturally or
artificially) have a higher incidence of tumour occurrence.
Immunosuppressed renal transplant patients have an increased incidence
of malignancies (Kinlen 1982). Such allograft recipients had mainly
received prednisolone and azathioprine, agents designed to
immunosuppress the host in order to prevent graft rejection.
1.2.3 Detection ofthe tumour cell
Fundamental to the concept of immune surveillance is the ability of
the host to identify the tumour cell. Therefore, a great deal of effort has
been invested in the identification of antigenic determinants which are
unique to the tumour cell. Unfortunately, investigations into the
expression of unique antigens by tumour cells has not proved fruitful. In
rare cases, a virally encoded protein/glycoprotein has been identified on
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the surface of the cell (Schreiber et al 1988). The existence of foreign
antigen can be understood in virally-induced tumours where viral DNA is
integrated with the hosts DNA and is transcribed into foreign protein. In
such instances the T-cell response may be involved in surveillance.
However, rather than tumour specific antigen, some tumours express
tumour associated antigen (TAA). Certain tumours express molecules
which are normally expressed only during foetal development or in the
adult at a low level. The two most thoroughly described antigens are
alpha-foetoprotein (AFP), and carcinoembryonic antigen (CEA).
There is no evidence at present that spontaneous, as opposed to
chemical- and viral-induced tumours (other than lymphomas and
leukaemias), express specific tumour antigens (Baldwin 1966). The
classical cytotoxic T-cell is restricted to the recognition of antigen in the
context of MHC class I molecules. However, recent evidence has shown
the existence of class II restricted T-cells with cytotoxic activities (Lancki
et al 1991). Furthermore, a unique subset of peripheral T-cells has been
described which exhibit spontaneous, MHC-unrestricted cytotoxic function
(Thiele and Lipsky 1989). One study demonstrated that mixtures of CD4+
and CD8+ T cells do not develop significant non-specific killing activity
when activated with IL-2 and antibodies to CD3 (Geller et al 1991).
However, following the removal of either the CD4+ or the CD8+ cells from
the culture, a significant level of non-specific killing activity was displayed.
The exact mechanism of such inhibition remains unclear, however
cytokines such as IL-4 and TGFP have been attributed with activities of
suppression of such responses in vitro (Kasid et al 1988. Kawakami et al
1989. Chapman et al 1990). However, it is possible that certain tumours
are infiltrated with a predominant population of either CD4+ or CD8+ T
cells, in which case non-MHC restricted, T cell mediated cytotoxicity could
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be exerted.
In addition to the T-cell response several other responses have been
postulated to partake in immune surveillance. NK cells are able to lyse a
limited number of tumour cells in vitro (Serrate et al 1982). Most NK cells
express CD56 and the low-affinity receptor for immunoglobulin (CD16)
(Herberman and Ortaldo 1981). NK cells have been observed in small
primary tumours and in implanted tumours (Gerson 1980). Furthermore,
in patients with Chediak-Higashi syndrome an increased tumour incidence
correlates with depressed NK activity (Dent et al 1966). A more recent
study investigated the effect of NK cell co-culture with bladder cancer cell
lines (Wang et al 1991). Although freshly isolated NK cells had little
cytolytic potential, increased cytotoxicity against bladder cancer cells was
observed following several days of co-culture. It is therefore possible that
NK cells within small primary tumours are somehow activated to kill the
tumour cells.
Many investigators have suggested that cells of the monocyte-
macrophage lineage may play a role in anti-tumour responses.
Macrophages have been identified in a variety of primary tumours
including bladder cancer (Mantovani 1990. Gauci and Alexander 1975.
Prescott et al 1992). It is now well established that macrophages
display in vitro a considerable potential to nonspecifically enhance or
suppress the growth ofmany cell types and to kill tumours cells with some
selectivity. However, in order for such functions to be exerted, the
macrophage must first become activated (Fidler et al 1976). The factors
involved in such activation ofmacrophages are the products of activated
T cells and include interferon-gamma, originally termed macrophage
activating factor. Activation of cell killing by macrophages is an
important function of interferon-gamma, since tumour-cell lysis by
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activated macrophages is in all likelihood part of the mechanism of
natural resistance to cancer (Le et al 1983). Activated macrophages,
therefore can kill some tumour cells in vitro and elicit tumour-destructive
reactions in vivo. Such macrophages kill tumour cells by releasing
reactive oxygen intermediates and by producing other cytotoxic cytokines
such as tumour necrosis factor-alpha (Urban et al 1986). Interestingly,
interferon-gamma induces the production and release of tumour necrosis
factor-alpha by macrophages (Philip and Epstein 1986). Furthermore,
macrophages, like NK cells, are able to exert antibody dependent cellular
cytotoxicity (ADCC) via the Fc receptor found on their surface. The
interferons alpha and beta are also capable of boosting the tumouricidal
activity of macrophages. The phagocytosis of tumour cells by
macrophages in the peritoneal cavity of mice is enhanced by treatment
with these cytokines (Gresser and Bourali 1970). Furthermore, in vitro
treatment of human monocytes with interferon-alpha induces cytolytic
activity against malignant target cells (Dean and Virelizier 1983).
Polymorphonuclear leucocytes (PMN) can be cytotoxic to certain
tumour cells. This cytotoxicity is thought to be mediated by ADCC, the
generation of free-radicals, and by the release of enzymes toxic to tumour
cells (Van Kessel and Verhoef 1990). It is, however, likely that if the
concept of immune surveillance is true then the most successful response
will be effected by a combination of all the branches of the immune
system.
1.2.4 Mechanisms ofevasion by the tumour
Another important aspect of immune surveillance is immunological
escape by the tumour. Although derived from a single cell, a tumour mass
39
is not a homogeneous collection of cells. Vast heterogeneity of growth rate
and phenotype exists throughout the tumour. A T-cell response against
TAA would have only minimal effect if there was heterogeneous antigen
expression. Several workers have documented the production of
immunosuppressive compounds, such as prostaglandins of the E series,
by tumours (Plesica et al 1975). Such compounds may serve to render
the host in an immunocompromized state. A summary of some of
the means by which a tumour may avoid detection by the host immune
system is given in Table 1.
1.2.5 The host immune response to bladder tumour
The lining of the urinary tract is constantly subjected to challenge
by a variety of infectious and carcinogenic agents. However, despite the
high incidence of contamination with bacteria, infection is rare, and
urothelial malignancy limited. This implies an efficient defence system in
the tract.
Bladder cancer is, for the majority of patients, a disease of the latter
decades of life. It is known that the immune response of an individual
varies with their age. The proportions of various immune cells in the
periphery have been reported to change (Ritchie 1983). Patients who
develop cancer at an advanced age are therefore at a disadvantage as
their immune system is less well prepared and able to deal with the
tumour. In addition to this, several studies have shown depressed humoral
and cellular responses in bladder cancer patients (Bean et al 1978.
Catalona et al 1974. Herr 1976. Brosman and Fahey 1987).
Studies with the peripheral blood of bladder cancer patients has
revealed a marked decrease in the numbers of lymphocytes present in
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Table 1. Mechanisms of escape from immune surveillance
A. Immunological unresponsiveness of the host eg.
i) specifc eg. tolerance, genetic
ii) non specific eg. genetic, ageing, iatrogenic
B. Immunological sanctuaries
C. Tumour "sneaking through"
D. Immunoselection




F. Shift in balance between immune helper and suppressor mechanisms eg.
i) increase in suppressive activities
ii) decreased helper T cell effects
G. Abrogation of immune response by humoral factors eg.
i) antigen/antibody complexes
ii) release of cytokines (eg. TGFfi)
iii) tumour products (eg. PGE)
H. Immune stimulation of tumour growth
A summary of some of the possible mechanisms of escape from immune surveillance.
This information is taken from a review by K. James (1983). Since that time, little
has changed in the filed of immune surveillance and tumour escape.
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patients with advanced bladder cancer when compared to normal controls
or even patients with superficial disease (Mukamel et al 1982).
Lymphocyte numbers in patients with superficial disease were similar to
those in control groups. The mixed lymphocyte reaction (MLR) has also
been investigated. Herr et al demonstrated significantly lower maximal
response by the lymphocytes of patients with metastatic disease
compared with controls (Herr et al 1976a). Although the number of
individuals in the study was low, Herr also suggested that the MLR might
offer a useful adjunct in the evaluation of the biological potential of
superficial bladder cancer in that those patients with a depressed MLR
progressed to invasive disease (Herr 1983). These observations are not
exclusive to bladder cancer and hold true for malignancies ofvarious origin.
1.2.6 Tumour Infiltrating Cells.
Tumour infiltrating lymphocytes (TIL) are attracted to a
vascularized tumour when the tumour cells secrete chemotactic,
angiogenic or colony stimulating factors (Evans 1986. Mantovani 1990).
Tumour infiltrating immune cells are theoretically of more benefit in
tumour eradication than those in the systemic circulation, as they have
the opportunity to be locally effective. However, their presence in the
tumour does not necessarily imply anti-tumour function. Their presence
in bladder tumours suggests a local immune response to the tumour, and
their prognostic value has been studied retrospectively. The interpretation
of the significance of such infiltrates may be complicated by superimposed
infection.
Studies of immune tumour infiltrates claimed that of 230 tumours
examined, those showing greatest tumour lymphocytic infiltration had the
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longest patient survival (Sarma 1970). The presence of interleukin-2
receptor on the surface of T-cells is a marker of activation which allows a
better functional assessment of the infiltrate. Positive correlation has
been noted between a favourable response and the presence of activated
T-cells within the tumour (Prescott et al 1992).
Most leucocytes which infiltrate bladder tumours are T-cells (Oliver
1982). Furthermore, the normal bladder has an infiltrate of mainly
cytotoxic T cells throughout the epithelium and lamina propria (El-Demiry
et al 1986). This would suggest a protective function against infection and
perhaps tumour. Prescott analyzed 43 bladder tumours with a range of
grades and stages (Prescott et al 1992). A quantitative assessment was
made of the infiltrates in both stromal and tumour compartments. The
infiltrating cells were predominantly found in the stromal compartment
and were mainly T-cells and macrophages. Significantly more T-cells
(most ofwhich were activated) and macrophages were found in high stage
tumours than in Ta tumours, and in G3 as compared with low grade
tumours. Although these results suggest an enhanced local cellular
immune response in invasive tumours, this had obviously not resulted in
tumour eradication.
Tsujihashi and colleagues isolated tumour infiltrating lymphocytes
from bladder cancer patients with tumours of various grades and stages,
and compared their cytotoxic capability with peripheral blood lymphocytes
(Tsujihashi et al 1988. Tsujihashi et al 1989). T lymphocytes were the
predominant cell type in the 2 populations of cells, contributing 44% of
TIL's and 66% of PBL's. Generally, NK cells, macrophages, and B cells in
bladder tumours were present in relatively small numbers. The
spontaneous NK cytotoxicity and LAK activity of the TIL's was low
(<5%). Interleukin-2 (IL-2) generated greater cytotoxic activity in the
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PBL's than in the TIL's. However, unlike PBL's, TIL's exhibited an
apparent specificity for autologous tumour killing, which was higher than
that against allogeneic bladder tumour cells. Such data support the
theory that the local infiltrates are directed against the bladder tumour.
Workers have investigated the characteristics and cellular
distribution of putative antigens on bladder tumours with the aim of
developing neoplastic markers for diagnosis, prognosis and therapy (Paulie
1985). With the aid of monoclonal antibody technology, a number of
groups have postulated the existence of several TCC-associated molecules
on bladder cancer cell lines, several of which appeared specific for high
grade tumour cells (Paulie and Perlmann 1987. Chopin et al 1984. Young
et al 1985). From these studies one may conclude that bladder tumours
are potentially immunogenic, thereby increasing the likelihood of detection
and eradication by the immune system.
Recently, monoclonal antibodies have been employed in the
detection of human bladder tumour (Bamias et al 1991). The tumour
associated monoclonal AUA1, which reacts with most human carcinomas,
was labelled with a radioisotope. The labelled monoclonal was instilled
intravesically into the bladders of patients who were known or suspected
of having bladder cancer for an hour prior to cystoscopy. Cystoscopic
biopsies of both normal and tumour tissue showed that AUA1 targeted
selectively to the tumour, uptake in normal urothelium being minimal.
Furthermore, there was also greater uptake with tumours of higher grade.
In summary, a number of changes in the immune cell function of
patients with bladder carcinoma have been observed. A deterioration in
the quantity and quality of lymphocyte function appears in those with
advanced disease. Evidence for immune function impairment in patients
with superficial disease is not strong but may be present. The use of in
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vitro measurements of immune function has been suggested for the
prediction of biological behaviour of superficial disease, but at present
inter-assay and intra-assay variables make reproducibility and
standardization unreliable.
1.2.7 Evidence against immune surveillance
The immune surveillance concept is by no means universally
accepted as several lines of evidence exist which appear to contradict the
above findings. For example, nude mice do not have an increased incidence
of tumours (Rygaard and Poulsen 1976), and tumours developing in
immunocompromized individuals are leukaemias and lymphomas not the
spontaneously occurring solid tumours commonly seen in clinical practice.
In fact, it has been postulated that the immune system may have
enhancing effects on tumour induction and growth (Prehn 1971).
According to Prehn's immunostimualtion hypothesis many tumour go
through a phase when their growth may be stimulated by immune
mechanisms. Such stimulation occurs early in their growth and may be
mediated by antibody, lymphocytes, macrophage and NK cells.
1.3 Cytokines
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During the past century a growing number of research workers
have reported findings of novel functions which could not be attributed to
molecules which were characterized. Terms such as "leucocyte ferments"
were used to describe the activity of a broth extracted from cultured
leucocytes. As technical expertise increased a number of these factors
were purified and investigated. A nomenclature was developed which
termed each factor according to its first reported function (eg. T-cell growth
factor [TCGF]). Unfortunately, as the number of known factors increased,
and as workers from different groups investigated the same factor, a
vastly complex array of terminology and abbreviations has arisen, which
has only served to isolate the cytokine biologist from their neighbours. In
order to rationalize the terminology several terms evolved which were
designed to encompass a variety of factors. The terms "interleukin" and
"lymphokine" are two such names. Interleukins were initially thought to
act as communication signals between leucocytes. However, the
interleukins could not be constrained and are known to act on, and be
produced by a wide variety of different cell types.
1.3.1 Cytokines in general
The term cytokine was initially proposed by Cohen and colleagues in
1974 (Cohen et al 1974) and literally translates as cell-move. Cytokines
are large polypeptides and glycoproteins (Mr 5 -50kDa) which are produced
by a wide variety of cell types with the function of local communication
between cells, typical actions being autocrine, paracrine but not endocrine.
Cytokines mediate their pleiotropic functions by specific cell surface
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receptors which characteristically exhibit a high-affinity for their ligand
(Kd 10-9-10 12M). Depending on the individual cytokine, the receptor can be
bound by either monomelic, dimeric or even oligomeric forms. Cytokines
tend to be produced by a variety of cell types which are often not closely
related {eg. lymphocytes and endothelial cells produce IL-1). One
remarkable feature of cytokines is the vast degree of redundancy and
ambiguity in their function, with many cytokines sharing similar functions
and individual cytokines exerting a superfluity of actions on an array of
cells and tissues. However, with the advent of recombinant DNA
technologies, and the subsequent study of pure cytokines, it has become
evident that the response to a cytokine is non-linear and that cytokines
interact on a single cell to give effects of different order or type to single
cytokines alone.
1.3.2 Interleukin-1
Honoured amongst cytokines, interleukin-1 (IL-1) has been
designated the first interleukin. The term IL-1 covers two related
polypeptides (IL-1 a and IL-ip) which share 25% homology at the amino
acid level. Both species of IL-1 are initially synthesized as 31 kDa
precursor molecules which are subsequently proteolytically cleaved to
yield a carboxy-terminal peptide ofmolecular weight 17.5 kDa. Neither IL-
la or p is glycosylated and is thought to be predominantly composed of p -
strands. Although the pro-forms of IL-1 have biological activity this is
minor when compared to the activities of the mature forms (Jobling et al
1988).
The relative amounts ofmRNA for the two species of IL-1 in PBMC
differ greatly; IL-lp being the predominant form by up to 50 fold (Demczuk
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et al 1988) and the two forms would appear to be separately regulated
(Turner et al 1989).
1.3.2.1 The interleukin-1 receptor
Despite the differences in amino-acid sequence and in
transcriptional control, the two species of IL-1 bind to common receptors.
Two major IL-1 receptors have been identified, type I and type II
(Bomsztyk et al 1989. Chizzonite et al 1989). The two receptors have
different molecular weights of 80 and 68 kDa respectively. The receptors
have different cellular distributions; transformed T-cells and fibroblasts
having high numbers of type I receptor, and B-cells, neutrophils and bone
marrow cells having high numbers of type II receptors (Matsushima et al
1986). Recent reports have indicated that the two receptors may bind IL-
la and (3 with different affinity (Benjamin and Dower 1990. Scapigliati et
al 1989). Furthermore, there are also studies showing differential
biological actions of IL-la and (3 (Boraschi et al 1990). The IL-1R has been
identified as a soluble form in tissue culture supernatants, capable of
binding IL-1 (Symons and Duff 1990). The soluble receptor was of the low
molecular weight type and would appear to be the result of proteolytic
cleavage rather than as a result of alternative splicing ofmRNA. More
recently, a great deal of interest has been shown in other possible
inhibitors of IL-1, namely IL-1 receptor antagonist (IL-lra). IL-lra would
appear to bind to the IL-1 receptor in a manner similar to IL-1, however, it
has no IL-l-like activity (Hannum et al 1990). The role of such proteins
may be in the tight regulation of the potent actions of IL-1.
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1.3.2.2 The biological effects ofIL-1
The biological effects of IL-1 are many-fold and diverse. Its effects
are manifested throughout the host in all tissues from the CNS to
immunocompetent cells. IL-1 is perhaps most well characterized for its T-
cell activating properties where it has been shown to induce IL-2 and IL-
2R expression (Alter and Bach 1990). Alone, IL-1 is a poor stimulator ofT-
cell proliferation, however, with antigen a synergistic effect is achieved by
inducing IL-2 and IL-2 receptor gene expression (Mizel 1987. Simic and
Stosic 1985).
Interleukin-1 appears to be a pivotal cytokine in the control of
immune response. This is well illustrated by the fact that production of a
vast number of cytokines are induced by IL-1 either alone or in
combination with other mediators such as TNFa or IL-6 (Howells et al
1988. Ghezzi and Dinarello 1988. Wellicome et al 1990. Portillo et al
1989).
Various pathological conditions have been associated with either
locally or systemically elevated levels of IL-1. In chronic conditions such
as rheumatoid arthritis (RA), hepatitis B infection, and HIV infection IL-1
levels have been reported to be increased (Bendtzen 1988). IL-1 mediates
the resorption of bone in vitro and therefore is thought to be essential in
the chronic destruction of the joints of RA patients (Gowen et al 1983.
Dingle et al 1987). Various neoplastic and leukaemic cells have been
demonstrated to produce IL-1. Lymph node cells of patients with
Hodgkin's disease, PBMC's of those with monocytic leukaemia, and renal
cell carcinoma tissue have all been found to secrete IL-1 (Bodel et al 1980).
1.3.3 Interleukin-2
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Interleukin-2 (IL-2) is a 15.5 kDa glycoprotein which is highly
hydrophobic. It is a product of activated T-cells, and recent studies
suggest that activated B-cells may also produce IL-2 (Walker et al 1988).
Mature human IL-2 comprises 133 amino acid residues and shares over
60% homology with murine, rat and bovine IL-2. Like IL-1, IL-2 is
secreted as a pro-molecule which requires post-translational modification
events to yield a biologically active polypeptide. These events involve
cleavage of a 20-residue signal peptide, addition of carbohydrate to the
threonine at position 3, and the formation of a disulphide bond between
residues 58 and 105 (Robb and Greene 1983). The polypeptide exists as
six alpha-helical domains, involving 89 amino acids (Brandhuber et al
1987). The three dimensional structure of human IL-2 is shown in
Figure 2.
1.3.3.1 The interleukin-2 receptor
The biological effects of IL-2 are mediated by binding to specific
receptors. Three forms of IL-2 receptor have been demonstrated to exist
giving rise to receptor structures with low, intermediate and high affinities
for the ligand. The high affinity receptor (Kd 10-50pM) is composed of two,
distinct membrane-associated binding units; the alpha subunit is 55 kDa
and the beta subunit is 70-75 kDa (Leonard et al 1982. Tsudo et al 1987).
The IL2-Ra and P subunits can exist as monomers on the cell surface and
both are capable of binding IL-2 (IL2-Ra Kd 10,000 pM, IL-2Rp 1^
lOOOpM) (Robb 1984). The three different affinities of the IL-2R are a
function of the differing binding kinetics of each of the subunits; the alpha
-M andh°&he>tcalP0M,etait9s
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unit having a rapid rate of association (T1/2=4 seconds), and the beta unit
operating far more slowly (7\/2=45 minutes) (Wang and Smith 1987.
Lowenthal 1987). The high affinity receptor binds IL-2 rapidly and
releases it very slowly.
1.3.3.2 The biological effects of interleukin-2
The biological actions of IL-2 include B-cell differentiation, T-cell growth
and differentiation, and actions on NK and LAK cells (Splawski et al 1990.
Grimm et al 1982). Quiescent T lymphocytes neither produce IL-2 nor
express high-affinity IL-2 receptors (Smith 1980. Robb et al 1981).
However, following activation with antigen or mitogen, the interaction of
IL-2 with its receptor produces rapid clonal expansion of the effector
population originally activated by antigen (Robb 1984). Furthermore, IL-2
mediates several of its actions by stimulating the production of a variety
of other cytokines including interferon-gamma (IFNy) and IL-4. (Farrar et
al 1982. Howard et al 1983). B-cells express IL-2R and respond to IL-2,
however, receptor expression is 10 fold lower than on activated T-cells
(Waldmann et al 1984). NK cells also proliferate in response to IL-2,
secrete IFNy and exhibit enhanced cytolytic activity (Ortaldo etal 1984).
Interleukin-2 is produced by activated T-cells of the TH1 sub-class
(Bottomly 1988). Normal mature T-cell clonal expansion is regulated in an
autocrine fashion by IL-2 (Smith 1980) however, abnormal regulation of
the IL-2 system is associated with malignant transformation ofmature T-
cells (Maruyama et al 1987. Yamada et al 1987).
1.3.4 Interferon-gamma
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Interferon-gamma is a glycosylated polypeptide which is the
product of a single gene located on human chromosome 12 (Naylor et al
1984). It shares no sequence homology or evolutionary relationship with
the other interferons. The four exons of the IFNy gene code for a
polypeptide of 166 amino acids, 20 of which constitute a signal peptide
(Gray and Goeddel 1982. Taya et al 1982). The mature polypeptide
contains two potential N-glycosylation sites (positions 28 and 100), as a
result of which two different molecular weight forms (20 and 25kDa) of
IFNy have been identified (Yip et al 1982. Rinderknecht et al 1984).
Human IFNy is acid labile, possibly as a result of the relatively high
content of basic residues (Devos et al 1982).
1.3.4.1 The interferon-gamma receptor
There is a single species of IFNy receptor, distinct from the IFNoc
and p receptors, ofmolecular weight of around 90 kDa, slight variations of
which are probably due to different N-glycosylation patterns (Mao et al
1989. Merlin et al 1985). The IFNy receptor is expressed on most
nucleated cells (Ucer et al 1986). The initial step in the action of IFNy is
binding to its specific receptor (Zoon and Arnheiter 1984). Therefore, the
susceptibility of a cell to the biological effects of IFNy should indicate the
presence of receptors on the plasma membrane. Following binding to the
receptor the entire ligand-receptor complex is internalized and can be
visualized in coated pits with the aid of electron microscopy (Filigueira et
al 1989). Following endocytosis the ligand is eventually degraded by
lysosomal enzymes and the receptor re-cycled to the cell membrane.
A considerable investment has been made into the predictive value
of receptor expression (both number and affinity) for the response of a cell
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or tissue. Recently, studies have emerged concerning the expression of
IFNa receptors by interferon sensitive and resistant urothelial
carcinomas (Grups and Bange 1990). Investigators could find no
significant difference in either the number of receptors per cell or their
relative affinity for ligand which might account for the differential response
of the cell. Ucer and colleagues have shown some correlation between the
expression of IFNy receptors and the biological response in a variety of
human tumour cell types (Ucer et al 1985). In this study the IFNy
sensitivity of inducible cells was dependent on the number of receptors, in
that with increasing numbers of receptors present on cells, lower doses of
IFNy were required for the induction of effect. Soluble cytokine receptors
have been identified in vivo. The soluble receptors for TNF, IL-6 and IFNy
have been identified in normal urine (Englemann et al 1989. Novick et al
1989). These receptors were shown to prevent the cytotoxic functions of
TNFoc and IFNy in vitro thus demonstrating a phenomenon that occurs
under normal physiological conditions. The presence of these receptors
has not been determined in the urine of patients with bladder cancer,
however their presence would undoubtedly influence the biological actions
of the relevant cytokines.
1.3.4.2 The biological functions of interferon-gamma
In the field of tumour biology, IFNy has been the subject of
considerable attention. Undoubtedly, IFNy can exert many effects on
tumour cells, however these can either be direct (via the specific receptor
on the tumour cell) or indirect via other effector mechanisms (some of
which are discussed in 1.2.3 and include macrophage activation, increased
MHC class I and II stimulation, and effects on T-cells, B-cells, and NK
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cells). The growth rate of tumour cells is slowed by IFNy by causing a
prolongation of the cell cycle. However, tumours respond to IFNy in a
heterogeneous manner, ranging from total cytotoxicity, through cytostatic
effects to total resistance (Bradley and Ruscetti 1981. Epstein and
Marcus 1981. Ludwig etal 1983. Balkwill etal 1983).
1.3.4.3 Signal transduction by the interferon-gamma receptor
Signalling by the IFNy receptor after ligand binding has been studied
in numerous cell types, and several pathways have been proposed that
implicate the involvement of various protein kinases. The activation of
protein kinase C (PKC) and Ca2+/calmodulin-dependant protein kinase
have been implicated in several studies (Nobukazu et al 1990. Koide et al
1988. Hamilton et al 1985). One such study in glioblastoma cell lines
demonstrated that IFNy inducible class II expression involved the
activation of PKC (Nobukazu et al 1990). In addition to this, calcium
influx appeared to be involved in the DR and DP molecule expressions on
T98G cells. These second messengers were found to induce the
transcription ofDRA and B and DPA and B genes without de novo protein
synthesis. Further studies on the monocytic U937 cell line showed that
following stimulation with IFNy an increase in intracellular calcium
concentration occurred (Klein et al 1990), PKC and calmodulin, however,
were not found to be involved in the signal transduction.
The functional role of specific signal transduction pathways in the
cellular response to exogenous cytokine stimuli can be investigated in
several ways. These include measurement of the second messengers
generated by the stimulus, determining the cellular response to the
stimulus in the presence of inhibitors of specific second messengers, and
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determining if direct stimulation of the signal transduction pathway
reproduces the cellular response. The understanding of the early events in
signal transmission have been greatly facilitated by the advent of
pharmacological agents capable of inhibiting or stimulating various
intracellular pathways. One such agent is the calcium-ionophore A23187,
which has been reported to mimic the effect of IFNy on the down-
regulation of the transferrin receptor and on the priming ofmacrophages
for tumouricidal activity (Weiel et al 1985. Johnson and Torres 1985).
The biochemical mechanisms by which IFNy induces phenotypic
and functional changes in a cell have not been fully elucidated. Therefore,
depending on the cell type investigated, the IFNy induced expression of
HLA class II molecules involves either a protein kinase C-dependent
pathway (Celada and Maki 1991. Koide et al 1988. Fan et al 1988), or a
Ca2+/calmodulin pathway (Klein et al 1990. Koide etal 1988).
1.3.5 Tumour necrosis factor-alpha
The tumour necrosis factors (TNF) are a two member family of
cytokines consisting of the alpha and beta forms. The first TNF to be
described was actually TNFp, originally termed cytotoxic factor and
lymphotoxin (Ruddle and Waksman 1968. Granger and Williams 1968).
Human TNF (5 is a 25kDa protein which shares 35% amino-acid homology
with TNFa, a fact which prompted a change in name from lymphotoxin to
TNFp (Li et al 1987). Human TNFoc was first cloned by Pennica et al in
1984 (Pennicia et al 1984). Like IL-1, human TNFa is produced as a pro-
molecule of 233 residues which is subsequently processed to reveal a
mature secreted form of 157 amino acids. The mature 17 kDa form of
TNFa is unglycosylated, and recent crystallographic studies have shown
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the association of monomers into a compact trimer, and it is in this form
that it is thought to associate with its receptor (Jones et al 1989).
1.3.5.1 The tumour necrosis factor receptor
As with the receptor for IFNy, the TNFa receptor is expressed on
most cells, with the exception of red blood cells (Aggarwal et al 1985.
Smith and Baglioni 1989). Two major TNFa receptors have been
identified. The smaller ofmolecular weight 55 kDa and the larger of 75
kDa (Loetscher et al 1990. Schall et al 1990. Smith et al 1990a). The
extracellular domains of both receptors are highly similar with six
characteristic cysteine residues, however, large differences exist
intracellularly indicating differences in signalling pathways. The 75 kDa
receptor is expressed by T- and B-cells following activation (Dembric et al
1990). However, endothelial cells, the monocytic cell line U937, and NK
cells appear to express the two TNF receptors both of which functionally
contribute to the actions of TNF. Furthermore, despite the differences in
the intracellular domains of the two receptors, both mediate similar
functions (Dembric et al 1990).
1.3.5.2 The biological effects of tumour necrosis factor
The biological functions of TNFa are diverse and many are held in
common with IL-1. TNFa was first shown to be responsible for the
chronic wasting condition cachexia found in rabbits infected with
Trypanosoma brucei and for the dramatic haemorrhagic necrosis of certain
types of transplantable tumour (Beutler and Cerami 1989). Both TNFa
and TNF (3 can act as co-stimulatory signals for activated T-cells, in turn
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regulating the growth and differentiation of B-cells. Two important
adhesion molecules, endothelial leucocyte adhesion molecule-1 (ELAM-1)
and intercellular adhesion molecule-1 (ICAM-1) are induced on vascular
endothelium following stimulation with TNFa or IL-1 (Pober et al 1986).
The receptor for TNF on T-cells, HLA class II antigen, high affinity IL-2
receptor, and the cytokine IFNy are induced by stimulation with TNF
(Scheurich et al 1987. Paul and Ruddle 1988).
In addition to its immunoregulatory role, TNFa has many
destructive effects and is thought to be central to several chronic
inflammatory disorders. Grau and colleagues showed that TNFa was an
essential mediator of murine cerebral malaria induced by Plasmodium
berghei (Grau et al 1987). Normally fatal within 14 days, the neurological
manifestations of cerebral malaria could be completely negated with a
single injection of anti-TNFa antibody on day 4-7. Other studies with
LD100 doses of Escherichia coli have shown that anti-TNF F(ab')2
fragments when administered 2 hours before the lethal dose can fully
protect against shock, vital organ dysfunction, and death (Tracey et al
1987). The resorption of cartilage and bone associated with such disease
as rheumatoid arthritis, has been found to be a function of TNF and IL-1
(Saklatavala 1986). Furthermore, the production of IL-1 by synovial cells
can be reduced by antibodies to TNFa, thus suggesting a possible
therapeutic approach for the treatment of the clinical manifestations of
RA (Brennan et al 1989). In general TNF exerts growth inhibitory effects
on some tumour cell lines, but not on untransformed cells (Sugarman et al
1985). Some tumour cell lines have been reported to secrete TNFa or P,
however, these lines are resistant to the cytotoxic actions (Porter 1991).
Elevated TNFa levels have also been implicated as a detrimental factor in
neoplastic disease. Systemic TNFa levels have been associated with
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cancer in some surveys but not in others (Balkwill et al 1987. Socher et al
1988). However, one reason for the detrimental effect of TNFa may lie in
the systemic metabolic effects rather than in the cellular effects. Many
cancer patients die not from the tumour per se, but rather from the severe
cachexia which frequently accompanies cancer. Antibodies to TNFa have
been shown to protect from the antilipogenic and protein wasting effects of
TNFa in an animal model (Sherry and Cerami 1988).
More recently, a novel application for TNFa in the treatment of
advanced melanoma, sarcoma, and carcinoma of the limbs has been
described (Lejeune et al 1992). In these clinical trials, limbs were isolated
by restriction of the blood supply and TNFa was introduced and allowed to
perfuse throughout the limb. Remarkably high rates of complete and
partial response were reported, however, the long term response of
patients remains to be seen.
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1.4 Lymphokine activated killer cells
There are several classical mechanisms of cell mediated killing.
Firstly, killing by cytotoxic T-cells involves the recognition of specific
processed antigen presented in the context of MHC class-I molecules
present on the surface of the target cell. Recognition is achieved by the T-
cell receptor (TcR), a heterodimeric structure capable of simultaneously
recognising antigen and self-MHC. The CD8 expressing, cytotoxic T-cell
recognises endogenous antigens and is therefore largely responsible for the
elimination of virally infected target cells. The second form of cytotoxic
cell is the natural killer (NK) cell. NK cells are large granular lymphocytes
which can kill some transformed, and virally infected target cells in vitro.
NK cells are characterized by the expression of CD56 (also termed NCAM)
and CD 16 (Fcy-III receptor), however, they lack the expression of TcR
(Lanier and Phillips 1986. Reynolds and Ortaldo 1987). Thirdly, the
macrophage is of central importance in cell mediated cytotoxicity. The
macrophage can function both as and APC and as an effector of
cytotoxicity.
One decade ago a novel form of cellular cytotoxicity was described.
The lymphokine-activated killer (LAK) phenomenon was first reported by
Grimm and colleagues (Grimm et al 1982). They reported the cytolysis by
interleukin-2 activated peripheral blood lymphocytes (PBL) of fresh solid
tumour cells which were shown to be resistant to NK mediated lysis. LAK
mediated lysis was found to be distinct from other forms of T-cell mediated
killing in that it was non-MHC restricted, and did not affect normal cells
(Grimm et al 1983. Rosenberg and Loetz 1986a). LAK cell were isolated
from many patients with solid malignancy, and so it was proposed that
LAK cells represented a unique and fundamental cytotoxic effector system
60
that may play a role in immune surveillance against NK resistant tumour
cells, and may be relevant to the adoptive immunotherapy of tumours.
1.4.1 The role ofcytokines in the generation ofthe LAKphenomenon
When non-adherent PBL are stimulated with IL-2 in vitro they
rapidly proliferate and acquire novel killing capabilities. LAK cells are
induced by IL-2 in a dose dependentmanner, depending on the source of IL-
2 requiring between 1 and 1,00011ml-1 (Yamamoto et al 1990. Migita etal
1989). The kinetics of LAK cell induction are maximal after 6 days of
stimulation (Colborn et al 1989) and evident following only 3 days of
stimulation (Grimm et al 1983).
Several other cytokines are able to stimulate the generation of LAK
activity in non-adherent PBL and to synergize with IL-2 in the generation
of such activity. Synergy between recombinant IL-1 and IL-2 in the
generation of LAK activity has been observed, however, a prerequisite was
the pretreatment of the cells with IL-1 (Crump et al 1989). One possible
mechanism by which these two cytokines could act synergistically would
be in the induction of the IL-2 receptor (3-chain by IL-1. Other
mechanisms could include the upregulation ofmolecules involved in target
cell recognition or in the cytolytic process per se. When PBL are
stimulated with IL-2 they secrete IFNy (Itoh et al 1985. Chapman et al
1990). Itoh et al hypothesized that IFNywas involved in the IL-2 induced
LAK cytotoxicity and the proliferative response. Interferon-gamma, but
not interferon-alpha or beta, has been shown to synergize with low doses
(2Uml-1) of IL-2 (Kaufmann et al 1991). This data suggests that IL-2
stimulates PBMC to produce IFNy, which in turn acts as a differentiation
signal that may be involved in the IL-2 initiated LAK generation and
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proliferative response. Tumour necrosis factor-alpha (TNFoc) has also
been reported to be produced by PBMC activated with IL-2 and enhance
the cytolytic and cytostatic capacity of IL-2 activated killer cells
(Chapman et al 1990. Matossian-Rogers et al 1989. Maghazachi 1990).
Such workers showed that TNFa synergizes with low doses of IL-2 or
exerted its effects on cells which reacted suboptimally to IL-2 stimulation.
Interleukin-7 in the absence of IL-2 induces LAK activity in human PBMC
(Stotter et al 1991). This novel inducer of LAK activity proved interesting
as induction was independent of IL-2 secretion as demonstrated by
antibody neutralization.
In contrast to the above observations, cytokines also appear to be
involved in the down-regulation of the LAK response. Two cytokines in
particular, namely IL-4 and TGFf), suppress IL-2 induced LAK activity
when present, especially during the first 48 hours of stimulation
(Kawakami et al 1989. Chapman et al 1990). Not only was LAK activity
inhibited but the PBMC failed to respond with proliferation. Neither IL-4
or TGF P was found to induce LAK activity when used on their own. Of
considerable interest are the findings of Higuchi (Higuchi et al 1989). This
study compared the actions of IL-4 on freshly isolated PBL and on PBL
which had first been activated in vivo by IL-2 therapy for advanced
cancer. As noted above, IL-4 had no effect of fresh PBL, however, PBL
from patients who had received several rounds of IL-2 therapy responded
to IL-4 stimulation with an augmentation of their cytolytic capabilities.
The positive role of IL-4 in the regulation of LAK activity following in vivo
activation by IL-2 could also be mimicked in vitro thus suggesting that IL-
2 activation alters the response of PBL to IL-4. One possible mechanism
by which IL-4 may prevent LAK cell generation is by the down-regulation
of the high-affinity IL-2 receptor expression (Fernandez-Botran et al
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1989). However, the changes which reverse the role of IL-4 following IL-2
activation remain unknown. It would seem that IL-2 and IL-4 may act as
sequential paracrine co-factors in the induction of precursor cells into LAK
effectors. Further studies have shown that the inhibitory effects of IL-4
can be partially reversed if exogenous TNFa or IFNy are added at the start
of culture (Swisher et al 1990). The same group also showed that IL-4
decreased the production of TNFa and IFNyby PBMC (Esner et al 1989).
Thus one mechanism by which IL-4 may depress LAK activity is by the
inhibition of endogenously produced cytokines such as TNFa and IFNy.
The regulation of LAK activity by cytokines is complex, depending
not only on the initial stimulus but also upon the endogenous production of
secondary cytokines. Stimulation of PBMC with IL-2 results in the
secretion of a plethora of secondary cytokines including both species of IL-
1, IL-6, IFNy, IFNa, TNFa and (3, and GM-CSF, some of which may be
involved in the LAK phenomenon (Lange et al 1991. Dett et al 1991) .
Furthermore, these cytokines may have direct effects on the target cell if
they were secreted in close proximity with the tumour by tumour
infiltrating lymphocytes (TIL).
1.4.2 Tumour infiltrating lymphocytes
It has been found that several types of primary tumour frequently
exhibit marked lymphocyte infiltration (Saito et al 1989. Shimizu et al
1991. Belldegrun et al 1989. Crannage et al 1991). This infiltration of
immunocompetent cells into tumour sites might be considered direct
evidence of a specific host immune defence mechanism in action
(Hiratsuka et al 1984). An association may exist between a greater extent
of infiltration by lymphocytes into the cancer and fewer metastases and
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an improved prognosis (Sarma 1970. Black et al 1971). TILs have been
identified and isolated from patients with bladder cancer (Tsujihashi et al
1988). The TIL were compared with autologous and allogeneic PBL
following IL-2 stimulation. There was little spontaneous LAK activity
resident in TIL's until stimulated with exogenous IL-2. Unlike the PBL,
these TIL exhibited an apparent specificity for bladder tumour; ie the
cytotoxicity against autologous cells was greater than against allogeneic
bladder tumours suggesting some T-cell mediated specific response. Other
workers have produced less promising results in that TIL isolated from
primary lung cancer patients had significantly lower levels of cytolytic
activity than PBL from the same donor (Yano et al 1989). The TIL
produced low levels of IFNy, a cytokine thought to be important in the
effective generation of LAK activity. A more recent study has shown a
correlation between the production of IFNy during TIL culture and their
effectiveness in eradication of established lung tumours in mice, and a
lesser relationship between in vitro cytotoxicity and clinical response
(Barth et al 1991). Miyatake and colleagues have transduced the cDNA
for IFNy into a cloned CTL specific for murine glioma, and observed greater
efficacy in the immunotherapy of subcutaneous tumours (Miyatake et al
1990). More recently, A. Belldegrun presented data concerning gene
therapy where the IL-2 gene was inserted into lymphocytes and these
subsequently introduced into the tumour (Belldegrun 1992). These studies
reveal one possible means of manipulating the TIL for greater clinical
benefit, by transducing the cells with cDNA coding for various cytokines
including IFNy and TNFa.
Tumour infiltrating lymphocytes have been demonstrated to
produce mRNA for a variety of cytokines following stimulation with IL-2
in vitro (Belldegrun et al 1989). Transcripts for TNFa, TNFp, GM-CSF,
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and the receptor for IL-2 were detected. It is of interest that no IL-2
mRNA was detected and that unstimulated TIL did not express
transcripts for any of the above cytokines. TIL may offer a more
successful approach to adoptive immunotherapy than LAK cells. This is
supported by the observation that TIL were 50 to 100 times more potent
in the killing of autologous tumour cells (Rosenberg et al 1986b).
1.4.3 Clinical results obtained using IL-2 and /or LAKcells
The mainstays of current cancer therapy are surgery, radiotherapy
and chemotherapy (DeVita 1983). Despite recent advances in early
detection of tumours, control of the energy types used in radiotherapy and
an increase in the number of chemotherapeutic agents, over 50% of all
newly diagnosed cancer patients will die ofmetastatic cancer (Rosenberg
1988a). Therefore we need a more effective adjuvant therapy and newer
effective treatment for systemic disease. Intensive efforts have therefore
been directed to the development ofnovel therapeutic modalities for cancer
treatment and the development of biological therapies has been foremost
in these efforts.
During the past decade, recent advances in recombinant DNA
technology have made available large quantities of highly purified
cytokines or biological response modifiers (BRM). One approach to
immunotherapy involves the use of such cytokines either directly (for
example by i.v. administration) or indirectly leading to adoptive
immunotherapy. Adoptive cellular immunotherapy (ACI) involves the
direct activation of the hosts immune cells ex vivo and the reintroduction of
such cells into the host to mediate an anti-tumour response, either directly
or indirectly. A variety of candidate cells have been investigated for
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potential ACI including T-cells, NK cells, monocyte-macrophages and LAK
cells. Such ex vivo activation of cells has potential advantages in that
many effector cells can be generated and therapy does not depend upon a
completely intact host immune system.
Adoptive cellular immunotherapy was initially undertaken by
Rosenberg at the National Cancer institute (Rosenberg et al 1985). Such
clinical trials in humans involved the single agent use ofeither IL-2 or LAK
cells in escalating doses with the intention of evaluating the toxicity and
efficacy of the treatment regimen. However, no response was observed in
patients receiving either agent alone. One major problem is the short half-
life of IL-2 when systemically administered, typically 2-3 minutes
(Donahue and Rosenberg 1983). Therefore, in order to obtain sufficiently
high concentrations of IL-2 in the body, extremely large doses of cytokine
must be used. Further trials with IL-2 alone showed more promising
results with complete remission in 4 and partial response in 9 out of 80
patients treated (Rosenberg 1988b). Although tumour regression can be
mediated by IL-2 alone, combined treatment with LAK cells plus IL-2 has
yielded greater effect than either treatment alone.
A major problem associated with the systemic administration of
high dose IL-2 with or without LAK cells is the high level of toxicity
(Stevenson 1989). The majority (>90%) of patients experience nausea,
fatigue and fever. Over half of patients have anaemia, abnormal renal
function, hypotension, pruritus, diarrhoea, CNS disturbance and
eosinophillia. Approximately 20% suffer severe respiratory distress,
cardiac arrhythmias, coma, or myocardial ischemia. Furthermore, less
than 5% have seizure, myocardial infarction or even death. Although the
exact mechanisms of these severe adverse effects has not been clearly
elucidated, one important factor seems to be the development of the
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capillary leak syndrome leading to fluid shifts in the extravascular tissues.
In addition to the high toxicity associated with IL-2/LAK therapy,
the instances of success are noticeably scarce. ACI appears to be most
effective in the treatment of malignant melanoma, renal cell carcinoma,
non-Hodgkin's lymphoma and colon cancer (Rosenberg et al 1987. Fisher
et al 1987. Dutcher et al 1987). Using this regimen an overall response
rate of only 25% was achieved for renal cell carcinoma, 21% of melanoma
patients and 13% of patients with colorectal carcinoma. Trials with
animal models of cancer and LAK cell therapy have shown results which
were considerably more encouraging than in clinical trials (Yamaki et al
1988. Lafreniere and Rosenberg 1985). Possible reasons for this include
the relatively high numbers of transferred effector cells and the ease of
administration directly into the lesion rather than systemically. A
summary of the responses of various cancer patients is presented in
Figure 3.
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Figure 3. The response of cancer patients to therapy with LAK cells
A summary of data obtained from Rosenberg et al (1986 Surgery 100: 262.).
The responses of cancer patients to adoptive cellular immunotherapy with
autologous LAK cells and recombinant IL-2. Shown are the total number of
patients (0), and the number of responders fl). A positive response was
defined as a reduction of tumour size by >50%. Other cancers included 1
oesophageal adenocarcinoma, 1 lymphoma, and 1 gastrinoma.
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As mentioned in chapter 1.1, recombinant IL-2 and LAK cell
adoptive therapy has recently been used to treat patients with advanced
bladder cancer (Hermann et al 1992). Substantial changes in the immune
system of patients were observed. A migration of leucocytes to the
tumours and increased expression of VLA-1 on both peripheral blood
mononuclear cells and the endothelial cells of small tumour vessels were
seen. Activated T cells (CD25+) and macrophages were seen to infiltrate
the tumour, however, few NK cells were noted in the tumour. Systemically,
the white blood cell count doubled during therapy and peripheral NK cells
were activated by the treatment. Despite the encouraging immunological
indicators, no patients responded to the treatment they received and all
were affected by varying degrees of toxicity. Recent evidence suggests
that following bolus injection of IL-2, a rapid and selective adherence ofNK
and NK-like lymphocytes to vascular endothelium occurs (Salvo et al
1992).
1.4.4 Clinical results obtained with TIL
The emphasis given to tumour infiltrating lymphocytes in recent
studies of adoptive immunotherapy stems from the observation made by
Rosenberg that TIL were highly effective in causing tumour regression in
mice bearing established tumours (Rosenberg et al 1986b). Early clinical
trials employing IL-2 expanded TIL in adoptive transfers to patients with
metastatic cancers refractory to conventional therapy were not especially
encouraging (Topalian et al 1988. Kradin et al 1987). Further human
investigations have also been undertaken using autologous TIL which had
been expanded in vitro. (Kradin et al 1989). Response rates of 29% of
patients with renal cell carcinoma and 23% ofmalignant melanoma were
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observed, results comparable to those achieved with IL-2/LAK therapy.
From the clinical data it would seem that the early promises of LAK
cell investigations in vitro have not been realized in the clinical
management of cancer. In only a few diseases, notably malignant
melanoma and renal cell carcinoma, have any useful clinical results been
obtained with LAK therapy. The systemic administration of IL-2 and LAK
cells for the treatment of advanced bladder cancer would seem not to be of
clinical use. However, this form of therapy may be more efficient when
administered into the bladder wall or when used to treat limited and
localized disease, rather than disseminated metastatic cancer.
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1.5 Cell adhesion molecules
1.5.1 Adhesion in general
The adhesion of cells to each other and to matrix components is a
fundamental requirement for successful communication between cells and
structurally correct orientation of individual cells into a tissue (Fleming
1991. Biddlestone and Fleming 1991). These vital functions are achieved
by an expanding series of cellular adhesion molecules (Fleming 1990).
These molecules may be passive (maintaining adhesion whilst further
processes occur) or active in that they can transmit intracellular signals.
1.5.2 Cell-cell adhesion molecules
The leucocytes are highly mobile, presumably so that they can
quickly migrate to sites of trauma to deal with repair and invading
pathogens. However, the cells must rapidly adhere to the vascular
endothelium adjacent to the site of insult in order to transmigrate and gain
access. The interaction of circulating cells of the immune system with
surrounding tissues, such as endothelium, is initially dependent upon a
series of transient adhesion events, controlled by various cell adhesion
molecules (see Figure 4). Three superfamilies of adhesion molecules exist:
the selectins which appear to interact with carbohydrate containing
ligands (eg ELAM-1 and GMP-140); the integrins composed of a
heterodimer (eg LFA-1 and VLA-4); and members of the immunoglobulin
superfamily (eg ICAM-1, 2, and 3).
The selectins, a family of three members, are implicated in
inflammatory and haemostatic response to tissue injury, attracting
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Figure 4. A generalized mechanism of recruitment of leucocytes to sites
of inflammation
No interaction
The model depicts the sequential action of selectin and integrin adhesion receptors
in the recruitment of leucocytes. I - a suitable leucocyte is attracted to the vascular
endothelium adjacent to the site of trauma. II - Using the selectin adhesion molecules
the leucocyte rolls along the endothelium until the integrins on its surface are
activated. Ill - following the firm adhesion the leucocyte migrates between adjacent
endothelial cells. Finally extravasating cell will terminate its adhesion with the
vascular endothelium and migrate to the required site.
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neutrophils and other leucocytes to sites of inflammation. They are
thought to recognize carbohydrate ligands (Springer and Lasky 1991.
Stoolman 1989. Pober and Cotran 1991. Feizi 1991). Two members,
ELAM-1 and CD62 are differentially expressed on endothelial cells and
platelets in response to a variety of stimuli and recruit T-cells, neutrophils
and other myeloid cells to sites of inflammation. Neither ELAM-1 or CD62
is constitutively expressed on endothelial cells or platelets. The expression
of ELAM-1 is induced by IL-ip, TNF (both species), IFNy, and also by
bacterial endotoxin (Leeuwenberg et al 1990. Bevilacqua et al 1987.
Bevilacqua et al 1989). Cell surface expression is induced after about 4-6
hours. ELAM-1 expression is usually transient, however, in certain
chronic inflammatory diseases such as rheumatoid arthritis expression is
maintained. The kinetics of CD62 expression are markedly different from
ELAM-1 in that newly expressed molecules are readily detected within
minutes of stimulation with phorbol ester (Geng et al 1990). Mel-14/LAM-
1, the third member, is constitutively expressed by some lymphocytes,
neutrophils and monocytes (Griffin et al 1990. Tedder et al 1990.
Lewinsohn et al 1987). Mel-14/LAM-l has been demonstrated to play a
role in the recruitment of neutrophils to sites of inflammation in vivo
(Watson et al 1991). ELAM-1 has been shown to bind to structures
related to the sialyated Lewis-X blood group antigen (SLex) (Tiemeyer et al
1991). These structures have been identified on the surface of neutrophils
and monocytes and termed CD 15 (Skubitz et al 1983). Furthermore,
antibodies to SLex have been found to inhibit ELAM-1 mediated adhesion
(Walz et al 1990). Evidence also exists which suggests that, like ELAM-1,
CD62 binds to SLex (Larsen et al 1990). The relevant ligand/s for Mel-
14/LAM-l have not yet been identified.
The integrins represent a family of cell adhesion receptors expressed
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on a wide variety of cell types. They are expressed as transmembrane,
non-covalently linked, heterodimers which can be divided into three groups
depending upon the expression of the three known available beta chains.
Those which share the beta-1 chain are known as very late activation-
antigens (VLA-1 - 7), the beta-2 chain as leucocyte-integrins (LFA-1
[leucocyte function associated-antigen-1], Mac-1 and p150,95), and the
beta-3 chain as glycoprotein Ilb/IIa and vitronectin receptors. The beta 1
and 3 integrins predominantly mediate cell attachment to extracellular
matrix, whereas the beta-2 subfamily is mostly involved in cell-cell
interactions with the immune system (Arnaout 1990. Mantovani and
Dejana 1989). A common feature of some integrins is their ability to
adhere to ligands showing a conserved amino acid sequence (arg-gly-asp),
the so called RGD sequence. The RGD sequence is present in a number of
extracellular proteins such as fibronectin, vitronectin and fibrinogen.
Those adhesion molecules which are members of the
immunoglobulin superfamily include such molecules as TcR, MHC classes
I and II, CD3, CD4, CD8, NCAM (Neural cell adhesion molecule), and
ICAM-1 (intercellular adhesion molecule-1). This group of structures
serves many fundamental purposes within the immune system including
antigen presentation and recognition.
1.5.3 LFA-1 and ICAM-1
The 132 integrins or leucocyte integrins represent a major sub-group
of integrins. Three alpha chains (CDlla, b, and c, Mr 175, 165, and 150
kDa respectively) share a common beta chain (CD 18, Mr 95 kDa) giving
rise to three distinct adhesion molecules with unique functions; LFA-1
(CDlla/CD18 heterodimer), Mac-1 (CDllb/CD18), and pl50-95
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(CDllc/CD18). There are three characterized ligands for LFA-1; ICAM-1, -
2 and -3 (Rothlein et al 1986). ICAM-1 is a monomelic cell surface
glycoprotein with a molecular weight of 95kDa. It contains 5
immunoglobulin-like domains, domain two containing an RGEKE (arg-gly-
glu-cyc-glu) sequence and an RVE (arg-val-glu) sequence located between
the first two domains, however, no RGD sequence exists (see Figure 5)
(Marlin and Springer 1987. de Fougerolles et al 1991. de Fougerolles and
Springer 1992). There is also evidence that ICAM-1 can serve as a ligand
for Mac-1 (CDlib) (Smith et al 1989). It has been shown that ICAM-1
plays a role in several pathological conditions including airway
hyperresponsiveness, renal and cardiac allograft rejection, and the influx of
neutrophils in rabbit inflamed lung (Wegner et al 1990. Cosimi et al 1990.
Flavin et al 1990. Barton et al 1989). ICAM-2 is a 60kDa glycoprotein
which has only two immunoglobulin-like domains. The most recently
described ligand for LFA-1 is ICAM-3, a highly glycosylated protein of
molecular weight 124 kDa (de Fougerolles and Springer 1992).
The cellular and tissue distribution of the three ICAM molecules
varies greatly, however one important site of expression unites the three,
namely vascular endothelium. ICAM-3 distribution differs markedly from
ICAM-1 and -2 in its expression on leucocytes. It is expressed at high
levels on resting lymphocytes, monocytes, and neutrophils, whereas
ICAM-1 and ICAM-2 were only weakly expressed. Upon activation of
lymphocytes with PHA, ICAM-1 expression increases many fold, whereas
ICAM-3 expression increases only two to threefold. De Fougerolles and
colleagues examined the adhesion of resting and activated lymphocytes to
purified LFA-1 (de Fougerolles and Springer 1992). The adherance of
resting lymphocytes was shown to be almost entirely ICAM-3 dependent,
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The single chain polypeptide molecule, ICAM-1, contains 5 immunoglobulin-like
domains. The fifth domain lacks a beta-strand. Instead of a RGD-sequence as
binding site for LFA-1 the amino acid sequence RVE (arg-val-glu) between the
first two domains and RGEKE (arg-gly-glu-cys-glu) within the second domain
occur. Also shown is the single chain glycoprotein, ICAM-2. The extracellular
domain of ICAM-2 comprises just two immunogloulin-like domains, which exert
34% homology to the first two N-terminal domains of ICAM-1. No RGD sequence
exists within the 202 amino acids of ICAM-2. Disulphide bonds are shown (ss).
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however, following activation adhesion occurred chiefly via ICAM-1, and to
a lesser extent ICAM-3.
The relative affinities of the three ICAMs for LFA-1 also differs
markedly, with ICAM-1 having the greatest affinity for its ligand, ICAM-2
and ICAM-3 having similar but lower affinities (de Fougerolles and
Springer 1992). The existence of three ligands for LFA-1, the differing
tissue distribution, the relative affinities and the varying control of
expression by various cytokines indicates specialization for the various
aspects of LFA-1 dependent leucocyte interactions. ICAM-1 is basally
expressed on endothelium and many epithelial cell types (Springer 1990).
The expression of ICAM-1 is strongly induced by a variety of cytokines,
including IL-1, IFNy and TNFa identified with the inflammatory response,
and is therefore hypothesized to regulate cell localization and facilitate
specific antigen recognition (Altmann et al 1989. Siu et al 1989). Retinoic
acid has also been shown to regulate the expression of ICAM-1 on a
variety of human tumour cell lines (Bouillon et al 1991). This finding is of
particular interest as retinoic acid is known to exert a variety of effects on
the growth and differentiation of normal and neoplastic cells (Sporn and
Roberts 1983). However, as the maximal induction of ICAM-1 required 4
days it is possible that retinoic acid mediates its action via secondary
cytokines. The expression ofmany other adhesion molecules is regulated
by such cytokines. The cytokines IL-1 and TNFa regulate the expression
of vascular adhesion molecule-1 (VCAM), the ligand for VLA-4 expressed
by leucocytes (Osborn et al 1989).
The predominant ligand for LFA-1 on resting endothelium is ICAM-
2. This adhesion pathway may have consequences for the recirculation of
LFA-1 expressing lymphocytes through endothelium (Hamann et al 1988.
Mackay et al 1990). As mentioned above, ICAM-3 is highly expressed by
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leucocytes, thus Springer et al (1992) postulated an important role for
ICAM-3 in the initiation of an immune response.
1.5.4 The mechanisms ofaction ofLFA-1
The interaction of LFA-1 with its known ligands is an intricate and
highly regulated process. LFA-1, and other integrins, mediate cell adhesion
in an energy and temperature dependent process which requires an intact
cytoskeleton (Dustin and Springer 1988). Molecular studies of the integrin
genes has revealed the presence of three or four potential cation binding
sites on the various alpha chains, the significance of which will be
discussed. Interestingly, it would appear that expression of LFA-1 alone is
not sufficient to permit the interaction with ligand to occur as resting
lymphocytes fail to adhere spontaneously yet express high levels of LFA-1.
Two main processes would appear to be involved in the activation of LFA-1
from an inactive to an active form. Firstly, the avidity of LFA-1 can be
modulated by treatment with agents such as phorbol ester which causes
capping of the antigen (Kupfer and Singer 1989). Phorbol myristate
acetate (PMA) treatment, therefore, strongly induces LFA-1 dependent
cell adhesion (Rothlein and Springer 1986). Following treatment with
PMA, the co-distribution of LFA-1 and talin has been reported. The
cytoskeletal component of the cell would appear to be important in the
function of integrins, as disruption ofmicrofilaments with cytochalasins
inhibits leucocyte LFA-1 function (Martz 1987).
The second form of control for functionally active integrin would
appear to be independent of avidity. When molecules such as CD2 and
CD3 are cross-liked with monoclonal antibodies, intracellular signals are
transmitted through the cell, across the membrane to the LFA-1 molecule
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resulting in an altered extracellular function (Van Kooyk et al 1989). Such
activation via CD2 or CD3 is thought to involve the metabolism of inositol
phospholipids, thereby activating protein kinase C (PKC), a further
mechanism by which PMA is thought to increase LFA-1 dependent
functions (Pantaleo et al 1987. Imboden and Stobo 1985). PMA has been
demonstrated to phosphorylate the cytoplasmic tail of the LFA-1 (3-chain
(Chatila and Geha 1988). This may induce a conformational change in
LFA-1 thereby modifying its affinity for ICAM (Alexander and Cantrell
1989).
The work of two independent research groups lead by Hogg and
Figdor have done much to elucidate the possible mechanisms of the
activation of LFA-1 from its "off' to its "on" state/s (see Figure 6). Two
monoclonal antibodies have served as key tools in the dissection of LFA-1
activation, namely mAb24 and NKI-L16 (Dougherty et al 1988. Keizer et
al 1988). Both monoclonal antibodies identify epitopes on the CD 11a
molecule, however, the mAb24 also binds to epitopes on the CD lib and c
molecules (Dransfield and Hogg 1989. Dransfield et al 1990). Binding of
the NKI-L16 monoclonal to its epitope on LFA-1 would appear to require
the presence of calcium ions. In the absence of calcium, the L16 epitope is
not expressed and LFA-1 dependent binding is abolished. Upon binding of
the NKI-L16 monoclonal antibody to LFA-1, LFA-l-dependent adhesion is
stimulated rather than inhibited. This novel function would appear to be
due to a change in conformation and has kinetics similar to those induced
by PMA, suggesting the mechanism of action of PMA involves a
conformational change (Keizer et al 1988). Resting PBL express LFA-1
but virtually lack expression of the L16 epitope (Keizer et al 1988. Van
Kooyk et al 1991). However, following 3-12 hours of stimulation with either
PMA or IL-2, the L16 epitope is expressed. Although such cells will now
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L16- L16- L16+ L16+ L16+
24- 24- 24- 24+ 24+
Inactive Inactive Active Active Active
Low affinity High affinity High affinity
A model of the activation of LFA-1 from inactive to fully active form based on
information from Figdor, Hogg and Dransfield. In its "off' state, LFA-1 does not
have cations bound to it and fails to express the L16 (0 ) or 24 (I) epitopes.
Following binding by calcium the L16 epitope is expressed and interaction with
ligand may occur, all be it at a relatively low affinity. Binding by magnesium
ions (or possibly manganese) causes conformational changes leading to expression
of the 24 epitope and high affinity binding of ICAM.
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acquire the ability to aggregate, the expression of the L16 epitope would
appear to be a prerequisite but not sufficient for LFA-1 dependent
functions. This is well illustrated by the fact that NK cell clones express
high levels of L16 but do not spontaneously aggregate (Dustin and
Springer 1989). The L16 antibody maymaintain the LFA-1 molecule in an
active state, thereby increasing LFA-1 dependent adhesion.
In contrast to the L16 antibody, the mAb24 antibody inhibits
leucocyte integrin-dependent functions (Dransfield et al 1992a). The alpha
chain of LFA-1 contains three divalent cation binding sites in domains V,
VI and VII. Expression of the mAb24 epitope is Mg2+ dependent and
parallels receptor activity. Furthermore, the binding of ligand by LFA-1 is
dependent upon the presence of divalent cations, in particular Mg2+ (Marlin
and Springer 1987). Therefore, control of LFA-1 affinity may be achieved
by the binding of divalent cations such as calcium and magnesium. The
epitope recognized by the mAb24 may be one of the three cation binding
sites mentioned previously, as its expression is magnesium dependent.
The use of calcium chelating agents such as EGTA have shown that in the
presence of Ca2+, the 24 epitope is not expressed (Dransfield and Hogg
1989). In contrast the L16 epitope, once expressed, cannot be reverted to
L16 negative. However, at suboptimal concentrations ofMg2+, Ca2+ may
synergize leading to increased binding (Marlin and Springer 1987). The
relative affinities ofMg2+ binding by LFA-1 is low when compared to Ca2+,
however, ImM Ca2+ does not affect the binding ofMg2+ dependent mAb24
(Dransfield et al 1992b). Unfortunately, the relationship between L16 and
24 expression has not been fully dissected. It remains to be determined
whether the expression of one epitope induces the other.
When the interaction between T-cells and ICAM-1 was studied in
the presence and absence of mAb24 a prolongation of the initial adhesion
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phase was observed in the presence of the antibody, thus suggesting that
mAb24 may act to stabilize the LFA-l/ICAM-1 interaction and prevent
the dissociation of these two receptors (Dransfield et al 1992a). Therefore,
rather than blocking adhesion in the traditional manner of neutralizing
antibodies, mAb24 would appear to "lock" the LFA-1 molecule around its
ligand.
It would seem therefore that LFA-1 exists in a variety of forms; an
inactive form, in which state it is unable to interact with ligand, a fully
active form possibly expressing both the L16 and 24 epitopes, and
intermediate forms which may be capable of limited interaction with
ICAM. The reasons for this remain unclear, however several possibilities
exist. The functions of leucocytes which require adhesion include antigen
presentation and the delivery of cytotoxic hits. Once initiated or
completed, it would be beneficial for the leucocyte to detach. Therefore,
some regulatory mechanism is required to mediated adhesion and de-
adhesion. As for the function of the intermediate forms of LFA-1 these
may serve to mark cells which have previously been activated and are
therefore of potential use in an inflammatory response, see for example
Haskard et al (1986).
In conclusion, the expression of LFA-1 by leucocytes is not sufficient
for its function in ligand binding, rather, changes must occur which will
modify both its avidity and, perhaps more importantly, its affinity for
ICAM. Furthermore, the expression of either the L16 or 24 epitope is not
sufficient to initiate adhesion. The interesting observations made with
NKI-L16 and mAb24 have provided essential and intricate data, in that
NKI-L16 increases the activity of LFA-1 and mAb24 decreases LFA-1
dependent processes, yet does not interfere with the binding of LFA-1 to its
ligand. However, as mAb24 has been shown to prevent the de-adhesion
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process necessary for re-adhesion to further target cells, this may be the
mechanism for the inhibition of LFA-1 dependent processes.
1.5.5 The role of intercellular adhesion molecule-1 in tumour biology
The expression of adhesion molecules which serve as counter
receptors for immunologically relevant cells (such as LAK cells) by a
tumour may at first glance appear to decrease the chances of survival for
that particular tumour. However, recent studies have correlated ICAM-1
expression with an increased propensity for tumour to metastasise
(Natalie et al 1990). In this study metastatic tumour was found to
express higher levels of ICAM-1, and in primary lesion ICAM-1 expression
was higher on cells which had undergone malignant transformation. One
possible mechanism by which ICAM-1 expression might lead to
metastasis is by the interaction with leucocytes lessening the homotypic
cohesion between neighbouring tumour cells (Johnson et al 1989). Further
lines of evidence for a negative role of ICAM-1 in tumour invasion come
from studies involving soluble ICAM-1 (Becker et al 1991). It has been
shown that following stimulation with IFNy and TNFa, shedding of cell
surface ICAM-1 takes place. This soluble ICAM-1 in turn is able to block
LFA-1 on leucocytes, thus inhibiting LFA-1 dependent processes. Other
studies have correlated increased levels of circulating ICAM-1 with the
presence of metastatic cancer, patients with primary lesion alone having
significantly lower levels (Tsujiska et al 1991).
In contrast to the above data, Vanky et al have provided evidence
that the metastasis of human tumours is less common when MHC class I
antigens and ICAM-1 are highly expressed (Vanky et al 1990).
Furthermore, a high incidence ofmetastasis was noted when the levels of
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MHC class I were high, and ICAM-1 low. In the light of this evidence it is
likely, as for other parameters, that ICAM-1 expression by tumour cells
has differing relevance to disease progression depending upon the tumour
type, size, and the environment within which it exists.
Recent studies have shown that retinoic acid is able to regulate the
expression of ICAM-1 on various tumour cells in vitro (Bouillon et al 1991).
In this study, treatment of four human tumour cell lines (glioma,
melanoma, neuroblastoma and teratocarcinoma derived) with 10pM all-
trans retinoic acid resulted in significant increases in ICAM-1 expression.
These increases were comparable with those obtained using lOOUml-1
IFNy, however the time course of induction was different. Induction with
IFNy took 24 hours and induction with retinoic acid required 96 hours of
continual stimulation. A group of nuclear retinoic acid-inducible trans¬
acting transcription-enhancing retinoic acid receptors have been
discovered (Mangelsdorf et al 1990). These receptors serve as
transcription factors, mediating response by directly binding to the
promoter regions of responsive genes. However, it is unlikely that such
elements are involved in the described regulation of ICAM-1 as the kinetics
of up-regulation are slow. Rather it is possible that autocrine growth
factors are induced which in turn may stimulate ICAM-1 expression.
Retinoids (analogues and derivatives of retinol, vitamin A) have been
employed in the treatment of bladder cancer with limited success.
However, the role of adhesion molecules such as ICAM-1, and its
regulation in response to intravesical chemo- and immunotherapy remain
to be determined in bladder cancer.
1.6 Currentproject
84
The interaction ofhost immune cells with the tumour cell is vital for
the detection and immune mediated eradication of cancer. As has been
mentioned, there are several mechanisms which may be utilized by the
tumour in order to prevent recognition by surveying cells of the immune
system, thus emphasizing the importance of this interaction.
The most successful form of immunotherapy for any solid human
malignancy is found in the treatment of superficial bladder cancer.
Intravesically administered BCG organisms would appear to cause an
acute immunologically based reaction, leading to the infiltration of the
bladder wall with T-cells, neutrophils, and monocytes, the production of a
variety of cytokines, the modulation of the phenotype of the bladder
tumour and the eventual eradication of the cancer. However, despite these
observations, little is known concerning the mechanisms of action of BCG.
A greater understanding of these processes would perhaps allow the
prediction of responders and non-responders, improvement of therapeutic
regimens for greater efficacy, and the development of novel
immunotherapeutic strategies for the treatment of human cancer.
Furthermore, an increased understanding of the role of leucocytes in the
anti-tumour response should lead to more effective manipulation of the
hosts immune system.
1.6.1. The strategy and experimental approach employed
The aims of these studies were to investigate the role of LAK cells in
the mediation of cytolysis of bladder cancer targets, and to elucidate the
mechanisms of action of intravesical BCG in the treatment of bladder
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cancer. The ideal outcome of this work would be a better understanding of
immunotherapy for the treatment of malignant disease and an improved
treatment regimen tailored for each patient.
In order to achieve these objectives a tissue culture model ofbladder
cancer was established using well characterized human transitional cell
carcinoma cell lines. These cells were established by Drs. P. Perlmann and
J. Masters, during the process ofwhich much was learned of their nature.
Several of the cell lines used, in particular RT4, RT112 and MGH-U1 (also
termed T24) have been the subject of much attention throughout the
world. Although this model is far removed from the situation in vivo, the
cell lines are representative of their parent tumours and in order to
minimize biological drift were used for only a limited number of passages.
The programme ofwork was as follows:
t The sensitivity of bladder cancer cells to natural and
cytokine enhanced cellular cytotoxicity. The interaction of LAK cells with
bladder cancer cells has not previously been investigated. This area of
investigation was a necessary forerunner to further dissection of the
mechanism of action of LAK cells. Some of the parameters which were
deemed important in the generation of LAK cells were investigated.
t The expression and modulation ofadhesion molecules. As
LAK cell mediated cytotoxicity most probably requires an intimate
contact between effector and target cells, the expression of various
adhesion molecules on both cell populations was investigated. Earlier
studies by Hawkyard et al (1991) had demonstrated the phenotypic
response of bladder cancer cells to various cytokines. Therefore, the
influence of various cytokines (namely IFNy) on the expression of certain
inducible adhesion molecules was investigated.
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t Functional evaluation of the role of adhesion molecules in
LAK mediated cytotoxicity against bladder cancer cells. With the aid of
monoclonal antibodies (kindly provided by Dr. T. A. Springer) and a variety
of techniques, a functional dissection of the role of cytokines and adhesion
molecules in the LAK mediated cytolysis of bladder cancer targets was
undertaken.
t The expression and function of interferon-gamma receptors.
As the cytokine IFNy had previously been shown to be present in the urine
of patients receiving BCG therapy (Prescott et al 1990), and to upregulate
the expression of HLA class II molecules by bladder cancer cells
(Hawkyard et al 1991), a study was made of the receptor for IFNy. Using
Scatchard analysis, the dissociation constant (K^) and the number of
receptors per cell was determined for a number of cell lines with differential
responses to IFNy. Furthermore, the kinetics of ligand binding to specific
receptor were investigated.
t The signal transduction of the interferon-gamma receptor.
As differences in the response of cells to IFNy could not be explained by the
receptor status, and were therefore deemed to be due to events down¬
stream of the receptor/ligand interaction, a pharmacological investigation
was made into the nature of the signal transduction mechanism for IFNy.
t The relationship of in vitro studies to the situation in vivo.
As this work is concerned with the disease of bladder cancer, it was
considered essential to relate some of the in vitro findings to the in vivo
situation. Therefore, the expression of adhesion molecules such as ICAM-
1 was studied in tumour biopsy material. The biological effects of urine
obtained from patients receiving intravesical BCG therapy were also
investigated in the tissue culture model. Furthermore, the secretion of
various cytokines into the the urine in response to BCG organisms was
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quantified, and a novel parameter, namely the secretion of soluble ICAM-1
into urine, was also investigated.
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2 Materials and Methods
2.1 Tissue Culture
All manipulations involving tissue culture were performed in a class
II laminar flow safety cabinet (Envair Ltd). Cells were cultured in
complete medium (RPMI 1640 (Gibco) supplemented with 5% foetal calf
serum (FCS) (Sera-Lab), sodium pyruvate (5mM) and L-glutamine (2mM)
(both Gibco), unless otherwise stated. FCS was first heat inactivated by
warming to 56°C for 1 hr prior to addition to RPMI medium. In
experiments requiring serum free media, HB103 media was used (NEN).
The cells were incubated and grown at 37 °C in a humidified atmosphere of
5% C02 in air.
2.2 Bladder tumour cell lines
Eight human transitional cell carcinoma (TCC) cell lines were used
throughout these studies. These cells were the generous gift of Dr. J.
Masters of the Institute of Urology, London, Dr. P. Perlmann, Stockholm,
Sweden and Dr. J. Boyd, University of Edinburgh, UK. All cell lines were
tested mycoplasma free by the Public Health Laboratory Service, Porton
Down, UK. The panel of cell lines represents various histopathological
tumour grades as detailed in table 2. The cells have proved to be stable
and their cytological appearances and growth characteristics have
remained representative of the parent tumours. In order to minimize
biological drift, cells were used for only a limited number of passages (n=10)
before they were discarded and early passage number stocks re-cultured.
For routine culture, cells were seeded at a density of 5xl04ml1 and
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Eight cell lines were used throughout these studies. They were derived from
human transitional cell carcinoma of the bladder. The table gives the grade of
the parent tumour and that of the cell line (as determined by a consultant
histopathologist). G1 represents well differentiated cells. G2 represents
moderately differentiated cells. G3 represents poorly differentiated cells which
least resemble the tissue of origin. These cell lines were kindly provided by Dr.
J. Masters and by Dr. P. Perlmann.
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cultured in antibiotic free complete medium in 25cm2 tissue culture flasks
(Sterelin). Cells were recovered for routine purposes by washing the
monolayer with phosphate buffered saline (PBS, Dulbecco A) and then
trypsinizing using 1ml trypsin/EDTA solution (0.5 gl_1 trypsin and 0.2 gl1
disodium EDTA (Sigma Chemical Co) for every 25cm2 of tissue culture
plastic. Immediately following detachment of the cells, 10ml of complete
medium was added to the cell suspension in order to neutralize the trypsin
and saturate the EDTA. For some experiments tumour monolayers were
released without the aid of trypsin by using 0.02% EDTA solution in PBS
for 15 minutes.
2.3 Isolation ofperipheral blood mononuclear cells
Peripheral blood was obtained from patients and normal healthy
laboratory volunteers using a 19 gauge needle. Mononuclear cells were
then isolated from the fresh, heparinized peripheral blood. Blood was
diluted with em equal volume of PBS and layered onto one third the volume
of Ficoll-Isopaque (density = 1.086 gem3) and centrifuged for 30 minutes at
400xg. Following centrifugation, the upper phase was carefully removed
and discarded. The interface was collected and subsequently washed three
times in magnesium free Hanks balanced salt solution (HBSS) (Gibco).
Adherent cells were removed by culture of the washed interface in 75cm2
tissue culture flasks for 1-2 hr. at 37°C. The non-adherent cells were
recovered, counted and re-suspended at a density of lxl06ml1 in complete
medium. Cells not required for immediate use were frozen in liquid nitrogen
as described below.
2.4 Cell freezing, storage and thawing
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Cells obtained from peripheral blood, fresh tumour samples, bladder
cancer cell lines and other cell lines were stored in a liquid nitrogen filled
vivo-stat. Washed cells were re-suspended at 2x10 6ml1 in 90% foetal calf
serum containing 10% dimethlysulphoxide (DMSO). Aliquots of 1ml were
placed in freezing vials (Gibco) and these placed in polystyrene boxes. The
boxes were transferred to a -70 °C ultra low temperature freezer overnight
prior to long term storage in liquid nitrogen until required (-196°C).
Cells were recovered from long term storage by rapid thawing to
37°C in a water bath. The 1ml aliquot was then washed twice with
complete medium in order to remove any cell debris and DMSO. Using dye
exclusion the viability of each vial was assessed prior to culture. Vials with
a cell viability of less than 95% were discarded.
2.5 Cytokines
The cytokines used during these studies were of the highest
obtainable quality. All cytokines were human recombinant E. coli. derived
and ofhigh purity containing less than 2 endotoxin units per mg of cytokine
protein, unless otherwise stated. The details of their specific activity,
source and unit definition are as follows;
Interleukin-1 alpha (IL-la);
Recombinant IL-1 was obtained from British Biotechnology Ltd.
and contained 5x108 Umg-1 protein. One unit was defined as the quantity
of IL-1 required to produce 50% maximal tritiated thymidine incorporation
in the mouse helper T-cell line D10.G4.1.
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Interleukin-2 (IL-2);
Recombinant des-alanyl-1, serine-125 IL-2 was generously provided
by Euro-Cetus B.V. and contained 1.8xl07Umg1 protein designed for
clinical administration. One unit was defined as the amount of IL-2
required to produce half-maximal tritiated-thymidine incorporation in
cultured HT-2 cells.
Interferon-alpha 2a (IFNa2a);
Recombinant IFNot was the generous gift ofDr. S. Langden, ICRF,
Edinburgh, and contained 2x10 7Umg-1 protein. One unit was defined as the
quantity required to produce equivalent anti-viral activity to that
expressed by 1 unit ofNIH reference standard.
Interferon-gamma (IFNy);
Recombinant human IFNy was purchased from Boehringer
Mannheim and contained 2.5x107Umg-1 protein. One unit was defined as
the amount of IFNy required to produce equivalent anti-viral activity to 1
unit ofNIH reference standard Gg 23-901-530.
Tumour Necrosis Factor-alpha (TNFa);
Recombinant human TNFa was the kind gift of Behringwerke and
contained S.lxlO^Umg-1 protein. One unit was defined by the half-
maximal cytotoxicity against the murine fibroblast cell line L929 in the
presence of actinomycin-D.
Transforming Growth factor-beta2 (TGFJ32);
Recombinant TGF(3 was purchased from Genzyme Corp and
contained Umg-1 protein. One unit was defined as the quantity of TGFp
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required to produce 50% maximal tritiated thymidine incorporation into the
mink lung epithelial cell lineMvlLu
2.6 Generation ofLAK cells
Non-adherent peripheral blood mononuclear cells (PBMC) were
cultured at a density of lxl06ml1 in complete medium. LAK cells were
generated by the addition of exogenous recombinant IL-2 (and other
cytokines) at concentrations up to ljOOOUml1. The mononuclear cells
were incubated at 37 °C in a humidified atmosphere of 5% C02 in air for up
to 6 days. After the incubation the cells were washed twice in HBSS and
resuspended at 4xl06ml1 and assessed for cytolytic activity against
labelled target cells.
2.7 Cytotoxicity Assay
Cytotoxicity was measured by means of a 4 hour chromium-release
assay. In brief, 106 target cells were radiolabelled with 100 [iCi Na125lCr04
(Amersham International) at 37 °C for 1-hr with shaking. After three
washes in HBSS the targets were resuspended in RPMI 1640 at a density
of 5xl04ml1. Labelled targets (5xl03well1) were dispensed into the wells of
96-well U-bottomed microtitre plates (Sterilin Ltd) and then graded
numbers of effector cells were added to give effector-to-target ratios (E:T)
ranging from 40:1 to 1.25:1 in a total of 200(il of medium. The
spontaneous release of chromium from labelled target cells was
determined by culture in the absence of effector cells for the duration of the
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assay. Maximal release was determined by the addition of 1M sodium
hydroxide to labelled targets. After a 4 hr. incubation at 37°C and
centrifugation at lOOxg for 5 minutes, 100 fil of supernatant was removed
from each well and the radioactive content determined using a liquid
scintillation counter (Canberra Packard Ltd). All assays were performed
in triplicate and the data were calculated from E:T of 40:1 in order to allow
comparison between lines of differing susceptibility. Results were
expressed as the percentage specific cytotoxicity, calculated as below;
%Specific Cytotoxicity = cpm exp release - cpm spontaneous release
cpm total release - cpm spontaneous release
The natural killer (NK) cell sensitive target K562, an
erythroleukaemic cell line, was used as the positive control for NK activity
resident in PBMC. The B lymphoblastoid cell line, Daudi, which is
insensitive to NK activity was used as the positive control for LAK
activity.
2.8 Preparation ofmononuclear cells from human spleen and lymph nodes
The spleen and mesenteric lymph nodes were removed from
cadavers who had been selected as multi-organ donors. Tissue was placed
in sterile PBS for transfer to the laboratory. Connective tissue was first
removed from the organ following which slices of tissue were placed in a
petri dish and sin-plus blood removed by washing with PBS. Using a pair of
19 gauge needles the tissue was gently teased apart and minced until a
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fine unicellular suspension was obtained. Large pieces of tissue were
discarded and the suspension of cells layered onto a ficoll density gradient
as described for the preparation of PBMC. Cells harvested from the
interface were washed and stored frozen until required.
2.9 Source ofMonoclonalAntibodies
For details of antibody specificity and source see table 3. For flow
cytometry, monoclonal antibodies which were not directly conjugated to a
fluorochrome were detected using a goat anti-mouse-IgG F(ab')2 fragment
fluorescein isothiocyanate (FITC) conjugate (Sigma Chemical Co).
2.10 Fluorescence Staining & Flow Cytometric Analysis
Single and dual colour immunofluorescence was performed on cells
stained indirectly or directly with monoclonal antibodies conjugated to
either fluorescein isothiocyanate (FITC) or PE (phycoerythrin). For each
analysis 1x105 cells were washed with washing buffer (PBS, 1% FCS,
0.01% sodium azide) and incubated at 4°C for 30 minutes with optimal
concentrations of primary monoclonal antibody. Following two washes by
centrifugation, the binding of unconjugated monoclonal antibodies was
detected using a sheep anti-mouse-FITC conjugate for a further 30
minutes at 4°C. Cells to be stained for two colour analysis were then
blocked with a 10% (v/v) solution of normal mouse serum for 30 minutes
and, after washing, incubated with a second monoclonal antibody
conjugated to PE for a further 30 minutes. The cells were washed twice
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CD2 - I 1:50
CD3 - I 1:50
CD4 - I 1:50
CD8 - I 1:50
CDlla LFA-la II 1:50
CD16 FcylllR III 1:100
CD18 LFA-ip II 1:50
CD22 - I -
CD25 IL-2R III 1:100
CD54 ICAM-1 IV 1:200
CD56 NCAM II 1:50
ICAM-2 - IV 1:100
EGF-R - V 1:400
MHC class I - II 1:50
MHC class II - VI 1:64
VCAM - VII 1:50
IFNy* - VIII -
TNFa* - VIII -
The table provides details of the monoclonal and polyclonal (*) antibodies used in the
studies. The name of the antigen and alternative name (if any) is given. The sources
of the antibodies are as follows; I - Scottish antibody production unit, II - Dako, III -
Becton Dickenson, IV - Dr. T. A. Springer, V - Genzyme, VI - Dr. I. Trowbridge, VII
- British Biotechnology, VIII - Dr. A. Meager (NIBSC). Also shown is the dilution of
monoclonal antibody which was used for flow cytometric staining procedures.
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more and resuspended in 1% para-formaldehyde prior to analysis using a
flow micro-fluorometer (Coulter). Non-viable cells were gated out of the
window and at least 10,000 events were accumulated by using logarithmic
amplification of fluorescence intensity.
2.11 Isolation offresh tumour cells
Viable tumour cells were obtained from bulky fragments selected
from cytoscopically resected bladder tumours. Debris and blood clots were
first removed and the tumour was washed with PBS. Soft, friable,
papillary tumours were gently teased apart using tweezers and scissors
until a unicellular suspension was formed. The larger fragments were
allowed to settle-out and the single cell suspension was layered onto ficoll in
the manner described for the preparation of PBMC. Cells at the interface
were collected and washed and stored frozen until required. Cytospins of
these cells were examined by a consultant pathologist and deemed to
consist almost entirely of tumour cells.
2.12 Dyes
Target cells were labelled with the dye hydroethidine (HE)
(Molecular Probes). After penetration of the cell HE is enzymatically
oxidised and intercalated into DNA as a red dye. The maximum emission
wavelength of intercalated ethidium is 610 nm. HE was prepared as a
stock solution of 253mM in N, N-dimethyl acetamide and stored at 4°C
protected from the light. On the day of assay, a working solution was
prepared by diluting the stock solution 1:1000 in PBS. Since this
concentration was close to saturation, the solution was filtered through a
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0.22(im membrane to remove precipitates.
Effector cells were labelled with the stain carboxyfluorescein
diacetate acetoxymethylester (CFDA.AM) also from Molecular Probes.
CFDA. AM is a vital stain and a pH probe (pKa=6.4) which stains the cell
cytoplasm green. Esterified CFDA.AM produces a fast cell staining which
is enzymatically modified within the cell by esterases. The maximum
emission wavelength for CFDA is 520nm. The stock solution was 2.5mM
in DMSO and was stored at 4°C in the dark. Working solution was
prepared by diluting 1:40,000 in PBS. Both dyes can be excited at a
common wavelength (488nm) using a single argon laser.
2.13 Staining procedure
Target and effector cells were washed and resuspended at 2xl06
cells ml1 in the working solution of the appropriate dye (HE: 253pM,
CFDA.AM: 62.5nM). The cells were incubated for 30 minutes at 37°C with
agitation every 10 minutes. Staining was stopped by washing twice in
PBS. The final wash was performed in the assay buffer of choice and cell
concentrations were adjusted to the yield appropriate effector to target
ratios. Labelled cells were stored at 20°C protected from the light.
2.14 Quantification ofeffector/target conjugate formation
Conjugates were formed by mixing lOOpl each of effector and target
cells in a 0.5ml eppendorf tube, pelleting rapidly by centrifugation and
vigorously resuspending using a vortex machine. The ratio of effector to
target cells was maintained at 10:1. The formation of conjugates was
assessed immediately after pelleting (t=l) and at 5 minute intervals
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thereafter by flow cytometry. Control for background conjugation was
performed by mixing effector and target cells without pelletting (t=0). In
all controls the number ofbackground conjugates recorded was low, usually
<2% of the experimental conjugates. Further controls involved the
analysis of effector or target cells alone. Finally, the extent of homophyllic
conjugation was determined by assaying effector or target cells, part of
each cell type being stained with HE and the other part with CFDA.AM.
2.15 Flow cytometric analysis ofconjugate formation
Flow cytometric analysis was performed using an EPICS-C flow
cytometer (Coulter) operating at 488nm and 200mW output. A 70|im
aperture was used with a low differential pressure between sheath and
sample. Three different parameters were studied; namely forward angle
light scatter, red and green fluorescence. The forward angle light scatter
was used to trigger analysis and to gate all other signals from debris
smaller than lymphocytes. Controls with stained target and effector cells
were performed separately to check the settings of the photomultiplier
tube gains.
Analysis was performed and halted when 1,000 target events (red)
were recorded. The quantification of conjugate formation based on a fixed
number of target cells at a standard effector to target cell ratio was a
fundamental element of the procedure.
2.16 Antibody blocking studies
Labelled effector and/or target cells were pre-incubated with
monoclonal antibodies ((Siigmk1) at 20°C for 30 minutes) to various
100
adhesion molecules prior to the formation of conjugates by centrifugation.
Control reactions were performed with an irrelevant monoclonal antibody
(anti-CD22).
2.17 The role ofdivalent cations and energy dependent processes
The role of various divalent cations in the formation of conjugates
was assessed using calcium, magnesium, and manganese chloride
dissolved in 0.15M NaCl. EGTA and EDTA (both ImM in 0.15M NaCl)
were used to chelate calcium ions and other divalent cations from the
assay buffer of choice. Immediately following the addition of either EGTA
or EDTA to the conjugation buffer, conjugates were formed by
centrifugation. The medium removed and replaced by PBS containing
1%FCS.
In addition to cation chelation, varying concentrations of divalent
cation chloride solutions were added to the conjugation buffer prior to
centrifugation to give final concentrations ranging between 0.1 and 16 mM.
Sodium azide was also briefly added to the conjugation buffer at a
concentration of 0.1%. Following centrifugation, the cells were
resuspended in PBS containing 1% FCS.
2.18 Source ofcytokines used in receptor studies
Highly purified recombinant mono-iodinated IFNy was purchased
from Amersham International and had a specific activity of approximately
760Ci mmol*1. The precise specific activity of each batch of radio-ligand
was determined prior to each assay. The percentage of free iodine in each
batch of radio ligand was determined by thin layer chromatography. The
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percentage free iodine was never greater than 2.5%. Radioligand was
discarded ifnot used within four weeks of the date ofmanufacture.
2.18 Determination ofoptimal number ofcells
The number of cells in each assay was fundamental to the
sensitivity and accuracy of the subsequent Scatchard analysis. Cell
monolayers were dispersed using 0.02% EDTA for 15 minutes. For each
cell line to be examined, varying numbers of cells ranging from 104-106
were placed in plastic RT30 tubes in triplicate. To each triplicate 0.3ng
radioligand was added and allowed to equilibrate for 4 hours at 4°C.
Following incubation the cells were washed with washing buffer (HBSS,
0.1% BSA (Sigma)) and the pellet associated radioactivity measured on a
multi-gamma counter (LKB).
2.19 Determination ofoptimal number ofwashes and optimal time
The optimal number of washes was investigated in order to
maximize the difference between the non specific binding and the specific
binding. Triplicate tubes containing 2xl05 cells were incubated for varying
durations with 0.3ng of radioligand in the presence and absence of a 100
fold excess of unlabelled ligand. Following incubation at 4°C, the cells were
washed repeatedly with washing buffer. The radioactive content of each
tube was determined following each wash.
2.20 Positive and negative controls for binding studies
In order to confirm the specificity of the assay technique used,
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positive controls in the form of human Daudi cells which had previously
been assessed for IFNy receptor expression were used. The negative
control cells were normal human erythrocytes which were presumed not to
bear the IFNy receptor.
2.21 Competitive binding experiments
Competitive binding experiments were carried out in plastic RT30
tubes. Cell monolayers were washed with PBS before incubation with
0.02% EDTA for 15 minutes. Trypsin was not used as damage to receptor
structures may have occurred. Released cells were washed and
resuspended at 4x10 5mH and incubated for the indicated times in binding
medium (complete medium) in the presence of a fixed concentration of
radiolabelled IFNy and increasing amounts of unlabelled IFNy for 2 hours
at 4°C. The total reaction volume was 500fj.l and the concentration of
radioligand was 0.3ng/ml. Non-specific binding was determined in the
presence of a 100 fold excess of unlabelled ligand. Binding was terminated
by washing the cells twice with ice-cold washing buffer. Cell bound
radioactivity was determined using a gamma-counter. Each experiment
was performed in triplicate.
The binding data were analyzed and calculated manually. Binding
curves and subsequent Scatchard plots were drawn using Cricket Graph
software. The correlation coefficients of Scatchard plots were always
significant to between the p<0.01 and p<0.001 level. Using a linear
regression of the Scatchard plot, analysis of the number of binding sites
per cell (Bmax) and the dissociation constant (Kd) was carried out assuming
that the molecular moieties of IFNy which bound to the cells were dimers
of molecular weight 34,400 Da, thereby giving a minimal estimate of the
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receptor density. If the monomeric form was to bind, the number of
binding sites per cell would simply be doubled. All experiments were carried
out a minimum of 6 times and the results expressed represent the mean ±
standard deviation.
2.22 Determination ofsurface associated and internalized ligand
To monitor the rate of internalization of IFNy, 2xl05 cells were
incubated, either in suspension or as adherent monolayers, with
approximately 0.3ng of 125I-labelled ligand at 37°C. Binding was
terminated by washing the cells twice at 4°C with washing buffer. Cells
were then incubated for 4 minutes at 4°C with 0.5M NaCl (titrated to pH
2.5 with acetic acid) in order to "strip" the membrane associated (acid-
dissociable) ligand. The cells were then centrifuged and the supernatant
and pellet associated radioactivity determined separately. The radioactive
content of the pellet was assumed to be due to internalized ligand.
2.23 Reagents for experiments concerning signal transduction
Fura-2AM, PMA, calcium ionophore A23187, ionomycin, H-7 (l-(5-
isoquinolinylsulfonyl)-2-methylpiperazine), W-7 (N-(6-aminohexyl)-5-
chloro-l-naphthalenesulfonamide), Diltiazem, TMB-8 (8-(diethylamino)-
octyl 3, 4, 5-trimethoxybenzoate hydrochloride), Digitonin, EGTA, and
staurosporine were purchased from Sigma Chemical Co. and were of the
highest obtainable grade.
2.24 Induction ofMHC class II and ICAM-1 molecules
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Bladder cancer cells were cultured in 24-well, flat bottomed culture
plates (Costar) at 2xl05/well at 37°C in a humidified atmosphere of 5%
C02 in air. IFNy was used at a concentration of 500Uml_1 for 48 hrs and
lOOUml"1 for 24 hrs in the case of MHC class II and ICAM-1 induction
respectively. After incubation, cells were washed twice with ice cold PBS
and harvested for analysis of expression of HLA class II and ICAM-1
molecules on their surface.
2.25 Depletion ofextracellular calcium
Cells were cultured in complete medium containing
1 hr before the addition of IFNy. As a control, CaCl2 at
added into the EGTA-containing medium to recover the
calcium to the original concentration in RPMI 1640.
2.26 Measurement offree cytosolic calcium flux
The cytosolic free calcium concentration of human TCC cells was
monitored using the calcium indicator Fura-2AM. The cell lines (lxl06/ml)
were loaded with 5|iM Fura-2AM for 20 minutes at 37 °C. Following loading
the cells were washed twice in HBSS before resuspension in HBSS. TCC
cells (lxl06/ml) were placed in temperature controlled cuvettes with
continuous magnetic stirring. Cells were stimulated with interferon-
gamma and/or various pharmacological agents for 30 minutes at 37°C.
Fluorescence was monitored on a Perkin-Elmer LS-50 spectrofluorometer
with the excitation and emission wavelengths set at 340 nm and 510 nm
respectively. The calcium concentration was determined using a dedicated





The maximum fluorescence was obtained by disruption of the cells with
digitonin and the minimum fluorescence obtained by the subsequent
addition of 5 mM EGTA, pH 8.0 (final concentration).
2.27Detection ofsoluble ICAM-1 in tissue culture supernatants
The presence of soluble ICAM-1 in tissue culture supernatants was
determined using a sandwich ELISA test kit (T-cell Diagnostics). Briefly,
samples of cell-free tissue culture supernatant were incubated in the wells
of a microtitre strip plate for 2 hours. Following washing, the presence of
soluble ICAM-1 was detected using a second monoclonal antibody to
ICAM-1, conjugated to HRP.
2.28Assessment ofthe rate ofproliferation
The growth rate of tumour cell lines in response to various stimuli
was determined by monitoring the incorporation of tritiated (3H) thymidine
into newly synthesized DNA. Cells were seeded and grown in 96-well, flat-
bottomed culture plates until they reached the log phase of growth (48
hrs.). Complete medium was then replaced with medium supplemented
with appropriate concentrations of various cytokines. Subsequently, at
various time points up to 100 hours wells were harvested in sextuplets.
Prior to each harvest, the wells were pulsed for 12 hours with 0.5pCi ofH3-
thymidine (Amersham). Cells were harvested after trypsinization using
an automated cell harvester (Skatron) onto glass fibre filter discs. After
drying, the radioactive content of each disc was determined using a liquid
scintillation counter (Tri-Carb 1900CA, Canberra-Packard).
2.29 Patient details
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Six patients with superficial bladder cancer were treated using six
weekly instillations of intravesical Evans BCG vaccine (formerly Glaxo
strain). Immediately before BCG instillation the bladder was voided.
Each instillation consisted of 1-5x109 colony forming units of BCG
suspended in 60 ml of 0.9% (w/v) saline. The solution is retained for 2
hours in the bladder. Routine cold-cup biopsy were taken for histological
examination before the course began and six weeks after the final
instillation.
2.30 Preparation and storage ofpatients urine
Urine from the twelve hours following each BCG instillation was
collected and processed within 12 hours. The volume of urine was
measured and the pH determined. Cellular debris was removed by
centrifugation at 2,000 rpm for 10 minutes. The cleared sample was then
dialysed through a lOkDa membrane against several changes of
phosphate buffered saline (pH 7.2) overnight at 4°C. The pH of the
sample was determined and the sample was finally filtered through a
0.22pm syringe filter and stored aliquoted at -70°C.
2.31 Preparation offrozen sections ofbladder tumour
Biopsy material and pieces of tissue obtained after cystoscopic
resection of tumour were collected and snap frozen in liquid nitrogen. Five
|im frozen sections were cut at -25°C, air dried overnight and fixed in fresh
100% acetone at room temperature for 2 hours. After further air drying
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they were wrapped in aluminium foil and stored desiccated at -20°C.
2.32 Immunohistochemical method
Frozen sections were recovered from -20 °C storage and rehydrated
with 0.2M tris buffered saline (TBS) pH 7.6 for 10 minutes. Following
rehydration the slide around the section was wiped dry and lOOpl of an
optimal dilution of primary monoclonal antibody was applied over the
section. The slides were incubated at 20°C in a humidified atmosphere for
60 minutes following which they were carefully washed twice in TBS.
Binding of the primary monoclonal antibody was detected using a 1:50
dilution of rabbit anti-mouse immunoglobulin pre-conjugated to horse
radish peroxidase (HRP) (Dakopatts) for 30 minutes. This antibody was
prepared in 10% normal human serum and pre-incubated for 30 minutes
at 20°C. After washing twice with TBS, the slides were flooded with
substrate solution (diaminobenzidine DAB (3mg in 5ml DAB buffer, pH
7.6) (Sigma Chemical Co.) which had been activated with 50pl of 3%
hydrogen peroxide solution in distilled water. After approximately 10
minutes the substrate was removed by washing with TBS and the
sections were lightly counter stained using Mayer's Haematoxylin (BDH
Chemical Co.) for 2 minutes. The counterstain was "blued" by washing in
alkaline tap water (pH 8.0) until all the excess stain had been removed.
The sections were then progressively dehydrated by immersing in 30%,
70% and 100% ethanol solutions for 1.5 minutes each prior to washing in
sulphur free xylene. The sections were then wet mounted using DPX
mountingmedium (BDH).
2.32 Sample preparation for electron micrography
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Cells were grown on plastic slides for 48 hours following which LAK
cells were plated on top and incubated for 30 minutes in a tissue culture
incubator. After incubation the slides were washed with PBS (pH7.2) and
stored in glutaraldehyde. Fixed slides were freeze dried and splutter coated
with gold particles. Samples were scanned and photographed on a Phillips
505 electronmicroscope (Phillips).
2.34 L929 Bioassay for tumour necrosis factor
The murine L929 fibroblast cell line, which is exquisitely sensitive to
the cytotoxic effects of TNF was used to determine the biological activity
ofTNF in urine samples. Briefly, L929 cells were seeded in 96 well plates
and cultured for 48 hours. Standards and samples were then added and
serially diluted across the plate. After a further 48 hours, 10|il of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (lmgml1) was
added to each well and incubated for 2 hours at 37 °C. The supernatant
was removed and replaced with 50pl of acidified isopropanol to dissolve the
blue crystals. After complete dissolving had occurred the optical density
was determined at 490nm and a standard curve constructed from the
results. Test results were interpolated with the standard curve.
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3 Results
3.1 The sensitivity ofbladder cancer cells to natural and cytokine
enhanced cellular cytotoxicity
Although previous workers have demonstrated the ability of LAK
cells to lyse a variety of human tumour targets, little attention has been
paid to urological malignancies, with the exception of renal cell carcinoma.
It was our intention to study the potential killing of bladder cancer cells by
LAK cells and to investigate the role of cytokines in this activity.
3.1.1 Bladder cancer cells are not susceptible toNKmediated lysis
Natural killer cells can mediate the cytolysis of a limited number of
tumour targets in vitro. When established bladder cancer cell lines were
co-incubated with freshly isolated non-adherent PBMC in a standard
chromium release assay, no specific cytotoxicity was observed within the 4
hour assay period. However the NK sensitive K562 cell line was lysed. At
a 40:1 effector to target ratio the observed specific cytotoxicity was
60%±10. On the other hand, the NK insensitive Daudi cell line was not
killed by fresh PBMC.
3.1.2 The dose response and kinetics ofLAKcell induction by IL-2
During the past decade many investigators have examined the
ability of IL-2 activated LAK cells to mediate the cytolysis of a wide
variety of tumour cell in vitro. Central to this project is the susceptibility
of bladder cancer cells (both freshly derived and established cell lines) to
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LAK mediated cytotoxicity. Therefore, the ability of IL-2 activated killer
cells to lyse bladder cancer targets was examined.
Firstly, the influence of varying the ratio of effector to target cell
was investigated. When the effector to target ratio was low (5:1) the was
little detectable cytotoxicity against the majority of the cell lines (Figure
7). However, increasing the effector to target ratio showed the
susceptibility of the different cell lines. At a ratio of 40:1 the differential
susceptibility of the target cells was most evident, therefore, it was decided
that this ratio was most suitable for further experiments. As mentioned,
the target cells were not equally sensitive to LAK mediated cytolysis.
Table 4 shows the maximal achievable specific cytotoxicity against the
eight cell lines. The least susceptible cell line was RT112, with J82 and
UMUC3 being several times more sensitive to the same effector cells. The
histopathological grade of each cell line is also shown in table 4. There was
no apparent relationship between the susceptibility of each line to LAK
mediated killing and the grade of the parent tumour.
Depending on the workers involved and upon the source of
recombinant IL-2 used, the concentration of IL-2 required in order to
generate maximal LAK activity ranges between 1 and l,000Uml_1. The
effect of increasing concentration of IL-2, and the duration of activation on
LAK activity in our studies is shown in Figure 8. After 3 days of culture in
the absence of IL-2, a significant increase in LAK activity above day 0
was evident. Dose dependent LAK activity was also observed following 3
days of continuous activation with IL-2. This activity was maximal when
cells were cultured with 1,00011ml-1 IL-2. Increased LAK activity was
seen following 6 days of activation. Any further increase in either the
concentration of IL-2 or the duration of activation failed to result in a
corresponding increase in lytic potential (data not shown).
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Effector to target cell ratio
The maximal achievable specific cytotoxicity against a panel of eight bladder
cancer cell lines at various effector to target cell ratios. Effector cells were
generated by incubation of PBMC with lOOOU/ml IL-2 for 6 days, these cells
were then tested for their ability to lyse bladder cancer cell lines in a standard
4 hour chromium release assay. Bars represent the mean of at least triplicate
determinations, error bars show standard error. The cell lines tested were;
RT4 01), RT112 (0), MGH-U1 <B), EJ18 0), SD (□), 5637 (■), J82 (M), and
UMUC-3 (H).
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Table 4. The susceptibility of bladder cancer cell lines to LAK
mediated cytolysis
Cell line RT4 UMUC3 RT112 MGHU1 EJ18 J82 SD 5637
Grade G1 G1 G2 G3 G3 G3 G3 G3
Specific 40 76 24 40 65 80 50 61
Cytotoxicity
Shown are the mean results obtained with the standard cytotoxicity assay for
the percent specific cytolysis against eight bladder cancer cell lines. The results
are those obtained with an effector to target ratio of 40:1 and represent the mean
of at least five determinations in triplicate. For the cell lines RT4, RT112,
MGH-U1 and EJ18 the number of determinations exceeded 20.
113


































The dose dependent kinetics of LAK activity induction by IL-2. PBMC were incubated
for the indicated periods with increasing concentrations of IL-2; OU/ml (■), lOU/ml (Q),
lOOU/ml (0), and lOOOU/ml (□). LAK activity was then determined against four
bladder cancer cell lines using a standard 4 hour chromium release assay. Bars
represent the mean of triplicate determinations and error bars represent the standard
error of the mean.
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3.1.3 The variability ofdifferent donors for LAK cells
The cytotoxic potential of LAK cell derived from different donors was
simultaneously assessed against two TCC cell lines (Figure 9). Differences
in the maximum achievable specific cytotoxicity were evident between
cells from different donors. The mean level of specific cytotoxicity against
RT112 (G2) cells was 18.2%±4, and against MGH-U1 (G3) cells 36.6%±3.9.
One donor, number two, had levels of cytotoxicity which were greater than
those achieved by cells from the other donors, however, the difference in
susceptibility between the two lines was maintained.
3.1.4 The effect ofdiffering lymphoid organ sources for LAKcells
The effect of lymphoid source for LAK cell precursors was
investigated by using the spleen and lymph node obtained from cadavers
where consent for multi-organ donation had been given. Following
activation for six days with IL-2 there was no discernible difference
between LAK cells generated from the spleen or the lymph node (Figure
10).
Unfortunately, considerable difficulty was encountered in obtaining
lymphocytes from the peripheral blood sample and therefore no data for
this source of cells exists. However, the results obtained with spleen and
lymph node are not dissimilar to those obtained with LAK cells derived
from the peripheral blood of healthy volunteers. As with the different
donors of PBMC (see above), small differences in the achieved specific
cytotoxicity were evident between the donors.
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Figure 9. The effect of different donors for LAK cells
1 2 3 4 5
Effector Donor
The simultaneous assessment of the cytotoxic ability of LAK cells derived from
five different donors against two different target cell lines; RT112 (■), MGH-U1
(E2). LAK cells were generated by activating non-adherent PBMC with lOOOU/ml
of recombinant IL-2 for 6 days. LAK activity was assessed using a standard 4 hr.
chromium release assay. Shown are the mean of triplicates with error bars
indicating 1 standard deviation.
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Effector to target cell ratio
The effect of different lymphoid organs as the source tissue for LAK cell precursors.
The spleen (open symbol) or lymph node (closed symbol) from four cadaver were
collected and processed to yield a unicellular suspension. This was activated with
IL-2 for six days and the resulting LAK activity determined against the bladder
cancer cell line RT112.
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3.1.5 The effect offoetal calfserum on LAKcell activity
Criticism has been levelled against workers who employed foetal
calf serum in cytotoxicity assays and in the generation of LAK cells
(personal communication, Lafreniere et al 1989). It was decided that this
parameter should be briefly investigated before undertaking further
studies. The presence or absence of foetal calf serum throughout the
generation of LAK activity and during the assay did not have an effect
upon the lysis of three cell lines (Figure 11).
3.1.6 Cytokines other than IL-2 can induce LAKactivity
The initial reports concerning LAK activity showed that stimulation
with IL-2 was required to generate such activity. However, other
cytokines have been shown to be produced following stimulation with IL-2.
The effect of these cytokines on LAK activity against three TCC cell lines
was investigated. Both interferon-alpha-2a and tumour necrosis factor-
alpha were found to stimulate LAK activity when used to stimulate PBMC
for six days (Figure 12). The maximal levels of LAK activity against the
three lines tested was, however, far less than that achieved with IL-2 (see
above). The optimal concentration of IFNa was found to be l,000Uml-1,
and for TNFa lOOUml*1. When the concentration of TNFa was increased
a further 10 fold, a decrease in specific cytotoxicity was observed.
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The influence of foetal calf serum containing medium on the generation of LAK
activity in PBMC following 6 days of activation in the presence of l,000U/ml
IL-2. LAK activity was determined against the indicated bladder cancer cell
lines using a standard 4 hour chromium release assay. Bars represent the mean
of triplicate determinations, error bars show 1 standard deviation. The presence
of 5% FCS is shown (■), as is the effect of serum free medium (E2).
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The dose dependent kinetics of LAK cell induction by interferon-alpha and
tumour necrosis factor-alpha. Freshly isolated PBMC were incubated for 6 days
with the indicated concentrations of recombinant cytokine following which their
LAK activity was determined against three bladder cancer cell lines; RT4 (■),
RT112 (0), and MGH-U1 (H). Bars indicate the mean of triplicates and error
bars indicate standard deviation.
120
3.1.7 The role of exogenous tumour necrosis factor-alpha with IL-2 in the
induction ofLAKactivity
From recent studies it is evident that cytokines other than IL-2
partake in the generation of LAK activity (Kaufmann et al 1991.
Matossian-Rogers et al 1989). In order to investigate the possible role of
multiple cytokines in the generation of LAK activity, the reported synergy
between IL-2 and TNFa in LAK cell generation has been investigated.
When LAK cells were generated by stimulation with both IFNy and TNFa
the resulting activity was greater than that achieved with either cytokine
alone (Figure 13). However, this was only the case when TNFa was used
at a concentration of lOOUml"1. Lower concentrations had no greater
effect than that achieved with IL-2 alone, and higher concentrations
resulted in a decrease from maximal LAK activity (Figure 13). There was
no decrease in the viability of cells stimulated with the higher
concentrations ofTNFa as determined by dye exclusion (data not shown).
3.1.8 Interferon-alpha synergizes with IL-2 in LAKcell induction
The number of reports on the role of IFNa in LAK activity are
limited and there are no reports of synergy with IL-2 in the induction of
such activity. WTien PBMC were stimulated with both IFNa and IL-2, at
a concentration of 1,00011ml-1 each for six days, a greater LAK activity
was observed against all three lines tested than with either molecule alone
(Figure 14). The increase in activity was greater than the sum of that
achieved by stimulation with either cytokine alone, thus indicating synergy
in the induction of LAK activity. Concentrations of IFNa lower than
l,000UmH were not observed to synergize with IL-2 (data not shown).
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Figure 13. Tumour necrosis factor-alpha synergizes with IL-2 in the














































The effect of IL-2 and TNFa on LAK activity against three bladder cancer cell
lines , RT4 (■ ), RT112 (0 ), and MGH-U1 (11). LAK cells were cultured with the
indicated concentrations of either IL-2, TNFa or a combination of both. LAK
activity was determined in a standard chromium release assay. The upper figure
shows the additive action of TNFa and IL-2, and the lower figure shows the effect
of suboptimal concentrations of TNFa. Bars indicate the mean of triplicate
determinations and error bars indicate the level of 1 standard deviation.
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The synergy of IL-2 and IFNa in LAK activity against three bladder cancer cell
lines , RT4 (■ ), RT112 (0), and MGH-U1 (H). LAK cells were cultured with the
indicated concentrations of either IL-2, IFNa or a combination of both. LAK
activity was determined in a standard chromium release assay. Bars indicate the
mean of triplicate determinations and error bars indicate the level of 1 standard
deviation.
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3.1.9 LAKactivity against bladder cancer in an autologous setting
The cytolysis of bladder cancer cell lines is of limited usefulness if
fresh bladder tumour cells are not susceptible to LAK activity. Therefore,
the ability of autologous LAK cells to mediate the lysis of freshly derived
tumour cells was investigated. The results obtained for the killing of
tumour cells from seven patients by autologous LAK cells are shown in
figure 15. The fresh tumour cells were differentially susceptible to LAK
activity, as was found to be the case for cell lines. The maximal achievable
specific cytotoxicity at an effector to target cell ratio of 20:1, was 62%±3.
The mean level of achievable cytotoxicity was 42.6%±18.
3.1.10 The effect ofprostaglandins of the E series and seminal plasma on
LAK activity
For many years there has been a great deal of interest in the
immunosuppressive activities of prostaglandins, particularly those of the
E series. Prostaglandins are known to be secreted by a variety of
tumours, both in vitro and in vivo. Furthermore, human seminal plasma
contains particularly high levels of PGE2, a fact which is of interest when
considered in the light of conditions such as retrograde ejaculation (Quayle
1988, 1989).
The effect of PGE1 and PGE2 on the generation and subsequent
killing potential of LAK cells was investigated by activating cells in the
presence of physiologically relevant concentrations of prostaglandin.
Furthermore, cells were also activated in the presence of seminal plasma
(known to contain high levels of PGE). When LAK cells were generated
with 1,00011ml-1 IL-2 and between 10-5 and 107M of PGE no suppression
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Effector to target ratio
The ability of autologous LAK cells to kill freshly derived tumour cells. LAK cells were
generated from patients PBMC by culture with l,000U/ml IL-2 for 6 days in autologous
serum. Target cells were isolated from tumour material obtained by cystoscopic resection
of tumour mass. Cytotoxicity was determined using a standard chromium release assay
and the results shown are those for seven patients. The standard deviation was within 5%
of the experimental value.
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Figure 16. The effect of PGE2 on the generation of LAK activity
80 -1 on
Concentration of PGE2 (M)
Freshly isolated PBMN were placed in culture with l,000U/ml recombinant
human IL-2 for 6 days. In addition some cultures were also treated with the
indicated concentrations of PGE2 (10 "5- 10"7mM). Following incubation, the
LAK activity of all cultures was examined using a standard cytotoxicity assay
against four bladder cancer cell lines. The results represent the mean of
triplicate determinations, error bars indicate the levels of 1 standard deviation.
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of activity to levels lower than those achieved with IL-2 alone was
observed (Figure 16). At the highest concentrations of PGE2 a decrease in
activity against RT4 and EJ18 was observed, however this failed to reach
significance (p>0.5). The results shown represent a single experiment.
The experiment was repeated three times by C. Harrison, and similar
results were obtained.
3.1.11 The endogenous production ofcytokines by LAK cells
A variety of cytokines have been found to be secreted from cultures
of PBL following activation with IL-2; Such cytokines include IFNy and
TNFa. The production of IFNy and TNFa was examined using sensitive
ELISA kit assay systems. Following culture of PBMC in the presence of
IL-2 high levels of IFNy and TNFa were detected. Levels of lOOpg per 106
cells and and 50U per 106 cells of TNFa and IFNy respectively were
detected in tissues culture supernatants. In the absence of IL-2 only low
levels of TNFa were detected (5pg per 106 cells). Spontaneous production
of IFNywas not observed. The function of such cytokines will be addressed
in chapter 3.2.16.
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3.2 The expression and modulation ofadhesion molecules
3.2.1 Scanning electron micrography of tumour and LAKcells
The mechanism of action involved in LAK mediated cytotoxicity
remains undetermined although several theories have been postulated. It
is known that several cytokines which are produced by LAK cells, notably
interferon-gamma, can have direct anti-tumour effects on bladder cancer
cells leading to cessation of proliferation and /or cytotoxicity. However, in
order for these effects to be mediated prolonged exposure to these
cytokines is required (>24 horns). It is therefore unlikely that humorally
mediated events are responsible for killing by LAK cells. A more likely
explanation would involve intimate contact between the effector and
target cells, similar to that observed in killing by cytotoxic T-cells.
Using scanning electron micrography (SEM) we attempted to
observe the intimate relationship between LAK cells and bladder cancer
cells. Cultured tumour cells were incubated with LAK cells for 30 minutes
and then processed for examination using SEM. Plate 1 shows two large,
flat, high grade tumour cells, on top of which there is a LAK cell. When
viewed from a lower angle (15°) the point of contact between the cells was
observed (Plate 2). This appeared to take the form of a flat structure
emanating from the LAK cell. The intimate nature of the relationship was
confirmed when a LAK cells was pulled away from its target (Plate 3).
Between the two cells, structures were evident and part of the LAK cell
remained behind on the target.
The observation of intimate and firm contact between the effector
and target cell prompted the search for adhesion molecules expressed by
the effector and target cells which could account for such activity.
Plates 1, 2, and 3
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3.2.2 The expression ofadhesion molecules by bladder cancer cell lines
Using flow cytometry with monoclonal antibody probes the panel of
TCC cell lines was examined for the constitutive expression of a variety of
adhesion molecules (HLA class I, HLA class II, CD2, CD3, CD4, CD8,
CD56 (NCAM), ICAM-1 (CD54), ICAM-2 and VCAM). The results are
summarized in Table 5. All cell lines expressed HLA class I molecules but
only RT4 (Gl) expressed HLA class II. Expression of HLA class II on
unactivated epithelial cells is unusual (personal communication, W.
Bodmer). In order to confirm the existence of HLA class II a variety of
monoclonal antibodies were used. Other than HLA molecules, the only
other adhesion molecules expressed by TCC cells were members of the
intercellular adhesion molecule family (ICAM). All eight cell lines
constitutively expressed either ICAM-1 or ICAM-2, however, no cell line
constitutively co-expressed both molecules. Cell lines of the lowest grade
(Gl) did not express ICAM-1, rather they expressed ICAM-2. The poorly
differentiated high grade cell lines expressed ICAM-1 and not ICAM-2.
The percentage of cells which constitutively expressed either ICAM
molecule varied between the different cell lines (Figure 17). Only a small
percentage of RT4 and RT112 cells expressed ICAM-2 and ICAM-1
respectively whilst over 60% ofEJ18 and J82 cells expressed ICAM-1.
One major mechanism by which leucocytes adhere to vascular
endothelium is via the cytokine inducible VCAM molecule. This molecule
was a candidate for the ligand on tumour cells as VLA-4 is known to be
expressed by lymphocytes. However, none of the cell lines constitutively
expressed VCAM.
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Table 5. The constitutive expression of adhesion molecules by TCC
cell lines
Cell line RT4 UMUC3 RT112 MGH-U1 EJ18 J82 SD 5637
Grade G1 G1 G2 G3 G3 G3 G3 G3
HLA class I ++++ ++++ ++++ ++++ ++++ ++++ ++++ ++++
HLA class II + - - - - - - -
CD2 - - - - - - - -
CD3 - - - - - - - -
CD4 - - - - - - - -
CD8 - - - - - - - -
CD56 - - - - - - - -
ICAM-1 - - + ++ ++++ ++++ +++ +++
ICAM-2 + ++ - - - - - -
VCAM - - - - - - - -
A summary of the constitutive expression of adhesion molecules by eight bladder cancer
cell lines. Expression was determined using flow cytometry with monoclonal antibody
probes. Also shown is the grade of the parent tumour from which the cell lines were
derived and are still representative. No expression (-), ,10% of cells expressing (+),
between 10 and 30% of cells expressing (++), between 30 and 50 % of cell expressing
(+++), over 50 % of cells expressing the antigen of interest (++++).
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Figure 17. Representation of the flow cytometric profiles of ICAM-1


























The constitutive expression of ICAM-1 and ICAM-2 by eight bladder cancer
cell lines as studied by flow cytometry. Solid curves show ICAM-1 expression
whilst shaded curves show the expression of ICAM-2. The vertical dividing
line on each profile indicates the level of non-specific fluorescence.
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Previous work has demonstrated that IFNy can induce and
augment the expression of HLA class I and II molecules on the surface of
bladder cancer cell lines in vitro. As ICAM-1 is an inducible molecule, the
effect on ICAM-1 expression of various cytokines, some of which have
been identified in the urine of patients receiving BCG therapy, by TCC cell
fines was investigated.
3.2.3 The modulation ofICAM-1 expression by interferon-gamma
Bladder cancer cells were incubated with increasing doses of IFNy
for 0-48 hours and the expression of ICAM-1 was determined by flow-
cytometry. ICAM-1 expression was induced or augmented on all the cell
fines with the exception of UMUC-3 (G3) (Figure 18). The increased
expression of ICAM-1 was dependent upon the concentration of IFNy and
upon the duration of the stimulus. Optimal induction was achieved using
lOOUml"1 IFNy after 24 hours of continuous stimulation. Further
increases in the concentration and duration of stimulus failed to result in a
corresponding increase in ICAM-1 expression. Rather, expression was
decreased below maximal levels (SD and 5637). No ICAM-1 expression
could be induced on the UM-UC-3 cell fine even with IFNy concentration of
2,000Uml"1 and exposure periods in excess of 200 hours (data not shown).
The expression of ICAM-2 on all cells fines was not affected by stimulation
with IFNy (data not shown).
When the panel of bladder cancer cell lines were optimally
stimulated for the expression of ICAM-1 there was a marked difference in
the percentage of cells which were deemed positive. Only 58%±2.4 of
optimally stimulated RT4 cells as compared to 97%±2 of EJ18 or 93%±3.6
of SD cells expressed ICAM-1.
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Interferon-gamma concentration (U/ml)
The effect of stimulation with IFNy on ICAM-1 expression by bladder cancer cell lines.
TCC cell lines were stimulated for 6(B), 12 {M), 24 (□), and 48 (E2 ) hours with the
indicated concentrations of IFNy. ICAM-1 expression was determined by flow
cytometry. Bars represent the mean of triplicates from a representative experiment.
All standard deviations were within 5 % of experimental values.
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When TCC cell lines were stimulated with IFNy not only was there
an increase in the percentage of cells expressing ICAM-1 but there was an
increase in the intensity of the ICAM-1 staining. For all cell lines which
expressed ICAM-1 following stimulation the maximum antigen density
was observed with lOOUmH after 24 hours stimulation (Figure 19).
Increases in the intensity of antigen staining may be due to a change in
the volume of the cell, however, no such change was observed during these
experiments (data not shown). An increase in the density of ICAM-1
expressed by a target cell may be important as both the affinity and the
avidity of the LFA-l/ICAM-1 interaction are important in determining the
extent of LFA-1 dependent cytotoxicity.
The effect of continual stimulation with IFNy on ICAM-1 expression
is show in Figure 20. Induction was rapid with significant increases in
ICAM-1 expression evident after as little as 4 hours stimulation (p<0.02).
Optimal induction occurred after 24 hours, following which a steady decline
in the level of ICAM-1 was observed.
Following BCG therapy, IFNy is transiently produced and secreted
into the urine in large quantities. Therefore, bladder cancer cells may only
be exposed to IFNy for a short and limited period of time. As has been
shown above, the induction of ICAM-1 expression by IFNy is a rapid event,
the earliest signs of which were observed 4 hours after stimulation. The
minimum duration of continuous stimulation required to generate a
response was investigated. When cells were stimulated with IFNy for 10
seconds, washed repeatedly, and then cultured for the remainder of 24
hours, a significant increase in ICAM-1 expression was observed (p<0.02)
(Figure 21). Longer periods of stimulation, up to 24 hours continuous
stimulation, resulted in increased ICAM-1 expression. Following 12 hours
stimulation (the duration received by cells in the bladder following BCG
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Tumour necrosis factor-alpha concentration
(U/ml)
The effect of IFNy stimulation on the intensity of ICAM-1 expression by bladder
cancer cell lines. Cells were incubated with the indicated concentrations of IFNy
for 6(B), 12 (E2), and 24 (H) hours. ICAM-1 expression was determined using flow
cytometry. Bars represent the mean of triplicate determinations.
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The time-course of induction of de novo ICAM-1 expression by RT4 following
stimulation with lOOU/ml IFNy. ICAM-1 expression was determined using
flow cytometry. Error bars represent 1 standard deviation.
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Figure 21. The duration of stimulus required for ICAM-1 induction
Duration of stimulus
(seconds)
The dependence of ICAM-1 expression by RT4 upon duration of stimulus. Cells
were exposed to lOOU/ml of IFNy for the indicated duration following which, the
IFNy was removed and the cells washed three times in order to remove the
remaining IFNy. The cells were then cultured for a total time of 24 hours from the
onset of stimulation. ICAM-1 expression was determined using flow cytometry.
Error bars indicate 1 sd.
138
therapy), over 80% of the maximal response had been achieved.
As mentioned, the bladder cancer cell lines in this study failed to
constitutively express VCAM. This observation was extended by studying
the expression of VCAM following stimulation with IFNy. The cell line
MGH-U1 was stimulated with a range of concentration of IFNy for 0-48
hours following which the expression ofVCAM was studied. No cells were
seen to express VCAM following such stimulation (data not shown). It
therefore seem unlikely that VCAM /VLA-4 interactions are involved in
the LAKmediated cytolysis of bladder carcinoma cell lines.
3.2.4 Tumour necrosis factor-alpha modulates ICAM-1 expression
As TNFa is readily detected in the urine of patients who received
BCG therapy for superficial bladder cancer, its effect on ICAM-1
expression by TCC cell lines was investigated. When cells were stimulated
with TNFa for 24 hours the ICAM-1 expression on such cells was
increased (Figure 22). Optimal induction was achieved with lOOUml"1 of
TNFa for all four cell lines tested. The ICAM-1 inducing effects of TNFa
were of smaller magnitude than those observed following stimulation with
IFNy.
3.2.5 Interleukin-1 modulates the expression ofICAM-1
Interleukin-1, a product of activated T-cells and macrophages, is
detected in the urine of patients following repeated instillations of BCG
vaccine. This cytokine has been shown to induce ICAM-1 expression on
vascular endothelium. Its ability to increase ICAM-1 expression on the
surface ofbladder cancer cells was therefore studied.
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Stimulation of TCC cell lines with IL-la for 24 hours elicited a dose
dependent response of increased ICAM-1 expression (Figure 23). Optimal
induction occurred when cells were stimulated with either lOOUml"1 (MGH-
Ul) or l^OOOUml"1 (RT4). In the case of MGH-U1 the effects of IL-la
were comparable to those of IFNy, however, for all the other cell lines
tested the effects of IL-la on ICAM-1 expression were far smaller than
those achieved using IFNy.
3.2.6 The effect ofother cytokines on ICAM-1 expression by TCC cell lines
A variety of cytokines other than IFNy, IL-1 and TNFa are detected
in the urine following BCG therapy. These include IL-2, a cytokine
produced by activated T-cells and in part responsible for the generation of
LAK cells.
Bladder cancer cells were stimulated with a variety of cytokines for
24 hours prior to determination of their ICAM-1 expression. The cytokines
IL-2, IL-3, IL-4, IL-7, IL-8, TGF13 and GM-CSF did not modulate the
constitutive expression of ICAM-1 on any of the bladder cancer cell lines
tested (Figure 24). No changes were observed in either the percentage of
cells positive or in the density of the antigen on the cell surface (data not
shown). Although these cytokines did not appear to affect the expression
of the ICAM-1 gene, this does not necessarily preclude them from
exhibiting other effects on the target cells (discussed later).
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Figure 22. Tumour necrosis factor-alpha induces ICAM-1 expression
lOO-i
RT4 RT112 MGH-U1 SD
Cell line
The effect of TNFa stimulation on the expression of ICAM-1 by four
TCC cell lines. Cells were exposed to 0 (B), 1 (0), 10 (0), and 100
(0) U/ml of TNFa for 24 hours. ICAM-1 expression was determined
by flow cytometry.
Figure 23. Interleukin-1-alpha induces ICAM-1 expression
100 -i
RT4 RT112 MGH-U 1 SD
Cell line
The effect of IL-la stimulation on the expression of ICAM-1 by four
TCC cell lines. Cells were exposed to 0 (■), 1 (□), 10 (HI), and 100
(□) U/ml of IL-la for 24 hours. ICAM-1 expression was determined
by flow cytometry. Error bars represent 1 standard deviation.
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The modulation of ICAM-1 expression by cytokines other than IFNy, TNFa or IL-la. TCC
cell lines were incubated with 0 (fl ), 10 (0), 100 (H) and 1000 (0) U/ml of the indicated
recombinant human cytokines for 24 hours. ICAM-1 expression was identified using flow
cytometry with monoclonal antibody probes. The bars represent the mean of triplicates,
standard deviations were within 10% of the experimental values. The upper figure shows
the response of RT4 cells and the lower the response of MGH-U1 cells.
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3.2.7 Interferon-alpha-2a does not modulate constitutive ICAM-1
expression but suppresses IFNy induced ICAM-1 expression
When cells were stimulated with IFNa no change in the constitutive
expression of ICAM-1 was observed (Figure 25). However, simultaneous
stimulation with IFNy and IFNa resulted in decreased ICAM-1 expression
as compared to that generated by stimulation with IFNy alone (Figure 26).
The decrease in ICAM-1 expression was dose dependent with optimum
activity occurring with lOOUmT1 of IFNa. The expression of ICAM-1 by
EJ18 was not reduced by simultaneous stimulation with IFNa.
3.2.8 Interferon-gamma synergizes with TNFa in the upregulation of
ICAM-1 expression
It has been demonstrated that IFNy and TNFa or IL-1 synergize in
the regulation of ICAM-1 expression on a variety of cell types. As both
molecules have been detected in the urine of patients receiving BCG
therapy, any possible synergistic actions were investigated.
When bladder cancer cell lines were stimulated with a combination
of IFNy and TNFa a greater response was seen than that generated with a
comparable concentration of either molecule singly (Figure 27).
Furthermore, the effect was greater than additive thus demonstrating
synergistic up-regulation of ICAM-1 expression. The synergy between the
two cytokines was greatest when stimulated with lOUml'1 of each for 24
hours. This concentration is of the same order as that produced in
response to BCG therapy (see section 3.6).
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Figure 25. Interferon-a does not modulate constitutive ICAM-1
100 n
en
RT4 MGH-U1 J82 5637
RT112 EJ18 SD
Cell line
The effect of stimulating bladder cancer cell lines with recombinant human
IFNoc-2a. Cells were stimulated with 0 (■), 10 (S3), 100 (H), and 1000 (0) U/ml
of IFNa for 24 hours. ICAM-1 expression was determined using flow cytometry.
Bars represent the mean of triplicate determinations and error bars represent
1 standard deviation.





Cells were stimulated with IFNy alone or in the presence of IFNa for 24 hours.
The four cell lines used wer RT4 (H), RT112 (0), MGH-U1 (H), and EJ18 (0).
ICAM-1 expression was determined using flow cytometry.Bars represent the
mean of triplicate determinations and error bars representl standard deviation.
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Figure 27. The synergy between IFNy and TNFa in ICAM-1 induction
80-,
Cells were stimulated for 24 hours with the indicated concentrations of
either IFNy (•), TNFa (□), or both cytokines simultaneously (■). The
expression of ICAM-1 was studied using flow cytometry with monoclonal
antibody RR1/1. The upper graph shows the results obtained with RT4
and the lower graph RT112. Standard deviations were within 10% of
experimental values.
145
3.2.9 The effect ofpulsed stimulation with IFNy on ICAM-1 expression
Following BCG treatment transient production (~12hrs.) of IFNy
has been observed (Prescott et al 1990). The effect of single and repeated
12 hour pulses of IFNy was investigated in an attempt to mimic the in
vivo situation of repeated stimulation.
Cells were firstly stimulated for 12 hours with lOOUml"1 IFNy
following which the cells were washed and the culture period continued for
the desired length of time. Following a single 12 hour pulse, the time course
of ICAM-1 expression was studied (Figure 28, experiments 1-8). Maximal
expression was again observed after 24 hours, declining to low levels with
120 hours total culture period (expt. 5).
When two pulses of IFNy were given, 12 hours apart, an increase in
ICAM-1 expression was noted (expt. 9). If the second pulse was delayed
for a further 24 or 48 hours, a lesser response was observed (expts. 10, and
11). Secondary stimulation after 72 hours failed to produce a response
greater than control (expt. 12).
The highest response was obtained with three pulses, each 12 hours
apart (expt. 13), however, a response greater than control was also
obtained when the second and third pulse were given with 72 and 96 hour
intervals respectively (expt. 14). Therefore, repeated stimulation with
IFNy at a point when ICAM-1 expression has not declined to baseline
levels, yields an increase in expression greater than that maximally
obtained following a single pulse.
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The expression of ICAM-1 molecules by RT4 following pulsed stimulation
with IFNy. Cells were exposed to lOOU/ml of recombinant IFNy for the
indicated 12 hour periods (EE33) following which they were washed with
PBS three times and allowed to remain in culture for the duration of the
stimulation ( ). Shown is the percentage of cells expressing ICAM-1
as determined by flow cytometry, results are expressed as the mean ± 1
standard deviation.
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3.2.10 Is there a role for mRNA pools in IFNy induced ICAM-1 expression ?
The above studies demonstrate the rapid appearance of membrane
associated ICAM-1 following stimulation with IFNy. One possible means
by which ICAM-1 could be rapidly expressed is by the existence of
intracellular pools ofmRNA and/or protein. In order to investigate this
possibility, we treated cells with actinomycin D (an inhibitor of mRNA
transcription) prior to stimulation with IFNy for 24 hours. Pre-treatment
with actinomycin D (lpgml"1 for 30 minutes) completely prevented IFNy
from inducing the expression of ICAM-1 on three of the four cell lines
tested (Figure 29). When MGH-U1 was treated with actinomycin D and
IFNy, an increase in ICAM-1 expression was observed which was greater
than control but less than that obtained with IFNy alone.
3.2.11 Is there a role for intracellular protein pools in IFNy induced ICAM-
1 expression?
The inhibitor of protein synthesis cycloheximide (CHX) was used to
prevent the production of new ICAM-1 molecules. Following treatment
with CHX (lpgml'1 for 30 minutes) the cells were stimulated with IFNy in
the presence of CHX. Pre-treatment with CHX prevented the induction of
ICAM-1 expression by IFNy in the cell lines RT4 and RT112 (Figure 30).
However, when MGH-U1 cells were stimulated in an identical manner the
levels of expression was marginally increased, rather than decreased.
When cells were first stimulated for 24 hours with IFNy, the IFNy
removed by repeated washing, and replaced by medium containing CHX,
and the time course of ICAM-1 expression studied, interesting results were
noted (Figure 31). Rather than the level of ICAM-1 expression remaining
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Treatment
Four bladder cancer cell lines were stimulated with IFNy (lOOU/ml), actinomycin
D (lpg/ml) or both for 24 hours. The expression of ICAM-1 was determined by
flow cytometry. The values shown represent the mean of triplicate determinations,
error bars indicate 1 standard deviation.
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Control IFNy IFNy + CHX
Treatment
The contribution of protein synthesis to IFNy induced ICAM-1 expression was
investigated using the protein synthesis inhibitor cycloheximide (CHX). Three
cell lines were used for this experiment; RT4 (■), RT112 (E0), and MGH-U1 (H).
Cells were cultured for 24 hours with no exogenous stimulus, IFNy at 100 U/ml,
or IFNy and CHX at lpg/ml. Following stimulation the expression of ICAM-1
was determined using flow cytometry with monoclonal antibody RR1/1. The
bars represent the mean of triplicate determinations, error bars indicating the
level of 1 standard deviation.
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Figure 31. The inhibition of protein synthesis serves to stabilize
cell surface ICAM-1 molecules
0 24 48 72 96 120
Duration of culture (hours)
The effect of inhibition of protein synthesis on the IFNy induced ICAM-1
expression by the cell line RT4. Cells were first stimulated for 24 hours with
lOOU/ml IFNy following which they were cultured in the absence (■), or
presence (0) of CHX (lpg/ml) for the indicated period. Results represent the
mean of triplicates, error bars showing 1 standard deviation.
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constant, an increase in the percentage of cells expressing ICAM-1 was
observed. Therefore, following stimulation maximal expression is observed
by 24 hours, after which the level of expression falls gradually. However, it
would appear that at 24 hours not all the ICAM-1 protein is expressed on
the cell surface, rather it is located intracellularly. Furthermore, it would
appear that CHX treatment serves to stabilize the ICAM-1 expressed on
the cell surface, thus preventing recycling or shedding.
3.2.12 Regulation ofICAM-1 expression by retinoic acid
In addition to various cytokines, retinoic acid has also been reported
to up-regulate the expression of ICAM-1 on a variety of tumour cells. The
effect of retinoic acid on the expression of ICAM-1 by bladder cancer cells
was therefore investigated. Two cell lines were stimulated with between
0.1 and lOOpgml"1 of ail-trans retinoic acid for between 24 and 96 hours,
following which the expression of ICAM-1 was studied. Expression of
ICAM-1 molecules on either RT4 or MGH-U1 was not increased by
treatment with retinoic acid at any concentration within the time-course
studied (data not shown). As a control, cells which were stimulated with
IFNy, and found to express elevated levels of ICAM-1 as expected.
3.2.13 Prostaglandins ofthe E series do not modulate ICAM-1 expression
The role of prostaglandins El and E2 in the regulation of molecules
which were potentially of immunological significance was investigated.
Neither PGE1 or PGE2 treatment of bladder cancer cell lines had any
detectable effect on the constitutive expression of ICAM-1 (Figure 32).
This was true for both the percentage of cell expressing ICAM-1 and for
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the relative intensity of the staining (data not shown). Prostaglandins also
failed to affect ICAM-1 expression as induced by IFNy (Figure 33).
3.2.14 The expression ofLFA-1 by IL-2 stimulated LAKcells
The ligand for the three ICAM molecules is LFA-1. As ICAM-1 and-
2 were expressed by bladder tumour cells it was considered pertinent to
examine the effector cells for the expression ofLFA-1.
Using monoclonal antibodies to CD 11a and CD18, freshly derived
PBL were found to express high levels of both these antigens at two
different densities. The mean levels of CD 11a expression by lymphocytes
and large granular lymphocytes was determined to be 93.8%±2, of CD18
expression 93.1%±2, of ICAM-1 34.6%±7.5, and of ICAM-2 73.9%±11.
Following six days of activation with recombinant IL-2 no changes in the
percentage of cells expressing the CD 11a or CD 18 molecules was
observed. It was noticed that both CD 11a and CD 18 antigens were
expressed at two different densities. The high density expression was
found to be due to LGL, the lower density to lymphocytes.
3.2.15 The secretion of soluble ICAM-1 molecules by bladder cancer cell
lines
When associated with the cell surface, ICAM-1 is a major ligand for
LFA-1 and its associated effector functions. However, in a soluble form
ICAM-1 has been shown to inhibit several LFA-1 dependent processes
(Becker et al 1991). Following stimulation with IFNy bladder cancer cell
lines express high levels of cell surface ICAM-1. However, after 24 hours
of stimulation the levels of cell surface ICAM-1 declines. The fate of such
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Control IFNy PGE1 PGE2
lOOU/ml 10-eM 10-sM
Figure 33. Prostaglandins do not alter IFNy induced ICAM-1
expression
60i
Control IFNy IFNy+ IFNy+
PGE1 PGE2
Treatment
The effect of prostaglandins of the E series on the expression of ICAM-1 by 3 bladder
cancer cell lines; RT4 (■), RT112 (E), and MGH-U1 (H). Cells were stimulated with
lOOU/ml of IFNy either alone or in the presence of 10"6M PGE1 or 2 for 24 hours prior to
determination of ICAM-1 expression by flow cytometry. The results show a
representative experiment in triplicate, error bars indicating 1 standard deviation.
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ICAM-1 was investigated by studying the production of sICAM-1 by
bladder cancer cell lines with the aid of a commercially available
immunoassay kit.
Constitutively, the four cell lines investigated did not produce large
quantities of sICAM-1. However, following stimulation with IFNy, high
levels of sICAM-1 were detected in tissue culture supernatants (Figure
34). Following 24 hours of stimulation, low levels of sICAM-1 were
produced by each line. The maximal levels of sICAM-1 were not detected
until after 48 (MGH-U1), 72 (RT4 and SD) and 96 hours (RT112).
Maximal levels in excess of 200ng per 106 cells were produced by the SD
cell line. Assuming a molecular weight of 95kDa, this corresponds to the
secretion of approximately 1.3xl06 molecules per cell during a 72 hour
period from the initiation of stimulation with IFNy, as opposed to only
6xl03 molecules per cell without stimulation.
3.2.16 Supernatants from LAKcell cultures induce the expression oflCAM-
1 on bladder cancer cells
As mentioned in 3.1.11 several cytokines are produced by PBMC
following stimulation with IL-2. The effect of such cytokines on ICAM-1
expression was studied. It had previously been demonstrated that IL-2
does not modulate ICAM-1 expression, therefore any effects were likely to
be due to secondary cytokines.
Following 24 hours treatment with a 1:2 dilution of 6 day LAK cell
supernatant, ICAM-1 expression was induced on RT112 (51%±3) and
MGH-U1 (90%±4). Pretreatment with polyclonal antibodies to IFNy (80%
reduction in effect), but not TNFa (8% reduction), almost completely
negated the effect of LAK supernatant. Simultaneous treatment with
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both antibodies did not decrease the effect any further than with anti-IFNy
alone. Whether such cytokines produced by tumour infiltrating cells would
have similar effects on tumour cells remains to be investigated. It is
interesting than despite cytokine neutralization, ICAM-1 levels did not
return to constitutive levels, indicating the presence of a further inducer of
ICAM-1 (such as IL-1).
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The production of soluble ICAM-1 (sICAM-1) by four bladder cancer cell lines
following stimulation with lOOU/ml of recombinant IFNyfor the indicated
periods. Control is the levels of production in the absence of IFNy. The four
cell lines used were RT4 (■), RT112 ®3), MGH-U1 (M), and SD (ED. The
production of sICAM-1 was detected using an ELISA kit and is expressed as
ng per million cells.
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3.3 Functional evaluation of the role of adhesion molecules in
LAKmediated cytotoxicity against bladder cancer cells
The work so far has shown that bladder cancer cells are
differentially susceptible to killing mediated by IL-2 activated LAK cells.
Scanning electron micrography has demonstrated an intimate relationship
between the LAK cell and bladder cancer cells. The differential sensitivity
of the target cells would appear to correlate with the expression of one
particular adhesion molecule, ICAM-1, expressed by the target cell. Using
flow cytometry, the existence of the ligand for ICAM-1 has been confirmed
on the potential effector cells. However, several points have been raised.
Firstly, a significant percentage of killing would appear to exist in the
absence of ICAM-1 and ICAM-2. Secondly, unactivated effector cells
express high levels of LFA-1 yet are unable to kill bladder cancer cells.
However, NK sensitive targets are killed, thus indicating the existence of a
differential mechanism of killing. Thirdly, ICAM-1 is sensitively regulated
by a variety of cytokines, most of which lead to the increased expression of
this molecule. The following series of experiments were designed to further
dissect the role of various adhesion molecules in the intimate relationship
between effector and target cell.
3.3.1 Immunohistochemical detection ofadhesion molecules in conjugates
between effector and target cells
Immunohistochemistry techniques provide us with a powerful
method for the visualization of antigens. When applied to cell biology, they
can reveal minute differences in the distribution of antigen, whether
surface bound or cytoplasmic, equally distributed on the surface of the cell
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or localized towards one pole. Immunohistochemistry for cell surface
antigens (when carefully undertaken) provides additional information to
that give by flow cytometry. The aim of this series of experiments was to
identify molecules expressed by target and effector cells and to visualize
conjugation events between the two cell types. Conjugates were formed
and using cytospin were transferred to a glass slide. Following fixation the
cells were stained for the expression of various adhesion molecules using
monoclonal antibodies. The frequency of the number of effector cells
conjugated to individual target cells is shown in Figure 35.
Cytospins of target and effector cells (10:1) were stained for ICAM-
1 and the number of conjugates per target cell was counted; the data is
shown in table 6. There was a significantly greater number of effector cells
conjugated to a single ICAM-1 expressing target cell than an ICAM-1
negative target cell for all four cell lines tested (p<0.02). Differences were
also evident between the individual cell lines in the case of ICAM-1
expressing target cells, however, these differences failed to reach
significance (p>0.2). When the data was corrected for the percentage of
cells expressing ICAM-1, differences were evident between the cell lines. A
greater number of effector cells was seen to conjugate to the cell lines
EJ18 and J82 than to MGH-U1 and RT112 (p<0.02). No difference was
detected between RT112 and MGH-U1. The correlation between the
susceptibility of targets to LAK activity and the number of LAK cells
conjugated to each target cell is shown in Figure 36. Although only four
data points exist, the correlation is significant to at least the 1% level.
159




















1 2 3 4 5 6 7 8 9 10
ib..









2 3 4 5 6 7 8 9 10
Number of effector cells conjugated
to a single target cell
The frequency of the number of effector cells conjugated to a single target
cell is shown. Targets and effector cells were mixed at a 1:10 ratio and briefly
centrifuged prior to preparing cytospins. Following immunohistochemical
staining for ICAM-1, the number of effector cells conjugated to either ICAM-1
positive (■), or ICAM-1 negative (0) cells was counted. The results shown
are for four cell lines as indicated.
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Table 6. Summary of the immunohistochemical binding data for
conjugates formed between LAK and TCC cells.
Number of effector cells per target Number of effector
Cell Line ICAM-1 + ICAM-1 - cells per target
MGH-U1 1.9±1.2 0.310.5 0.4010.6
EJ18 2.6±1.6 0.310.5 1.9611.2
RT112 2.3±1.3 0.210.4 0.310.4
J82 3.712.0 0.310.5 2.4111.4
The data presented is based on information provided in figure 35. The
results show the mean number of effector cells (±lsd) for four target cell
lines. This number is calculated from the number of effector cells per
ICAM-1 positive and negative target cell and is adjusted for the mean
percentage of cells expressing ICAM-1.

















Shown is the correlation between susceptibility to LAK killing and
the number of LAK cells per target cell for four target cell lines.
Also shown is the correlation coefficient (R) and the probability (p).
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When conjugate cytospins were stained using a primary monoclonal
antibody to LFA-1, it was noted that all effector cells which formed
conjugates with target cells, expressed this antigen. Furthermore, both
lymphocytes and LGL were observed to form intimate conjugates with
bladder cancer cells. Representative results of the immunohistochemistry
are shown in plates 4 and 5.
162
Plates 4 and 5.
Immunohistochemical staining for CD 11a of conjugates formed
between IL-2 activated LAK cells and RT4 (upper) or MGH-U1 (lower).
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3.3.2 The effect of adhesion blockade of ICAM-1 and ICAM-2 on target
cells
In order to demonstrate the role of ICAM-1 and ICAM-2 as ligands
for effector cells, targets were pretreated with monoclonal antibodies
known to inhibit the function of various adhesion molecules.
When targets which were known to strongly constitutively express
ICAM-1 (J82, 5637, EJ18, SD) were pretreated with blocking antibodies to
ICAM-1, a significant decrease in their susceptibility to LAK mediated
cytolysis was observed (Figure 37). Furthermore, when antibodies were
also present for the duration of the cytotoxicity assay a further decrease in
specific cytotoxicity was observed. The mean maximal suppression of
specific cytotoxicity was as follows: J82-70%, 5637-47%, EJ18-62%, and
SD-28%. When the two cell lines which constitutively express ICAM-2
were pretreated with anti ICAM-2 no significant decrease in specific
cytotoxicity was observed (p>0.2). However, when these antibodies were
present throughout the assay period a decrease was observed in the killing
ofUMUC-3, 17%. Only a minor decrease was observed in the killing of the
G2 cell line RT112, however, this did not reach significance. Antibodies to
either ICAM-1 or ICAM-2 failed to reduce the specific cytotoxicity
achieved against RT4 (Gl).
The presence of antibodies to adhesion molecules which were not
expressed by the target cell did not affect the sensitivity of that target to
LAK cells. Furthermore, the presence of antibodies to HLA class II
molecules did not inhibit specific cytotoxicity for any of the eight cell lines.
When the percentage of target cells which expressed ICAM-1 (and
or ICAM-2) was plotted against the specific cytotoxicity obtained against
such cells a significant correlation was observed (Figure 38). With only
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The functional dissection of the role of adhesion molecules in the LAK cell mediated
cytotoxicity against bladder cancer cell lines. A standard 4 hour chromium release
assay was performed at an effector to target ratio of 40:1. Prior to assay, the target
cells were incubated with a variety of monoclonal antibodies for 30 minutes at a
concentration of 10(ig/ml (pre) or antibodies were present throughout the assay
period (during). The monoclonal antibodies employed were as follows; none (■),
anti-ICAM-1 pre (□), anti-ICAM-1 during (□), anti ICAM-2 pre (0), anti-ICAM-2
during O), anti-HLA class II pre and during (Q).
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Figure 38. The correlation between constitutive ICAM expression









In the upper figure the correlation is shown for the expression of both
ICAM-1 and ICAM-2 with LAK susceptibility. The lower figure shows the
correlation with ICAM-1 alone. Also shown is the correlation coeficient (R)
for both regressions.
166
two cell lines expressing ICAM-1 it was not possible to assign any
significance to their correlation. However, it is possible that the
relationship to LAK activity is different for ICAM-1 and ICAM-2.
3.3.3 Interferon-gamma treatment of tumour cells increases their
susceptibility to LAKmediated cytolysis
If the cell adhesion molecule ICAM-1 serves as a ligand for the LAK
effector cell then, in a non-linear manner, a cell with increased ICAM-1
expression on its surface should have an increased susceptibility to LAK
mediated killing. In order to test this hypothesis tumour cells were first
incubated for 24 hours with IFNy at a maximal concentration of lOOUml"1.
The specific cytotoxicity achieved against these targets was then
compared to that against untreated target cells. The percentage of cells
expressing ICAM-1 was also measured.
Stimulation of the RT4 (Gl) cell line with increasing concentrations
of IFNy resulted in an apparent increase in the susceptibility of the
tumour cells to cytolysis by LAK effector cells (Figure 39). Although
incubation with lUmL1 of IFNy resulted in a small increase in the
percentage of cells expressing ICAM-1, there was no corresponding
increase in LAK activity. Stimulation of the tumour cells with higher
concentrations of IFNy did produce an increase in killing. Incubation with
lOUml"1 gave an increase in killing of 35% of the control value for
untreated cells. Stimulation with lOOUml"1 resulted in an increase in
specific killing of 215%. The correlation line between increased ICAM-1
expression and increased sensitivity to LAK cells is shown (Figure 39).
The fit to this line is good for all points bar that obtained with unstimulated
cells (the correlation coefficient gives p<0.01).
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The relationship between IFNy induced ICAM-1 expression by RT4 and increased
sensitivity to LAK mediated cytotoxicity. Cells were incubated for 24 hours with
the indicated dose of IFNy following which both the specific cytotoxicity (■) and the
percentage of cells expressing ICAM-1 (□) were determined (upper figure). The
correlation between these two parameters is shown in the lower figure.
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When the RT112 cell line was incubated with increasing
concentrations of IFNy an increase in the susceptibility of the cells to LAK
mediated killing was also observed (Figure 40). The increased
susceptibility was not evident after stimulation with lUmH despite an
increase in the expression of ICAM-1. However, following stimulation with
lOUml1 a 40% increase in specific cytotoxicity was noted. The
augmentation of specific cytotoxicity was even greater when cells were
treated with lOOUmT1 IFNy. A 250% increase in LAK activity was
observed over the control value for unstimulated cells. A corresponding
increase in ICAM-1 expression was also observed. When the percentage
specific cytotoxicity and the ICAM-1 expression following stimulation with
increasing doses of IFNy were plotted against each other a significant
correlation was found (p<0.02) (Figure 40).
Stimulation of the high grade cell lines EJ18 and J82 with lOOUmT1
of IFNy was found to increase their expression of ICAM-1. However, no
significant increase in specific cytotoxicity against these targets was
observed (Figure 41). Previous data has shown that the TCC cell line
UMUC-3 (G3) cannot be stimulated to express ICAM-1, even when
exposed to high concentrations (>1000Uml"1) and prolonged periods of
exposure (>200 hours). When this cell line was exposed to IFNy and its
susceptibility to LAK killing subsequently determined, there was no
evidence of an increase in vulnerability to LAK cells (Figure 42).
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The relationship between IFNy induced ICAM-1 expression by RT112 and increased
sensitivity to LAK mediated cytotoxicity. Cells were incubated for 24 hours with
the indicated dose of IFNy following which both the specific cytotoxicity (■) and the
percentage of cells expressing ICAM-1 (0) were determined (upper figure). The
correlation between these two parameters is shown in the lower figure.
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The relationship between IFNy induced ICAM-1 expression by EJ18 and J82 and
sensitivity to LAK mediated cytotoxicity. Cells were incubated for 24 hours with
the indicated dose of IFNy following which both the specific cytotoxicity (■) and
the percentage of cells expressing ICAM-1 (E2) were determined. Upper figure
gives the results for EJ18 and the lower figure for J82. Bars represent means of
triplicates and error bars indicate 1 standard deviation.
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Figure 42. Interferon-gamma fails to increase target suceptibility
Interferon-gamma concentration
(U/ml)
The relationship between IFNy induced ICAM-1 expression by UMUC-3 and its
sensitivity to LAK mediated cytotoxicity. Cells were incubated for 24 hours with
the indicated dose of IFNy following which both the specific cytotoxicity (■) and
the percentage of cells expressing ICAM-1 (0) were determined. Bars represent means (
triplicates and error bars indicate 1 standard deviation.
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3.3.4 Adhesion blockade studies concerning the effector cell
The data presented so far concerning the function of adhesion
molecules in the activity of LAK cells against bladder cancer targets has
concentrated mainly upon the function of adhesion molecules expressed by
the target cell. Using various monoclonal antibodies these molecules have
been shown to partake in the LAK response. If this is not artifactual then
similar adhesion blockade studies with respect to the ligands on effector
cells should realize similar findings. It was on this premise that
investigations into the counter-receptor for ICAM, namely LFA-1, were
undertaken. Using monoclonal antibodies known to inhibit the function of
various adhesion molecules the role of such structures as expressed by the
effector cell was investigated.
When effector cells were pretreated with monoclonal antibodies to
ICAM-1 or ICAM-2 no changes in the specific cytotoxicity exhibited
against any of the targets was observed (Figure 43). Antibodies to LFA-2
gave similar results on most of the cell lines tested. However, LAK cells
which had been pretreated with anti-LFA-2 antibodies and then used to kill
the line MGH-U1 had a slight but significantly decreased ability to do so
(p<0.02). A depression of 14% of the control value was consistently
observed.
The pretreatment of LAK cells with monoclonal antibodies to LFA-1
alpha chain (CD 11a) resulted in a marked and significant decrease in the
ability of LAK cells to kill their bladder cancer targets. The percentage
decrease ranged from 70% (RT112) to 96% (J82) with a mean depression
of 83% of control value. Intermediate levels of depression in activity were
achieved against other cell lines; 76% (UMUC-3), 84% (MGH-U1), 77%
(RT4), 75% (SD), 80% (5637), and 83% (EJ18).
173


























The functional dissection of the role of adhesion molecules in the LAK cell mediated
cytotoxicity against bladder cancer cell lines. A standard 4 hour chromium release assay
was performed at an effector to target ratio of 40:1. Prior to assay, the effector cells were
incubated with a variety of monoclonal antibodies for 30 minutes at a concentration of
lOpg/ml. The monoclonal antibodies employed were as follows; none (■), anti-LFA-1 (□),
anti-LFA-2 (□), anti-ICAM-1 (□), anti-ICAM-2 (B). Bars show the mean of triplicate
determinations, error bars indicate the level of 1 standard deviation.
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When the percentage depression in LAK activity for target cell
blockade and effector cells blockade are compared, either per individual cell
line or as the mean of all eight cell lines, a marked difference is observed.
The mean level for target blockade is 31±24% as compared to 82±9.7%
following effector cell blockade for all eight cell lines. Therefore, as there is
a portion ofLAK activity which is LFA-1 dependent but independent of the
function of both ICAM-1 and ICAM-2, the existence of a further ligand for
LFA-1 on bladder cancer cell lines is suggested.
3.3.5 The formation ofstable conjugates between effector and target cells
As various adhesion molecules appear to be involved in the activity
of LAK cells against bladder cancer targets, it is reasonable to assume
that effector and target cells form stable conjugates in order for cytotoxic
events to be initiated. Using a modified flow cytometric-based conjugation
assay (Caverec et al 1990) the rate of conjugation for each of the bladder
cancer cell lines was studied. An effector to target ratio of 10:1 was chosen
as a compromize between the cytotoxicity assay and the constraints of
flow-rate. Conjugation was carried out in complete medium at 37 °C, these
conditions being chosen for their similarity to previous experiments
concerning cytotoxicity.
The percentage of targets which were conjugated to at least one
effector cell was expressed as a function of time. Assay before pelletting
the cells gave t=0. At this time point the number of conjugates was
extremely low, usually less than 1%. Immediately following pelletting and
vigorous resuspension, t=l, the conjugates were again assayed. A
representative time course for each cell line is shown in Figure 44.
Following centrifugation, conjugation was observed to be a rapid (<1
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minute) and stable event. In fact, the maximal level of constitutive
conjugation was observed at 1 minute. When cells were subjected to
vigorous vortexing or repeated pipetting, no decrease in the percentage of
conjugates was observed (data not shown). Although previously a
significant correlation had been demonstrated between ICAM-1 expression
and LAK activity, interestingly there was no such significant correlation
(p>0.2) between the constitutive susceptibility to LAK mediated
cytotoxicity and the ability to form conjugates (Figure 45). The mean
results from repeated conjugation experiments are shown in table 7. The
two low grade cell lines RT4 and UMUC-3 were found to conjugate the
least, G2 and G3 cell lines forming more stable conjugates. In apparent
contradiction to the cytotoxicity assay, RT112 was found to form the most
conjugates, suggesting further mechanisms other than conjugation are
involved in LAK mediated cytolysis.
3.3.6 Fresh PBMC do not form conjugates with bladder cancer cells
In order to more fully understand the mechanisms of LAK activity
against bladder cancer cell lines, the ability of fresh PBMC to conjugate
with target cells was investigated. As the expression of LFA-1 by PBMC is
high, the question of ligand activation could be addressed. Fresh PBMC
were unable to conjugate with any of the bladder cancer cell lines
investigated (data not shown). The level of conjugation was never greater
than the control levels obtained without centrifugation.
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Figure 44. The kinetics of conjugate formation
A representative time course of conjugate formation between LAK cells and
eight bladder cancer cell lines. Target cells were labelled with dihydroethidium
and effector cells with CFDA.AM. The fluorescence was determined using a
flow cytometer. Conjugation was initiated by briefly centrifuging the cells in
complete medium at 37^, followed by rapid resuspension. The target cells
used were as follows; RT4 (+), RT112 (A), MGH-U1 (■), EJ18 (o), J82 (A),
5637 (□), UMUC-3 (•), and SD (x ).
177




















The correlation between constitutive susceptibility to LAK mediated cytotoxicity
and conjugate formation. The correlation coefficient does not reach significance
(p>0.2).
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3.3.7 Antibody blockade ofconjugate formation
The studies have demonstrated a role for the LFA-1/ICAM
interaction in the activity of LAK cells against bladder cancer cells. In the
presence of monoclonal antibodies to LFA-1 and ICAM-1, the specific
cytotoxicity of LAK cells was reduced. In order to further illustrate the role
of these adhesion molecules and to dissect the mechanisms involved in
LAK activity, adhesion blockade was undertaken with the conjugate assay.
When effector cells were pretreated with monoclonal antibodies to
CD 11a, their ability to form conjugates with bladder cancer target cells
was negated (Figure 46). The mean level of conjugation in the presence of
antibodies to CD 11a was reduced by 70.5%±23. The level of conjugation of
UMUC-3 was not greatly reduced by anti-LFA-1 antibodies (20%
reduction). When the cells lines known to express moderate or high levels
of ICAM-1 (MGH-U1, EJ18, SD) were incubated with anti-ICAM-1
antibodies and marked reduction in conjugation was observed. This level of
reduction was equivalent to that achieved by antibodies to LFA-1. The
level of conjugation of cell lines RT4 and RT112 was not greatly reduced by
antibodies to either ICAM-1 or ICAM-2. Finally, when UMUC-3 was pre-
incubated with antibodies to ICAM-1 and ICAM-2 a reduction in the level
of conjugation was observed. In the case of anti-ICAM-2 this level of
reduction was greater than that achieved with anti-LFA-1.
3.3.8 Conjugation to target cells is an energy dependent event
The requirement for an active process in conjugation was
investigated by using sodium azide to inhibit metabolic processes. When
LAK cells were treated with sodium azide the level of conjugation was
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usually less than 3% (Figure 47). However, similar treatment of the target
cells did not affect their ability to form conjugates (data not shown). When
both cell populations were separately incubated with sodium azide prior to
conjugate formation, no decrease below that obtained with effector cells
alone was observed.
3.3.9 The conjugation ofeffector and target cells is dependent upon divalent
cations
Previous work by Marlin and Dransfield has elegantly demonstrated
the role of several divalent cations, notably magnesium, manganese and
calcium, in the function of LFA-1 (Dransfield et al 1989. Marlin et al
1987). The role of such cations in the function of LFA-1 as a counter-
receptor for ligands on bladder cancer cells was investigated with the aid of
the above conjugate assay.
When calcium ions were removed from complete medium with the
aid of ImM EGTA, a small but consistent reduction in the level of
conjugation was noted (Figure 48). However, removal of all divalent
cations, by treatment of complete medium with ImM EDTA, resulted in
levels of conjugation little greater than those achieved following treatment
with sodium azide (Figure 48).
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Figure 46. Adhesion blockade of conjugate formation
40 t RT112
Control ICAM-1 ICAM-2 LFA-1 Control ICAM-1 ICAM-2 LFA-1
Antibody used for adhesion blockade
The effect of adhesion blockade on the formation of conjugates between LAK cells
and bladder cancer cell lines. Target cells were incubated with saturating
concentrations of monoclonal antibodies to ICAM-1 and ICAM-1 and effector cells
were incubated with antibodies to LFA-1 for 30 minutes. Control incubations were
performed in the presence of antibody diluent. Conjugates were formed by
centrifugation and assessed using the flow cytometric methods described. Shown
is a representative experiment for each line.
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The effect of sodium azide (0.05%) on the formation of conjugates between LAK cells
and bladder cancer target cells. Bladder cancer cell lines were briefly pre-treated
with sodium azide or medium alone prior to the formation of conjugates by
centrifugation. The cell lines shown are RT4 (■), RT112 (E0), MGH-U1 (M), EJ18
(0), SD O), UMUC-3 (■), and J82 O). A representative experimental value is shown
for each cell line.
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The role of divalent cations was investigated with the aid of calcium chelating
agent EGTA (ImM) and divalent cation chelating agent EDTA (ImM). Conjugates
were formed in medium containing either EGTA or EDTA , or in complete medium
alone (control). Shown are the results for six cell lines; RT4 (■), Rtll2 (E3), MGH-U1
<M), EJ18m, SDO, and J82 «).
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3.3.10 The role ofcalcium, magnesium and manganese divalent cations in
conjugation
The above studies demonstrate the dependence of conjugation upon
the presence of divalent cations. Dransfield and colleagues demonstrated
that the binding of mAb24 to LFA-1 required the presence ofmagnesium
ions (Dransfield and Hogg 1989) and the work of Figdors group has shown
the expression of the L16 epitope is dependent on the presence of calcium
cations (Keizer et al 1989). In order to further dissect such phenomenon,
the effect of increasing the Mg2+ or Mn2+ concentration in both the presence
and absence of Ca2+ was investigated.
When the concentration of either calcium, magnesium or
manganese in complete medium was increased an increase in the levels of
conjugation was observed for the three lines tested (SD, EJ18 and J82,
Figures 49, 50 and 51 respectively). The increase in binding was
dependent upon the concentration of divalent cation. Optimal binding
occurring in the presence of between 4 and 8mM of each of the cations
investigated. In the case of SD and EJ18, the presence of manganese
cations resulted in an increase in binding grater than in the presence of
magnesium or calcium. This was not the case for J82, increased
manganese concentration resulted in little change in the percentage of
conjugates formed.
Following removal of calcium ions from complete medium, the
addition ofmagnesium ions had a dramatic effect upon the percentage of
targets which formed conjugates with LAK cells (also Figure 49, 50 and
51). As little a ImM Mg2+ resulted in a significant increase in the level of
conjugation above control. Maximal conjugation was seen with between 8
and 16 mM Mg2+. The level of conjugation in the presence of magnesium
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Figure 49. Conjugation is dependent upon divalent cations
The effect of different divalent cations in the presence and absence of EGTA on the
formation of stable conjugates between the cell line SD and LAK cells. Conjugates
were formed in RPMI containing the indicated concentrations of either calcium (□ ),
magnesium (■), manganese (♦ ), or containing EGTA + magnesium (o ), or EGTA +
manganese (A ). Shown is a representative experiment.
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Figure 50. Conjugation is dependent upon divalent cations
The effect of different divalent cations in the presence and absence of EGTA on the
formation of stable conjugates between the cell line EJ18 and LAK cells. Conjugates
were formed in RPMI containing the indicated concentrations of either calcium (□ ),
magnesium (■), manganese (♦ ), or containing EGTA + magnesium (o ), or EGTA +
manganese (A ). Shown is a representative experiment.
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Figure 51. Conjugation is dependent upon divalent cations
The effect of different divalent cations in the presence and absence of EGTA on the
formation of stable conjugates between the cell line J82 and LAK cells. Conjugates
were formed in RPMI containing the indicated concentrations of either calcium (□ ),
magnesium (■), manganese (♦ ), or containing EGTA + magnesium (o ), or EGTA +
manganese O ). Shown is a representative experiment.
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but in the absence of calcium was far greater than in the presence of
calcium, suggesting competition between these two ion species.
The maximal degree of conjugate formation was observed in the
presence of manganese following removal of calcium ion using EGTA
(ImM). Treatment with between 4 and 16mM manganese increased
conjugation by over 100% for all three cell lines investigated.
3.3.11 Calcium ions compete with magnesium ions for binding to LFA-1
In order to investigate the relationship between Mg2+ and Ca2+ in
conjugate formation, a competition study was employed. The addition of
ImM Ca2+ to complete medium containing ImM EGTA and 4mM Mg2+
resulted in almost complete negation of the increased binding attributable
to Mg2+ (Figure 52). Further increases in calcium ion concentration
resulted in a progressive decrease in conjugate formation reaching baseline
levels with 16mM calcium ions.
3.3.12 Manganese increases conjugate formation by an LFA-1 dependent
mechanism
The mechanism by which manganese increases conjugate
formation was investigated. As LFA-1 is known to contain several cation
binding sites, one possibility was that manganese ions were binding
directly to LFA-1 thereby leading to conformational changes. Another
possibility was that Mn2+ was increasing conjugation by an LFA-1
independent mechanism.
When conjugates were formed in the absence of Ca2+ and in the
presence ofMn2+ elevated levels of conjugation were observed. When cells
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were also treated with EGTA and Mn2+ and conjugates formed in the
presence of sodium azide or anti-CD 11a antibodies, a reduced levels of
conjugation was observed (Figure 53). This indicated that the increased
binding due to manganese was at least partially due to changes in LFA-1.
3.3.13 Calcium does not compete with manganese for binding to LFA-1
Calcium competes with magnesium ions thereby lowering the
binding capacity of cells to the level observed in controls. This did not
appear to be the case for manganese as calcium ions were unable to
compete for binding (Figure 54). Interestingly this result contrast with
that obtained for manganese ions in the absence of EGTA (ImM) (Section
3.3.10).
3.3.14 Treatment with IFNyincreases the ability to form conjugates
Previously it has been demonstrated that following 24 hours
stimulation of target cells with IFNy their susceptibility to LAK mediated
cytolysis was increased. Furthermore, it has been shown that IFNy
induces and augments the expression of the intercellular adhesion molecule
ICAM-1 on bladder cancer cells. In order to investigate the mechanism by
which IFNy leads to increased susceptibility to LAK, and to confirm the
role of augmented ICAM-1 expression, cells were stimulated with IFNy for
24 hours prior to assay in the described conjugation assay.
Following stimulation of bladder cancer cell lines with lOOUml"1
IFNy for 24 hours an increase in the percentage of targets cells with which
effector cells had conjugated was observed (Figure 55).
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Figure 52. Calcium competes with magnesium for binding to




The competition between calcium and magnesium ions for LFA-1 cation binding
sites. Cells were washed in medium containing the indicated concentrations of
magnesium or calcium ions prior to determination of the percentage of conjugates.
All tests except control were performed in the presence of ImM EGTA.
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Figure 53. Manganese increases conjugation by an LFA-1
dependent mechanism
The mechansim by which manganese ions increase conjugation was
investigated by treating cells with agents known to inhibit LFA-1 dependent
conjugation. Cells were either untreated (■), treated with EGTA and
4mM manganese (E3), treated with EGTA, 4mM manganese and sodium
azide (0.05%) (H), or treated with EGTA, 4mM manganese and antibodies
to CDlla (E3). Conjugation was determined after brief centrifugation and
resuspension. The data shown are those for three bladder cancer cell lines.
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Figure 54. Calcium does not compete with manganese for binding




The competition between calcium and manganese ions for LFA-1 cation binding
sites. Cells were washed in medium containing the indicated concentrations of
magnesium or calcium ions prior to determination of the percentage of conjugates.
All tests except control were performed in the presence of ImM EGTA.
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Figure 55. Pretreatment with interferon-gamma increases the




Cells were pretreated for 24 hours with IFNy and the ability to form
conjugates was comared to that of untreated cells. The three cell lines
used were RT4 (■), RT112 (E3), and MGH-U1 (p).
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3.4 The expression and function of interferon-gamma receptors
3.4.1 Positive and negative controls for Scatchard analysis
Prior to the more detailed analysis of receptor expression by bladder
cancer cell lines a number of control experiments were carried-out in order
to determine the specificity of the assay technique. Negative controls, in
the form of normal human erythrocytes, and positive controls, in the form
of human cells which had previously been assessed for IFNy receptor
expression (Daudi cells) were used. Scatchard analysis was carried out
using 1x106 cells per test in a competitive assay system as described in
materials and methods.
No specific binding of IFNy to erythrocytes could be demonstrated
and therefore the cells were presumed not to express the receptor in
question. Specific binding was demonstrated by the Daudi cell line and
subsequent Scatchard analysis of the binding data showed the expression
of high affinity receptors for IFNy. The mean Kd was 0.6 xl010M (Range
0.5-0.8) and the mean number of receptors per cell was 4,200 (range
2,800-6,100). The results are in broad agreement with those of other
workers who reported Kd=5 xl010M and Bmax=3,500-7000 for the receptor
on Daudi (Merlin et al 1985).
3.4.2 The number of cells used in Scatchard analysis is critical to the
evaluation of receptors
Having confirmed the specificity of the assay technique, the
optimum concentration of cells for competitive assay was investigated. A
fixed amount of radiolabelled ligand (0.3 ng) was incubated with increasing
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numbers of cells (0-2xl06) in triplicate. Following a single wash, the
radioactive content of the cellular pellet was determined. The binding
curves for 4 bladder cancer cell lines are shown in figure 56. Specific
binding increased with the increasing number of cells. Although the
maximal number of counts bound was observed with the largest number of
cells, this value was not chosen for subsequent experiments. The number
of cells which specifically bound approximately half the maximum number
of counts was used for further studies. For all four cell lines this value was
determined to be 2x105 cells. Unlike specific binding, non-specific binding
increased in a linear fashion with increasing numbers of cells.
3.4.3 The duration of the assay is an important factor in determining
receptor expression
The kinetics of IFNy binding to the cells was dissected at 4°C.
Binding was rapid with over 75% maximal binding occurring within 15
minutes of assay (Figure 57). After 120 minutes no further increase in
specific binding was observed. From this data an assay duration of 120
minutes was chosen for subsequent competitive binding studies.
3.4.4 Minimizing non-specific binding in Scatchard analysis
The effect ofwashing on the NSB following the equilibration of ligand
binding was determined. The aim of this experiment was to maximize the
difference between the NSB value and the specifically associated
interferon-gamma. Figure 58 shows the results obtained for the RT4 cell
line. Although a clear difference exists between specifically bound IFNy
and NSB after zero washes, this difference was improved following one
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Number of cells (xlO )
The effect of increasing numbers of cells on the binding of a fixed amount of
ligand. Increasing numbers of bladder tumour cells were incubated for 4 hours
with 0.3ng of radiolabelled interferon-gamma. Following a single wash the
radioactive content of the pellet was counted. Specific binding is represented by
the open symbols (q), and non-specific binding by the closed symbols (■). Results
are the mean of triplicates and error bars represent one standard deviation.
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Figure 57. The kinetics of ligand binding
Time (minutes)
The kinetics of binding of iodinated interferon-gamma to bladder cancer cells
(RT4). Cells were incubated with a fixed amount of radio-ligand for varying
lengths of time, following which the cells were centrifuged and the supernatant
discarded. The radioactive content of the pellet was assessed and the results
presented represent the mean± sd. Specific binding is shown by the open
symbols <H), non-specific binding by the closed symbols B.
Figure 58. The effect ofwashing on NSB levels
Number of washes
Determination of the optimum number of washes to be given to cells
after a competitive binding assay. Cells were incubated for 2 hours
with 0.3ng of radiolabeled interferon-gamma. The tubes were
centrifuged, supernatant removed, and the radioactive content of the
pellet was determined. The pellet was then resuspended in washing
buffer and recentrifuged prior to counting. This was repeated up to
three times. Solid bars represent specific binding, hatched represent
non-specific binding. Results are the mean of triplicates ±1SD.
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wash. Further washes, however, failed to result in further improvements
in the difference between specifically associated IFNy and NSB. From this
data a single wash was chosen for use in the competitive binding studies.
3.4.5 The Scatchard analysis of interferon-gamma receptors expressed by
bladder cancer cells
Using a competitive binding assay the number of IFNy receptors
per cell and their relative affinity for ligand was determined. All four cell
lines tested displayed large numbers of high affinity receptors for IFNy.
Representative binding curves and the derived Scatchard plots are shown
for the four cell lines studied (Figure 59). From the Scatchard plots a
regression line was calculated the correlation coefficients of which resulted
in significance values of p<0.05 - p<0.001. The binding of radiolabeled
IFNy could be displaced by a 100 fold excess of unlabelled ligand. The non-
displacable binding ranged between 7 and 27% of the total bound, the
upper levels of this being exhibited by the RT4 cell line. The four cell lines
had an average Kd of between 1 and 4 x 10 "10 M and a mean number of
receptors per cell of between 19,000 and 37,000 (Table 8). Although
marked differences in the-mean dissociation constant and number of
receptors expressed by some of the cell lines existed, (EJ18<RT4; p<0.02),
some of the differences failed to reach statistical significance (EJ18<MGH-
Ul; p>0.2, MGH-U1<RT4; p>0.2). These differences were not found to
correlate with biological response.
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Bound (pM) Bound (pM)
Representative Scatchard plots (main graphs) and the binding curves
from which they were derived (inserts) for four bladder cancer cell lines.
A linear regression line has been calculated for each Scatchard plot, each
point on which represents the mean of a triplicate. Briefly, increasing
amounts of unlabelled IFNy were added to a Fixed amount of labelled
IFNy and incubated with 2x10.5 cells for 120 minutes at 4*0. Each
Scatchard plot shows the "tail-back" phenomenon, the likely cause of
which is due to the over estimation of NSB. From the gradient of the
line the dissociation constant (Kd) is calculated and Bmax gives the
number of receptors per cell.
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Table 8. Summary of the results obtained from Scatchard






(Kd xlO "10 M)
RT4 36,859 ± 20,000 3.6 ±1.3
RT112 26941 ±9000 3.3 ± 1.0
MGH-U1 40,812 ± 22,000 4.1 ±2.0
EJ18 19,827 ± 3,800 1.1 ±0.6
The table details the results of Scatchard analysis for the interferon-gamma
receptor as expressed by four bladder cancer cell lines. The number of receptors
per cell was calculated from Bmax and it was assumed that the moiety of interferon-
gamma which bound the receptor was a dimer. The dissociation constant was
calculated from the gradient of the linear regression from the Scatchard plot. All
data represent the mean of at least six independent determinations, each in
triplicate. Results are presented as mean ± sd.
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3.4.6 The kinetics of ligand internalization and degradation following
receptor binding
As the differences in biological response of the four cell lines to IFNy
could not obviously be accounted for simply in terms of their receptor
status, the rate of ligand binding and internalisation by the cells at
physiological temperature (37 °C) was investigated. The cell lines were
analysed in suspension (as in the Scatchard studies) and also as adherent
monolayers.
The kinetic studies on TCC cells in suspension at 37°C revealed
extremely rapid surface binding which was maximal after 10 minutes after
which, the amount of surface bound ligand declined rapidly (Figure 60).
Following receptor binding, an increase in the concentration of internalized
ligand was observed which reached maximum levels after 60 minutes.
After this, a steady decline in internalized ligand was observed. The total
of cell associated ligand was greatest after 30 minutes and declined
thereafter. After 240 minutes total cell associated ligand was less than
20% maximal levels. Figure 58 shows representative kinetics for MGH-U1
in suspension at 37 °C, the other three cell lines followed similar patterns.
At 4°C surface binding was again a rapid event but was not followed by a
marked degree of ligand internalisation. Only when the temperature was
increased to 37°C was the ligand internalised (Figure 61).
The rate of binding and internalization by adherent cells was
different to that of cells in suspension. The kinetics of surface binding were
less rapid with halfmaximal binding occurring after 10 minutes (Figure
62). This proceeded to a maximum after 60 minutes with all lines except
RT4 (maximum 100 minutes), following which a gradual decrease in the
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amount of surface bound ligand was observed. Surface binding was
followed by a steady increase in the levels of internalized ligand. Levels of
internalized ligand continued to increase until 180 minutes in all lines
except RT4, where the increase continued until 300 minutes. Significant
differences were apparent between the maximum amount of ligand bound
by the cell lines; MGH-U1 5,124±497cpm, EJ18 3,875±1022cpm, RT4
7,989±648cpm, RTR112 15,661±1720cpm (MGH-U1<RT4<RT112,
p<0.02). MGH-U1 and EJ18 (G3) both bound the least ligand. The two
lower grade tumour lines maximally bound higher levels of ligand, with
RT112 (G2) binding the highest.
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Figures 60 & 61. The binding of IFNy to MGH-U1 cells
Time (mins)
The kinetics of IFNybinding and internalization by MGH-U1 at two different
temperatures (A-37, B-4). Cells were incubated with IFNy for the indicated times
and surface bound ligand was removed using acidic buffer. After centrifugation
pellet and supernatant associated radioactivity were determined separately. In
figure B the temperature was increased to 37°C after 240 minutes. Shown is the
amount of surface bound ligand (o), internalized lignad (□), and the total cell
associated ligand (A).
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Figure 62. The rate of binding of IFNy to four TCC cell lines
Incubation time (mins)
The kinetics of cell surface binding, internalization and degradation of interferon-gamma by
four bladder cancer cell lines. Cells in suspension were incubated with 0.3ng of radiolabeled
IFNyfor the indicated periods. Cell surface ligand was removed by acid stripping techniques
and separated from the pellet by centrifugation. The cell associated and supernatant associated
radioactive content were determined separately, the addition of both giving the total cell associated
ligand. The experiments were carried out in triplicate and standard deviations were within 5%.
The total cell associated ligand (■), the receptor bound ligand (□), and the internalized ligand
(E3) are depicted.
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3.5 The signal transduction ofthe interferon-gamma receptor
3.5.1 Induction ofICAM-1 and HLA class II molecule expression.
The constitutive expression of these molecules varies between cell
lines. Following incubation with IFNy further expression of both class II
and ICAM-1 molecules can be induced. However, cell lines which respond
well in terms of class II induction do not necessarily respond well with
ICAM-1 induction, or vice versa. The mechanisms of signal transduction
from the IFNy receptor are not clearly defined, major differences being
reported by different groups. The mechanisms of signal transduction were
investigated in terms ofHLA class II and ICAM-1 expression with the aim
of firstly determining any differences between cell lines, and secondly any
differences between class II and ICAM-1 expression induced by IFNy.
3.5.2 The role ofPKC in IFNy inducedHLA class II expression.
Protein kinase C is a common intracellular messenger, the role of
which was investigated using specific inhibitors and activators of its
function. The IFNy induced class II molecule expression on RT4 and
RT112 was not inhibited by a PKC inhibitor H-7 (l-40pM) (Figure 63).
The second step in the investigations concerning PKC involved
activation via PMA. When RT4 cells were treated with PMA at either 100
or 500ngml_1, increased expression ofHLA class II was observed, however,
no similar induction was observed with RT112 (Figure 64). The increased
class II expression by RT4 resulting from treatment with PMA was less
than that achieved with IFNy, suggesting the involvement of other factors
in optimal signal transduction.
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Figure 63. An inhibitor of PKC fails to block IFNy induced class-
II expression
Control IFNy IFNy IFNy IFNy IFNy
0|iM 5^M lO^M 20 |rM 40nm H7 concentration
Treatment
The effect of protein kinase C inhibitor H7 on the expression ofMHC class II
molecules induced by interferon-gamma. Cells were stimulated for 48 hours
with 500U/ml IFNy and increasing concentration of H7. Control values are
those obtained in the absence of IFNy. MHC class II expression was determined
by flow cytometry. The two bladder cancer cell lines shown are RT4 (■), and
RT112 (E2). Error bars represent 1 standard deviation.
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Control IFNy PMA PMA
500U/ml 100 ng/ml 500ng/ml
Treatment
The effect of activation of PKC via treatment of cells with PMA. Cells were
incubated with either medium alone (control), interferon-gamma, or PMA at
the concentrations indicated for 48 hours. The expression ofHLA class II
molecules was determined by flow cytometry. The cell lines used were RT4
(■), and RT112 (E3). Error bars show 1 standard deviation.
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3.5.3 The effect ofcalcium ionophore on HLA class II expression
A further important second messenger pathway involves the
activation of calcium/calmodulin dependent protein kinases. When RT112
cells were treated for 48 hours with the calcium ionophores A23187 and
ionomycin, no change in class II expression was observed. However, the
expression of class II antigens on RT4 was induced following stimulation
with calcium ionophore (Figure 65).
Several workers have reported the "cross-talk" phenomenon
involvement in the signal transduction of various cytokine receptors. This
involves two (or more) signalling pathways acting together to generate a
response. Simultaneous activation of protein kinase C and an increase in
intracellular calcium by PMA and ionomycin or A23187 failed to result in
increased expression ofHLA-DR by either RT4 or RT112 (data not shown).
3.5.4 Effect of inhibition of calmodulin-dependent activity on IFNy-
induced Ag expression.
Because calmodulin can be activated by an increase in intracellular
calcium ([Ca2+]}), we determined if inhibition of calmodulin dependent
processes prevented the induction of surface antigens by IFNy. When
RT112 cells were treated with W-7 (an inhibitor of calmodulin dependent
processes) the induction of class II by IFNy was inhibited in a dose
dependent manner (l-40pM) (Figure 66). This was not the case for RT4
cells in which no inhibition of IFNy induced DR expression was observed.
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The effect of calcium ionophores A23187 and ionomycin on the expression of
HLA class II molecules by two bladder cancer cell lines RT4 (■) and RT112
(E0). Cells were stimulated for 48 hours with the indicated agents and class
II expression determined by flow cytometry. Error bars indicate 1 standard
deviation.
209
Figure 66. The calmodulin inhibitorW7 prevents IFNy induced HLA
class II expression
100 n
Control IFNy IFNy IFNy IFNy IFNy
O^M 5^M 10p.M 20 40 nM W7 concentration
Treatment
The effect of calmodulin inhibitor W7 on the expression of MHC class II
molecules induced by interferon-gamma. Cells were stimulated for 48 hours
with 500U/ml IFNy and increasing concentration of W7. Control values are
those obtained in the absence of IFNy. MHC class II expression was determined
by flow cytometry. The two bladder cancer cell lines shown are RT4 (■), and
RT112 G2). Error bars represent 1 standard deviation.
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3.5.5 The role ofextracellular calcium in IFNy induced class II expressions
In order to investigate the role of extracellular calcium in IFNy
induced DR expression, extracellular calcium was chelated using EGTA (1
mM). Depletion of extracellular calcium in this manner appeared to inhibit
the IFNy induced MHC class II Ag expression by RT112, suggesting the
involvement of calcium influx in its induction, but did not inhibit DR
expression by RT4 (Figure 67). The inhibition of expression was not due to
the toxic effects of EGTA as replenishment of the calcium concentration to
original levels reversed the reduction in class II expression.
3.5.6 Effect of inhibition ofcalcium transients on the induction ofclass II
expression by IFNy
To study the functional significance of calcium influx through ion
channels, cells were pretreated with diltiazem (lpM) for 30 min and
incubated in the presence of diltiazem with IFNy (500UmH) for 48 hr.
Diltiazem failed to inhibit the induction of surface class II expression by
RT4 and RT112 cells (Figure 68).
The effect of inhibition of an increase in [Ca2+]j mobilisation by
TMB-8 on IFNy induced class II expression was determined by pretreating
RT4 and RT112 cells with TMB-8 (75 pM) followed by incubation in the
presence of TMB-8 with IFNy (SOOUmh1) for 48 hr. TMB-8 partially
inhibited the IFNy induced HLA-DR Ag expression by RT112 cells but not
by RT4 (Figure 69). A mean reduction of 53±10% of the level obtained
with IFNy was observed on the RT112 cell line following treatment with
TMB-8.
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Figure 67. Depletion of extracellular calcium ions prevents IFNy
induced class II expression by RT112
100


















The role of extracellular calcium in the signal transduction of the IFNy
receptor. Extracellular calcium was chelated with ImM EGTA and the
cells were stimulated with 500U/ml of IFNy for 48 hours prior to the
determination of class II expression by flow cytometry. The two cell lines
shown are RT4 (■), and RT112 (E0). Error bars show 1 standard deviation.
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Figure 68. Calcium channel blockade does not inhibit IFNy






The effect of calcium channel blockade on IFNy induced class II expression by
RT4 (■), and RT112 (E3). Cells were pre-treated with lpM diltiazem for 30
minutes prior to stimulation with 500U/ml IFNy for 48 hours. Antigen
expression was determined via flow cytometry.


















The effect of inhibition of an increase in intracellular calcium by 75itM
TMB-8 on IFNy induced class II expression by RT4 (■), and RT112 (0).
Cells were pretreated with TMB-8 and then stimulated with IFNy for
48 hours. MHC class II expression was determined by flow cytometry.
Error bars represent 1 standard deviation.
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3.5.7 IFNyfails to induce calcium mobilisation in bladder cancer cells
As pharmacological manipulation of calcium mobilisation appeared
to alter the ability of IFNy to induce class II expression by RT112, we
loaded the cells with Fura-2AM, a calcium indicating dye, and subsequently
monitored the cytosolic calcium concentration in the absence and presence
of IFNy. The basal levels of calcium concentration for RT4 and RT112
were approximately lOOnM. When MGH-U1, RT4 and RT112 cells were
stimulated with IFNy no increase in intracellular calcium concentration
was observed. As confirmation of the correct functioning of the system,
cells were stimulated with the calcium ionophore ionomycin. Immediately
following stimulation with ionomycin, an increase in intracellular calcium
was observed (data not shown). The subsequent treatment of the cells
with digitonin caused the level of intracellular calcium to fall to baseline
(data also not shown).
3.5.8 The role ofPKC in IFNy induced ICAM-1 expression
Following 24 hours stimulation with lOOngmT1 PMA, the MGH-U1
cell line was observed to express high levels of ICAM-1, however, RT4 and
RT112 did not behave in a similar manner (Figure 70). In fact, the levels of
ICAM-1 induced by PMA treatment ofMGH-U1 were significantly greater
than those achieved with the optimal concentration of IFNy alone
(p<0.02). Unlike the IFNy induced antigen expression the PMA inducible
ICAM-1 expression was partially inhibited by pretreatment with CHX
(lpgrnl"1 for 30 minutes) as shown in Figure 71.
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The effect of activation of PKC via treatment of cells with PMA. Cells were
incubated with either medium alone (control), interferon-gamma, or PMA at
the concentrations indicated for 24 hours. The expression of ICAM-1
molecules was determined by flow cytometry. The cell lines used were RT4
(■), RT112 (E2), and MGH-U1 di). Error bars show 1 standard deviation.
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Figure 71. The contribution of protein synthesis in PMA induced
ICAM-1 expression
Control IFNy PMA IFNy + PMA +
CHX CHX
Treatment
The contribution of protein synthesis in PMA induced ICAM-1 expression
was assessed using CHX. MGH-U1 were stimulated with either IFNy (lOOU/ml)
or PMA (lOOng/ml) in the absence or presence of CHX (l(ig/ml) for 24 hours.
Following incubation the expression of ICAM-1 was studied using flow
cytometry with monoclonal antibody RR1/1. Bars show the mean of triplicate
determinations, error bars indicating 1 standard deviation
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3.5.9 Protein kinase C inhibitors H7 and staurosporine fail to inhibit IFNy
induced ICAM-1 expression
Treatment of the MGH-U1 cells with PMA resulted in augmented
expression of cell surface ICAM-1 within 24 hours. As PMA is a known
activator of PKC, the role of this kinase was investigated with the inhibitor
H7 and the specific PKC inhibitor staurosporine.
The pharmacological inhibition ofPKC did not result in a decreased
response to IFNy (Figure 72). Furthermore, in the case ofMGH-U1, when
ICAM-1 expression was induced by PMA no inhibition was seen in the
presence of staurosporine or H7. This indicated that PKC was not
involved in the signal transduction from the IFNy receptor, and that PMA
acts by another mechanism to increase the expression of ICAM-1.
3.5.10 The role ofcalcium ions in IFNy induced ICAM-1 expression
The role of divalent calcium ions in IFNy induced ICAM-1 expression
was investigated using calcium ionophores (A23187), calcium chelating
agents (EGTA) and drugs known to influence to mobilization of
intracellular calcium (TMB-8) or calcium channel function (diltiazem).
When the three bladder tumour cell lines were treated with either A23187
or ionomycin for 24 hours no induction or augmentation of ICAM-1
expression was observed (Figure 73).
When RT4 and MGH-U1 cells were pretreated with EGTA in order
to chelate extracellular calcium prior to stimulation with IFNy, an increase
in ICAM-1 expression was noted (Figure 74), however no change was
observed with RT112. Neither blockade of calcium channels (diltiazem)
nor inhibition of calcium mobilization (TMB-8) in RT4 caused any change
Figure 72.
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Inhibition of PKC does not prevent IFNy or PMA
from inducing ICAM-1 expression on MGH-U1
The contribution of PKC to IFNyand PMA induced ICAM-1 expression was
assessed using PKC inhibitors H7 (40gM) or staurosporine (st, 50nM). Cells
were first pretreated with these agents prior to stimulation with IFNy for 24
hours. ICAM-1 expression was determined using flow cytometry with the
monoclonal antibody RR1/1. Bar represent the mean of triplicat values, whilst
error bars indicate the level of 1 standard deviation.
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Figure 73. Calcium ionophores do not induce ICAM-1 expression
on bladder cancer cell lines
80-,
Control IFNy A23187 Ionomycin
Treatment
Cells were treated with either IFNy (lOOU/ml) or calcium ionophore (lOOnM)
for 24 hours. The three cells lines used were RT4 (■), RT112 (E3) and MGH-
U1 (H). ICAM-1 expression was determined using flow cytometry with the
monoclonal antibody RR1/1. Bars represent the mean of triplicate values,
whilst error bars indicate the level of 1 standard deviation.
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Figure 74. The role of calcium ions in IFNy induced ICAM-1
expression on bladder cancer cell lines
100 n
Control IFNy EGTA TMB-8 Diltiazem
Treatment
Cells were treated with either IFNy alone (lOOU/ml) or first pre-treated with
EGTA (ImM), TMB-8 (75|iM) and Diltiazem ( 2|iM) for 24 hours. ICAM-1
expression was determined using flow cytometry with the monoclonal antibody
RR1/1. The three cell lines used were RT4 (■), RT112 (0) and MGH-U1 (0).
Bars represent the mean of triplicate values, whilst error bars indicate the
level of 1 standard deviation.
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in ICAM-1 expression (Figure 74). However, channel blockade in the case
of MGH-U1 and inhibition of calcium mobilization in the case of RT112
was observed to decrease the response of these cells to IFNy (Figure 74).
Only partial blockade of response was achieved.
3.5.11 The effect of inhibition of calmodulin dependent protein kinase
activity on IFNyinduced ICAM-1 expression
The expression MHC class II molecules as induced by IFNy on
RT112 cells was inhibited by W7, an inhibitor of calmodulin dependent
protein kinase activity. However, ICAM-1 induction on the same cell line
was not inhibited by pretreatment with W7 (10-50(J.M). Similarly, IFNy
induced ICAM-1 expression on RT4 and MGH-U1 cells was not inhibited
by W7 at any concentration (data not shown).
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3.6 The relationship of in vitro studies to the situation in vivo
The studies presented so far have examined a variety of parameters
associated with the immunotherapy of bladder cancer, the role of various
cytokines and the function of adhesion molecules in an artificial killing
system. In vitro the killing of tumour cells by LAK cells would appear to
involve the LFA-1/ICAM interaction as a primary recognition signal
between effector and target cell. Tumour cells which express higher levels
of the ligand for effector cells would appear to be more susceptible to
conjugation and lysis by these cells. Cytokines which are known to be
produced as a result of intravesical BCG therapy for bladder cancer (IFNy,
TNFa, IL-1) are able to regulate the expression of several molecules which
are important for a wide variety of immunological interactions. When
recombinant human IFNy or TNFa are applied to bladder tumour cell lines
in vitro the expression of ICAM-1 and HLA class II molecules is induced or
augmented.
These studies provide interesting and useful data on the disease of
bladder cancer, the possible mechanisms of successful response to
immunotherapy, and the mode of action of lymphokine-activated killer
cells. However, if the molecules discussed are not expressed by bladder
cancer cells, if the cytokines thought to be produced as a direct result of
BCG therapy do not exert immunomodulatory and cytotoxic effects on
bladder cancer cells, and if the lymphocytes which infiltrate the bladder
wall do not interact with the tumour cells, then these in vitro studies are of
limited use. For these reasons it was thought vital that some reference be
made to the clinical situation of bladder cancer and its immunotherapy.
3.6.1 The effect of urine from patients receiving intravesical BCG therapy
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on the expression ofICAM-1 by bladder cancer cell lines
The work of several major urological research groups has
demonstrated the existence of a variety of cytokines in the urine of
patients who had received intravesical BCG for the treatment and
prophylaxis of superficial bladder cancer. The effects of these cytokines
have been investigated by stimulating bladder cancer cells in vitro with
purified, recombinant human cytokines, either as single agents or in
combination with one other cytokine. Although this provides useful
information on the possible role of such molecules, these studies are limited
by the very purity of the cytokines used. In urine, a vast and complex
"cocktail" of cytokines is produced by patients who respond to BCG
therapy. In addition, other non-cytokine, immunologically relevant
molecules such as soluble receptors are known to be secreted in urine. The
effect of such urine per se, however, has not been investigated. The aims of
this area of work were to determine if BCG urine, and the mixture of
molecules contained within, were able to mimic any of the findings in vitro.
From the work of Prescott et al (1989), it would seem that following
repeated BCG instillation in to the bladder cytokines are produced during
the twelve hours post treatment. For this reason, the following
experiments were conducted using urine obtained during the twelve hours
following instillation. Urine from each of the six therapeutic instillations
was collected and processed prior to storage. There exists some
controversy concerning the presence of IFNyin the urine ofbladder cancer
patients. One possible reason for this is the acid labile nature of this
cytokine. Even short term exposure to a pH of 6.5 can cause a loss of
biological activity. It was decided, therefore, to dialyze the urine against
PBS (pH7.2) in order to prevent such destruction of cytokines taking
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place.
Bladder cancer cell lines were stimulated with the dialyzed urine
collected over the twelve hours following each instillation of BCG. The
expression of both ICAM-1 and HLA class II molecules was monitored
using flow cytometry; ICAM-1 expression was determined after 24 hours
and HLA class II expression after 48 hours of stimulation.
There was a heterogeneous response to the urine from BCG treated
patients. When the cell lines RT4, RT112 and MGH-U1 were stimulated
with urine taken from the first instillation, three urines failed to induce or
augment ICAM-1 expression, however, the urine of three patients caused
an increase in antigen expression (Figure 75). When cells were stimulated
for 24 hours with instillation 6 urine, a significant (p<0.01) increase in
ICAM-1 expression was observed (Figure 76). The effects were of similar
magnitude on each of the three cell lines. The increase was not identical
for all the patient samples tested. Urine from patient 3 only stimulated a
small increase in ICAM-1 expression when compared to patients, 1, 2 or 4,
whilst patients 5 and 6 gave an intermediate response.
The immunomodulatory effects ofurine from the sixth instillation of
BCG were apparent at dilutions as high as 1:32 (Figure 77). The biological
effects of this urine were equivalent to lOOUmT1 of recombinant IFNy (if
due to IFNy alone).
The effect ofurine from each of the six instillations on both ICAM-1
and HLA class II molecule expression was investigated (Figures 78 and
79). Urine from earlier instillations (1 and 2) generally failed to elicit a
response. Urine from the latter instillations induced the expression of
ICAM-1 and HLA class II antigens. Generally, the maximal response was
observed with samples obtained following the latter instillations, however,
the responses were heterogeneous. One point of interest may be observed
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Cells were stimulated for 24 hours with dialyzed urine (pH7.2) which had been
diluted 1:2 in complete medium. The expression of ICAM-1 was determined
using flowcytometry with the monoclonal antibody RR1/1. Bars represent the
mean of triplicate determinations, error bars represent 1 standard deviation.
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Cells were stimulated for 24 hours with dialyzed urine (pH7.2) which had been
diluted 1:2 in complete medium. The expression of ICAM-1 was determined
using flowcytometry with the monoclonal antibody RR1/1. Bars represent the
mean of triplicate determinations, error bars represent 1 standard deviation.
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The effect of BCG urine from the sixth instillation on the expression of ICAM-1
by the cell line RT4 (Gl). Dialyzed urine was diluted in complete medium
and the cells incubated in its presence for 24 hours. The expression of ICAM-1
was determined via flow cytometry using monoclonal antibody probes. Bars
represent the mean of triplicate determinations and error bars represent 1
standard deviation.
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The biological response of the RT4 bladder cancer cell lines to urine collected
during the first twelve hours following each of six instillations of BCG.
Urine was first dialyzed and then added to the cells for 24 hours at a dilution
of 1:2. The urine from six patients was analyzed; patient 1 (—a—■),
patient 2 (—♦—■), patient 3 (—■—), patient 4 (—-o—), patient 5 (—0—•), and
patient six (—»—). The expression of ICAM-1 is shown and was determined
by flow cytometry with the monoclonal antibody RR1/1.
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Fig 79. The induction of MHC class II expression by urine from
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Instillation
The biological response of the RT4 bladder cancer cell lines to urine collected
during the first twelve hours following each of six instillations of BCG.
Urine was first dialyzed and then added to the cells for 24 hours at a dilution
of 1:2. The urine from six patients was analyzed; patient 1 (—□—•),
patient 2 patient 3 (—■—), patient 4 (—<>—), patient 5 (—a—•), and
patient six (—»—). The expression of HLA-class II was determined by flow
cytometry with the monoclonal antibody DA6-231.
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with patient 4 urine, instillation 5. At this point the biological response to
urine is poor and not greatly raised above the control values.
Retrospective enquiries revealed that the fifth instillation had not been
given to that particular patient due to a prolonged reaction to earlier
instillations. However, a urine sample was still collected by the patient
and this was processed as usual.
3.8.2 Controls for neutralizing experiments
One approach commonly used to dissect out the role of specific
cytokines in a complex mixture of substances is to use antibodies which
not only specifically bind to the cytokine, but also neutralize its biological
effects. Such neutralizing antibodies are often polyclonal in nature and are
therefore extremely effective at inhibiting the biological response. Bladder
cancer cells were stimulated with recombinant IFNy and TNFa for 24
hours in the presence or absence of neutralizing antibodies to both these
cytokines. When neutralizing antibodies were used at a 1:100 dilution they
totally abolished the effect of these cytokines on ICAM-1 expression
(Figure 80). When RT4 cells were stimulated with l.OOOUmT1 of either
IFNy or TNFa a large biological response was seen, as expected. In the
presence of a 1:100 dilution of antibody this effect was completely negated.
It should be noted that lOOOUml"1 of both cytokines corresponds to a level
far greater than that detected in the urine following BCG instillation. This
concentration of cytokine was chosen as it is approximately one order
greater than that found in urine.
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Fig 80. Controls for neutralizing experiments
0 20 40 60 80
Percentage of cells
expressing ICAM-1
Neutralizing antibodies to IFNy and TNFa can effectively negate the biological
effect of these cytokines. Cells were stimulated with l,O00U/ml of either cytokine
in the presence and absence of a 1:100 dilution of neutralizing polyclonal antibody
specific for that cytokine. Following a 24 hour incubation the percentage of cells
expressing ICAM-1 on their surface was determined using flow cytometry. Solid
represent the mean of triplicate determinations, error bars indicate 1 standard
deviation.
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3.8.3 Neutralizing antibodies to IFNy but not TNFa abolish the
immunomodulatory effects of BCG urine
When urine from sixth instillation samples was pre-incubated with
neutralizing antibody to IFNy, its ability to modulate ICAM-1 expression
was almost completely negated (p<0.01) (Figure 81). However, some
activity remained cm-neutralized by anti-IFNy antibodies. When samples
were pre-incubated with neutralizing antibodies to TNFa, no significant
decrease in ICAM-1 expression was observed for any patient.
Simultaneous pre-incubation with both antibodies had no greater effect
than with anti-IFNy antibodies alone.
3.8.4 Detection ofIFNy in the urine following BCG therapy
Although the above biological assay with neutralizing antibodies
demonstrated the presence of IFNy in the urine of patients who had
received intravesical BCG vaccine, it was decided to use immunological
methods in order to confirm its existence. As previously mentioned
considerable controversy exists over the presence of this cytokine in the
urine of patients receiving such adjuvant immunotherapy (E. de Boer and
A. Bohle, personal communications). For this reason two independent
commercially available immunoassay kits were employed to quantify the
IFNy in the urine samples.
No difference in the concentration of IFNy detected in the urine was
evident when two different immunoassay systems were employed (data
not shown). Using the two site ELISA assay and an immunoradiometric
assay, the presence of IFNy in urine was confirmed. Peak levels as high as
100 Uml-1 of urine were detected in the latter samples. If the volume of
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The effect of neutralizing polyclonal antibodies to IFNy and/or TNFa on the
immunomodulatory potential of urine taken from patients receiving BCG
therapy. Urine from the twelve hours following instillation six was dialyzed
against PBS (pH7.2). Samples for neutralization experiments were incubated
with a 1:100 dilution of polyclonal antibody for 30 minutes at 20C prior to
stimulating RT4 cells for 24 hours. Bars represent the mean of triplicate
determinations. Error bars show 1 standard deviation. Six patients were
used; #1 #2 (0), #3 W, #4 tfDD, #5 (O) and #6
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urine produced during the twelve hours post instillation is considered then
total IFNy production can be assessed. Figure 82 shows the concentration
of IFNy in the urine and the total IFNy production during the first twelve
hours following the sixth instillation of BCG. It should also be noted that
the concentration of IFNy in the urine of patients 2, 3, 5 and 6 never
exceeded 15 Uml"1 whilst the other patients secreted higher levels. Patient
4 secreted levels in excess of 100 Uml"1. The total IFNy production per
instillation varied with each patient. Patients 1 and 4 produced peak levels
in excess of 30,000U per instillation. However, no change in the ranking of
the patients was evident when urine volume (ie total output) was taken
into consideration.
3.8.5 Detection ofTNFa in the urine following BCG therapy
The work of Bohle and colleagues (1990) has demonstrated the
presence of TNFa in patient's urine following BCG therapy. Although
TNFa did not appear to have an important role in the biological assay of
urine, its presence was non-the-less investigated. Using a commercially
available ELISA kit the quantity of TNFa in the urine was determined
(Figure 83). Not all patients produced detectable levels of TNFa in their
urine. Patient 3 failed to produce any. However, as with the production of
IFNy, a vast heterogeneity of response was observed. There was general
agreement between the production of IFNy and the production ofTNFa.
Again patient 4 produced the highest levels, with peak production
occurring following the sixth instillation (>900Uml-l). Upon consideration
of the urine volume, patient 4 maximally produced nearly
6x105U/instillation.
234



















































The production of IFNy and its subsequent secretion into the urine of patients receiving
intravesical BCG therapy. Urine was collected from the twelve hours following each of
six instillations of BCG. Dialyzed urine (pH7.2) was then assayed for IFNy using an
ELISA kit system. Shown is the concentration of interferon (—□—), and the total out¬


































































































The production of TNFa and its subsequent secretion into the urine of patients receiving
intravesical BCG therapy. Urine was collected from the twelve hours following each of
six instillations of BCG. Dialyzed urine (pH7.2) was then assayed for TNFa using an
ELISA kit system. Shown is the concentration of interferon (—□—), and the total out¬
put per instillation (—•—) for each of six patients tested.
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3.8.6 The response ofL929 murine fibroblasts to urine containing TNFa
Immunoassay detection systems have identified the presence of
high levels of TNFa in the urine of patients following BCG therapy,
however, three bladder cancer cell lines apparently failed to respond to
such TNF, thereby questioning the biological capabilities of such TNF. It
was decided that the TNF sensitive L929 bioassay should be used to
further investigate such a possibility. The urine from the sixth instillation
of four patients was applied to the L929 system, as were the relevant
controls and standards. Although recombinant TNF proved toxic to the
L929 cells, the urine from all four patients was not found to exert any
significant cytotoxicity (data not shown).
3.8.7 The secretion ofsoluble ICAM-1 molecules into the urine following
intravesical BCG therapy
In recent years several forms of non-cytokine, immunologically
relevant soluble molecules have been identified, often in the sera of normal
individuals or in that ofpatients with malignancies or chronic pathological
states (Lisoni et al 1989). A form of circulating ICAM-1 (cICAM-1) has
been identified in the sera of normal humans and the the sera of patients
with leucocyte adhesion deficiency (LAD) (Rothlein et al 1991). Levels of
cICAM-1 in normal individuals were around 100-200ngml1. In individuals
with LAD elevated levels of cICAM-1 were detected (200-700ngml-1). In
vitro, both cICAM-1 and sICAM-1 have been shown to be fully functional
in that they mediate LFA-1 dependent lymphocyte adhesion. The cellular
source of cICAM-1 was deemed to be from mononuclear cells. The authors
proposed that cICAM-1 may act as a useful marker for inflammatory
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disease. Elevated cICAM-1 expression has also been correlated with a
number of malignant diseases (Tsujisaka et al 1991). An increased
propensity to metastasise in malignant melanoma has been correlated
with an increase in the expression ofmembrane associated ICAM-1.
Using a sandwich ELISA assay system we studied the secretion of
sICAM-1 into the urine following intravesical BCG administration. The
presence of soluble ICAM-1 was not detected in the urine of all patients
(Figure 84). Patient 1, in whose urine large amounts of both IFNy and
TNFoc had been detected, failed to secrete any ICAM-1 into the urine. In
contrast, patient 3 who produced relatively low levels of IFNy, secreted
detectable levels of sICAM-1. Some patients who produced moderate or
high levels of IFNy also secreted moderate or high levels of sICAM-1
(patients 2 and 4). The maximum concentration of sICAM-1 detected in
the urine was observed in patient 4 following the sixth instillation
(120ngml1).
When the urine volume was considered the maximal level of sICAM-
1 was equivalent to nearly 6pg per instillation. This level of sICAM-1 is
equivalent to 3.7x1013 molecules per instillation. Assuming the same rate
of production per cell as was demonstrated for the SD cell line, this would
correspond to secretion by 1.7xl08 cells.
3.8.8 The expression ofICAM-1 and ICAM-2 by bladder tumours
Several tumour types have been found to express the adhesion
molecule ICAM-1, including malignant melanoma and colonic carcinoma.
The constitutive expression of ICAM-1 and ICAM-2 by bladder cancer cell
lines has been demonstrated, however, in vivo, no information exists as to
the expression of ICAM-1 and ICAM-2 by tumour cells. The constitutive
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The production of sICAM-1 and subsequent secretion into the urine of patients receiving
intravesical BCG therapy. Urine was collected from the twelve hours following each of
six instillations of BCG. Dialyzed urine (pH7.2) was then assayed for ICAM-1 using an
ELISA kit system. Shown is the concentration of sICAM-1 (—p—), and the total out¬
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expression of ICAM molecules by bladder tumour was investigated using
5p.m frozen section obtained from tissue removed by cystoscopic resection
of tumour. Tumours representing various grades and stages of bladder
cancer were investigated. The results are summarized in Table 9. The
majority of tumour cells failed to express ICAM-1. A small percentage of
T1 and T2 tumours expressed ICAM-1. Even fewer tumours expressed
ICAM-2. Isolated positive events were recorded in some tumours but
these were thought to be macrophages. The stromal tissue located
between areas of tumour was often strongly positive for ICAM-1, and
sometimes positive for ICAM-2. The vascular endothelium of small
vessels throughout the section were strongly stained for ICAM-1 and
ICAM-2 (data not shown). In Plates 6 and 7, tandem sections of a
superficial bladder tumour are stained with antibodies to ICAM-1 and
ICAM-2. No staining was identified in the tumour, only in the surrounding
stroma.
3.8.9 The expression ofICAM-1 by freshly derived bladder tumour cells
The expression of ICAM-1 by bladder tumour cells was studied by
flow cytometry. A unicellular suspension of tumour cells was prepared
from freshly ressected material which had been purified by density
centrifugation. The tumours of six patients of various grades were studied
by this method. Few or no cells were found to express ICAM-1 (data not
shown). The maximum percentage of cells found to express ICAM-1 was
3.5%. This result confirms the above immunohistochemical observations
and findings in that bladder tumour cells do not constitutively express the
ICAM-1 molecule.
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Table 9. The expression of ICAM-1 and -2 by bladder tumours
Tumour
ICAM-1 (%) ICAM-2 %
Stage Mean Grade ++ + +/- - ++ + +/- -
Ta 1.6 0 0 25 75 0 0 0 100
T1 2.5 25 25 25 25 0 25 0 75
T2 3.0 20 0 75 25 0 0 20 80
T3+ 3.0 0 10 28 58 14 0 0 86
Stroma
ICAM-1 (%) ICAM-2 %
Stage Mean Grade ++ + +/- - ++ + +/- -
Ta 1.6 60 0 40 0 0 0 80 20
T1 2.5 75 0 25 0 25 50 0 25
T2 3.0 60 0 20 20 20 0 40 40
T3+ 3.0 67 0 0 33 32 0 32 36
The expression of ICAM-1 and ICAM-2 by bladder tumour and the surrounding
stromal tissue. Frozen sections were immunohistochemically stained for either
ICAM-1 or ICAM-2. The sections were scored as follows: 0% of cells expressing (-),
0-5% of cells expressing (+/-), 5-30% of cells expressing (+), >30% of cells expressing.
The results are shown ordered for tumour stage and the mean grade for each stage
is also shown.
Plates 6 and 7.
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The immunohistochemical localization of ICAM-1 (upper) and
ICAM-2 (lower) in tandem frozen sections of a high grade superficial
bladder tumour. The expression of the ICAM genes is restricted to the
stroma whilst the tumour remains negative.
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4 Discussion
Bladder cancer is a common disease with increasing incidence and
mortality in the western world (Koroltchouk et al 1987). Fortunately the
majority of patients present with superficial disease which is not
immediately life threatening. Unfortunately, a significant proportion of
patients will progress to invasive disease, associated with which is a high
degree ofmortality. In the United States of America almost all patients
who present with superficial disease will receive intravesical adjuvant
immunotherapy consisting of repeated instillations of viable BCG vaccine
(D. Lamm, personal communication). In the United Kingdom, however,
many patients still receive conventional therapy consisting of surgical
resection, chemotherapy and radiotherapy.
In these studies, a series of human tumour cell lines representing
different histopathological grades of superficial bladder cancer was used as
a model for the analysis of the possible mechanisms of immunotherapy as
employed in the treatment of such tumours: the histopathological grades
and growth characteristics of these cell lines correspond to those of the
parent tumour of similar grade.
4.1 The sensitivity ofbladder cancer cells to natural and cytokine enhanced
cellular cytotoxicity
A limited variety of tumour cell lines and freshly isolated tumour
cells are susceptible to killing by NK cells (Serrate et al 1982). Such cells
in vivo may be more easily destroyed by the host than NK resistant
tumour cells. Unfortunately, the majority of tumour cells would appear to
fall into this latter category, therefore presenting the host with increased
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difficulties. A series of major research initiatives have been directed
towards the identification of tumour specific antigens (Baldwin 1966.
Lancki et al 1991). Several virally induced tumours have been
demonstrated to express such molecules, however it would seem that most
tumours do not (Schreiber et al 1988). Some tumours express tumour
associated antigens such as CEA and AFP, however these have proved of
limited use in anti-tumour strategies. The discovery of a novel killing
capability, distinct from T-cell and NK mediated cytotoxicity was heralded
as a breakthrough for cancer therapy (Grimm et al 1982). However, with
only two exceptions (namely renal cell carcinoma and malignant
melanoma) the clinical use of LAK cells has proved disappointing.
The preliminary experiments for this series of investigations showed
that human bladder cancer cells were not killed by the NK activity
resident in normal peripheral blood. However, following activation with
recombinant IL-2 the exhibition of LAK activity against all eight bladder
cancer cell lines was observed. The kinetics and IL-2 requirements of
LAK generation were similar to those reported by other workers; namely
optimal LAK activity was observed after six days of culture with
ljOOOUml"1 of IL-2 (Grimm etal 1982).
It is well known that cytokines other than IL-2 partake in the
generation of LAK activity (Kaufmann et al 1991. Matossian-Rogers et al
1989). Furthermore, other cytokines when used as the primary stimuli
can generate LAK activity (Matossian-Rogers et al 1989). In these
studies both TNFa and IFNa were found to marginally stimulate the
generation of LAK activity. The levels of cytotoxicity achieved with these
stimuli were lower than achieved with IL-2 alone. When placed in
combination with IL-2, both IFNa and TNFa were seen to behave
synergistically in that LAK activity was increased to levels above that
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achieved with either agent alone. If LAK cell therapy was to be employed
then a fundamental requirement would be maximal cytotoxic potential, in
such a case several cytokines might be used to achieve this.
Of interest was the differential susceptibility of the tumour cell lines
to LAK activity. As there was little difference in LAK activity generated
from different donors and as the ranking of susceptibility was consistent,
the differential susceptibility was not considered to be attributable to the
effector cell. There was no evidence of correlation between tumour grade
and LAK susceptibility.
When freshly isolated tumour cells were mixed with LAK cells they
were killed, all be it in a differential manner. It is of interest that recent
clinical trials with LAK cells for the treatment of bladder cancer have been
completed (Hermann et al 1992). When LAK cells were administered
systemically no clinical responses were observed despite changes in
several pertinent immunological parameters, namely increase in
leucocytes, activation of NK cells and infiltration of the tumour with
activated lymphocytes. Whether such cells if administered intralesional or
adjacent to the tumour would give a clinical response remains to be
investigated. However, the bladder is easily accessible and intralesional
administration of LAK cells may be more effective for the treatment of
advanced, muscle invasive bladder cancer. Furthermore, local
administration of IL-2/LAK cells would have considerably lower
cytotoxicity than that observed with systemic administration.
4.2 The expression and modulation ofadhesion molecules
From the early studies it is apparent that the differential
susceptibility of bladder tumour cells would appear to be attributable to
245
differences in the target cells rather than to the effector cells. Therefore,
investigations were undertaken to dissect mechanisms which would
account for such differences.
Scanning electron micrography of the interaction between effector
and target cells revealed the adhesion of effector to target cells. Such
adhesion appeared to be strong as the separation of two cells after
adhesion did not occur at the points of adhesion but through the cell body.
For these reasons a phenotypic evaluation of adhesion molecules
expression by bladder cancer cells was undertaken.
The expression of HLA class I molecules by bladder cancer cell lines
is ubiquitous, a fact which could account for the insensitivity of such lines
to NK activity, as a negative correlation has been established between
HLA class I expression and NK mediated killing (Moretta et al 1992). In
particular the loss of one particular HLA class I allele, Cw3, causes cells
to become susceptible to NK lysis. Interestingly, the RT4 cell line
constitutively expressed low levels of HLA class II molecules on its
surface. One of the most striking differences between these closely related
groups ofmolecules is their tissue distribution. The MHC class I antigens
are widely distributed, being expressed by most nucleated cell types in
varying amounts. The MHC class II antigens have a highly restricted
tissue distribution: they are found primarily on certain cells of the immune
system, and can be induced on a few other cell types. The restricted
expression of class II antigens is closely related to their function; indeed
the maintenance of tissue specific expression appears to be critical for
normal function of the immune system. The adhesion molecule NCAM is
thought to be an important ligand for NK activity, mediating homophillic
adhesion between NK and target cell, however it presence was not
confirmed on bladder cancer cells. Neither was VCAM, the ligand for VLA-
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4. Such molecules were candidates for the interaction between LAK and
target cells. The existence of two members of the ICAM family of adhesion
molecules on bladder cancer cells has been established. Although no
significant conclusions can be drawn, the expression was indicative of a
relationship to the tumour grade. Low grade cells express ICAM-2, a
molecule not identified on the G2 and G3 cell lines. The higher grade cells
constitutively express ICAM-1 at varying levels. The significance of a
grade related expression remains undetermined. However, several reports
have suggested that ICAM-1 expression correlates with an increased
propensity to metastasize (Tsujisaka et al 1991). It is established that
high grade bladder tumours have a worse prognosis than low grade
tumours (Heney et al 1983).
Following the administration of intravesical BCG a variety of
cytokines are produced and can be detected in the patients urine (Bohle et
al 1990. Prescott et al 1989. Fleischmann et al 1989). The effects of
these cytokines on bladder cancer cells has been investigated in order to
investigate their possible anti-tumour mechanisms. Interferon-gamma is
a potent modulator of ICAM-1 expression on bladder cancer cell lines.
Following stimulation with IFNy ICAM-1 expression is rapidly induced. On
vascular endothelium such rapid induction of ICAM-1 expression serves an
obvious function, that of an anchorage point for leucocytes prior to their
transmigration to sites of trauma (Figure 4). However, the role of ICAM-1
expression on bladder cancer cells is not so blatant. Hawkyard and
colleagues (1991 and 1992) have demonstrated other actions of IFNy on
bladder cancer cells. In vitro, IFNy induced the expression ofMHC class II
molecules on three bladder cancer cell lines in a grade dependent manner
(G1 - highly inducible, G3 - poorly responsive). However, unlike ICAM-1,
the induction of class II required high concentrations of IFNyG^OOUml"1)
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and prolonged exposure (>100 hours in some cases). One possible
explanation for this may lie in the reported down-regulation ofMHC genes
due to activated oncogenes and their products (Morris 1990) the
implications of which remein to be determined. Hawkyard et al also
demonstrated a grade related cytotoxic and cytostatic effect directly
exerted by IFNy on bladder cancer cells (Hawkyard et al 1992). These
effects, like those involving class II expression, also required several days
exposure to high concentrations of cytokine. It would appear that bladder
cancer cells respond in a variety of ways following exposure to
recombinant IFNy. The initial response is increased ICAM-1 expression,
found to be maximal after 24 hours of continuous stimulation. Secondly,
following a further 24-72 hours the tumour cells express MHC class II
molecules. Thirdly, continuous exposure to IFNy results in cell death, or at
very least an arrest of cell proliferation. The mechanisms of such
scheduled events remain undelineated. Although VCAM is a cytokine
inducible adhesion molecule, its expression was not increased following
stimulation with IFNy. Furthermore, the expression ofNCAM and ICAM-
2 remain unaltered following similar stimulation.
Cytokines other than IFNy are produced in response to BCG
therapy, these include IL-1, IL-2 and TNFa. An increase in ICAM-1
expression is mediated by stimulation with TNFa and IL-la. In general,
the effect of these cytokines is less than IFNymediated effects. However,
in combination with IFNy, TNFa acts synergistically to increase the level
of ICAM-1 expression. As cytokines are probably never produced singly,
the combined results of several cytokines are of greater importance than
those of a single agent. Bladder cancer cells do not respond with modified
ICAM-1 expression to a variety of other cytokines, some of which are
detected in the urine (eg IL-2) and some not (eg IL-4, K. James personal
248
communication). These cytokines also do not modify MHC class II
expression by similar cells (Hawkyard, personal communication).
Therefore, the role of such cytokines in the response to BCG may not
directly involve the tumour cell, but instead may severe as activation
signals to infiltrating lymphocytes, NK cells, neutrophils and
macrophages.
Bladder cancer cells respond to IFNy in a heterogeneous manner.
Cells which respond poorly in terms of class II expression (eg MGH-U1)
may respond well in terms of ICAM-1 expression, and vice versa. One
reason for this may be that MGH-U1 does not constitutively express MHC
class II but does express ICAM-1. Therefore, the gene for ICAM-1 is
already partially activated. Interestingly, recent evidence from our
laboratory has shown that MGH-U1 cells constitutively secrete TNFa (A.
Alexandrov personal communication) a factor which may account for the
constitutive expression of ICAM-1 by this cell line. The nature of the
response is dependent upon the concentration of cytokine. Therefore, with
lOOUml-1 IFNy , MGH-U1 will express elevated levels of ICAM-1 but will
not express MHC class II antigens, with lOOOUml1 both ICAM-1 and
MHC class II antigens will be expressed. Therefore, it is possible to gain
insight into how different concentrations of cytokine may exert different
effects on their target. In classical T-cell communication both MHC
antigens and ICAM-1 are required (Altmann et al 1989), however, less
specific cytotoxic mechanisms may only require the expression of ICAM-1
for the necessary communication to occur. Most recently, Lattime and
colleagues (1992) have investigated the antigen presenting ability of
murine bladder cancer cells. These cells, which usually fail to express
MHC class II antigens, express class II molecules following stimulation
with IFNy (lOOUml-1). Furthermore, their most alluring finding was that
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these tumour cells presented BCG to specific CD4+ T-cells obtained from
draining lymph nodes following intravesical BCG administration. This
action resulted in the production of TNFa and IL-2, cytokines found in
patients receiving BCG therapy. Unfortunately, the investigators did not
examine the cells for the production of IFNy, a cytokine which our system
indicates is pivotal for immune response.
The regulation of genes such as ICAM-1 may be controlled at a
number of critical points. The transcription of genes appears to be tightly
regulated, controlled by a superfluity of DNA binding proteins whose
function is either to enhance or inhibit the activity of RNA polymerase II
(Sen and Baltimore 1986). Splicing of immature RNA and poly-A tailing
may also be rate limiting, however little is known of its control. The rate of
transport of mature mRNA from the nucleus to the cytoplasm could
present a restriction point. The stability of various mRNA species in the
cytoplasm and the translation of mRNA into protein are among the best
characterized mechanisms.
Induction of membrane ICAM-1 expression is a rapid event,
detectable changes being evident within 4 hours of stimulation. However,
with the exception of MGH-U1 there would not appear to be an
intracellular pool of untranslated mRNA. For all the lines tested (except
MGH-U1), actinomycin D pretreatment inhibited the induction of ICAM-1
expression due to IFNy. Untranslated pools ofmRNA have been described
for a number of cytokines including IL-1, TNF and TGF(3 (Beutler et al
1986a and b). The importance of such pools is that they can provide the
potential for an extremely rapid response to external stimuli, particularly
when the translation product is not stored in an intracellular vesicle. Only
partial depression of ICAM-1 induction was achieved with MGH-U1,
indicating the existence of cytoplasmic pools of untranslated mRNA or
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protein.
Inhibitors of protein synthesis (such as cycloheximide, CHX) have
been used to determine ifprotein synthesis is required for the induction of
transcription (Fenton et al 1987). As expected, the cells which were
sensitive to actinomycin D were also inhibited by CHX, thus indicating the
requirement de novo mRNA and protein synthesis. In the case ofMGH-
U1 pretreatment with CHX failed to significantly depress ICAM-1
induction by IFNy indicating the existence of intracellular pools of protein.
Interestingly, later studies showed that PMA also induced ICAM-1
expression, this effect being inhibited by CHX to a greater extent than that
of IFNy. CHX would also appear to stabilize membrane associated ICAM-
1 as treatment following IFNy stimulation increases the percentage of
cells expressing ICAM-1. The significance of these finding remains unclear,
however the regulation of the genes for adhesion molecules is fundamental
to the immune response and increased understanding of such mechanisms
should lead to more comprehensive therapeutic strategies.
Following stimulation, ICAM-1 expression transiently increases.
The fate of such ICAM-1 was investigated using ELISA able to detect
soluble ICAM-1. The secretion of high levels of soluble ICAM-1 was noted,
maximal levels correlating approximately with the decease in surface
associated ICAM-1. Therefore, CHX may stabilize ICAM-1 by prevention
of shedding. Furthermore, the links drawn between increased invasion of
tumour and ICAM-1 expression (Tsujisaka et al 1991) may be in part due
to the production of sICAM-1 rather than to the expression of ICAM-1
perse.
4.3 Functional evaluation of the role of adhesion molecules in LAK
mediated cytotoxicity against bladder cancer
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A number of lines of evidence suggest that in order for LAK cells to
mediate their cytolytic effect, intimate liaison with the target cell is
fundamental. Bladder cancer cell lines express two important cell adhesion
molecules (ICAM-1 and ICAM-2), therefore a functional dissection of their
role in LAK activity was undertaken.
Immunohistochemical data obtained from conjugates formed
between LAK and TCC cells shows that the majority of LAK cells adhere
to tumour cells which express ICAM-1. Those cells which fail to express
ICAM-1 had significantly fewer LAK cells conjugated to them. Cell lines
expressing the highest levels of ICAM-1 are more able to form conjugates
than those which express less. This data indirectly implicates the ICAM-
1/LFA-l interaction in LAK activity.
Direct evidence for the role of ICAM-1 and ICAM-2 as target
structures for primary recognition by LAK cells comes from adhesion
blockade studies. Using the standard 4 hour cytotoxicity assay, the
blockade of ICAM-1 (or ICAM-2) expressed by bladder cancer cells results
in decreased susceptibility to LAK mediated killing, implicating these
molecules as candidate ligands for LAK cells. The presence of antibodies to
ICAM-1 and ICAM-2 throughout the duration of the assay results in
greater inhibition of LAK activity than when used to pre-treat target cells.
The reasons for this are unclear as treatment of LAK cells with anti-ICAM
antibodies does not decrease their potency of killing. One possible
explanation could involve the capping, internalization (and re-expression)
or shedding of ICAM-1 molecules to which antibody has bound. It is also
possible that following the interaction with LAK cells, the expression of
ICAM-1 is induced on the target cell. This would not, however account for
the result obtained with the ICAM-2 expressing cell line UMUC-3.
Blockade of LFA-1 (CD 11a) on effector cells results in almost
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complete abrogation of LAK activity (mean 83% depression). This levels
of inhibition is greater than achieved by ICAM blockade on target cells. In
one instance, MGH-U1, antibodies to LFA-2 caused a decrease in LAK
activity. It is probable that ligands other than LFA-1 are important in
LAK activity. Therefore, target lysis by LAK cells is critically dependent
upon target binding properties. Several studies have addressed the
question of adhesion molecules in NK and LAK activity. Quillet-Mary and
colleagues (1991) demonstrated that binding of LAK cells to B-cell lines
was essential for cytolysis, however LFA-1, LFA-3 and ICAM-1 were not
the major ligands involved. This conclusion was reached following adhesion
blockade and by a lack of correlation between expression and lysability,
some of the premises under which the work presented in this thesis was
carried out. However, a recent study has shown that in some cases the
interaction of of LFA-1 with its ligand is necessary but not sufficient for its
function (Dransfield et al 1992). Therefore, in addition to the initial LFA-
1/ICAM-l interaction, signalling events may dictate the functional
consequences of adhesion. Rivoltini etal (1991) demonstrated that a drug
resistant, epithelial colon carcinoma cell line was more sensitive to LAK
activity than its drug sensitive counterpart. In addition, higher levels of
adhesion molecules (including ICAM-1) were observed, which when blocked
with antibodies resulted in a decrease in LAK mediated cytolysis. It is
possible that the ligand for LAK cells will differ with different tumour cells.
The primary adhesion events involved in LAK activity against
bladder cancer cells are almost entirely LFA-1 dependent, however a
portion of these events are independent of ICAM-1 and ICAM-2. This data
suggests the existence of a further ligand for LFA-1 expressed by bladder
cancer cell lines. The existence of such a ligand on both NK cells and on T-
cell lines has been suggested for some time (de Fougerolles et al 1991.
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Akella and Hall 1992). Recently a third ligand for LFA-1 has been
identified, characterized and termed ICAM-3 (de Fougerolles and Springer
1992). This ligand is highly expressed on lymphocytes, monocytes, and
neutrophils, but is not expressed by endothelial cells. Its expression on
epithelial cells remains to be determined but investigations are already
underway.
Following the administration of intravesical BCG therapy high
levels of IFNy are detected in the urine. As discussed, this cytokine can
rapidly induce and augment the expression of ICAM-1 on bladder cancer
cells. The significance of such induction in vivo (in a manner similar to
class II expression) remains to be determined. However, the function of
increased ICAM-1 expression in vitro has been addressed. Cells
stimulated with IFNy are more susceptible to LAK mediated killing. Such
increased lysis correlates well with increased ICAM-1 expression by the
tumour cell. Furthermore, on cells which are not induced to express ICAM-
1 (UMUC-3) no increase in cytolysis is observed. Similar observations
have been made concerning the lysis of IFNy treated neuroblastoma cells
by LAK cells (Naganuma et al 1991). Stimulation with lOOUml1 IFNy
resulted in increased ICAM-1 expression and increased cytolysis, which
was preventable by antibodies to ICAM-1.
Therefore, it would appear that the lysis of tumour target cells is
non-specific in that no specific antigen or antigen-recognition structures
are involved. However, depending upon the tumour type (and possibly
upon individual tumour cells) ICAM-1 would appear to serve as a primary
recognition structure for LFA-1 bearing LAK cells. This would appear to
be the case for bladder cancer cell lines. The function of LFA-1 and ICAM-
1/-2 in LAK activity against bladder cancer cells is probably to maintain
the cells in juxtaposition in order to permit delivery of a lethal hit. It is
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unlikely that the adhesion interaction per se is responsible in the cytotoxic
events which ensue.
Using a flow cytometric method the role of adhesion molecules in
conjugate formation has been further dissected. It would appear that
conjugation between LAK cells and bladder tumour cell lines is an
extremely rapid event, occurring in less than one minute. Such conjugates
once formed are very stable as repeated agitation and vigorous pipetting
have no effect. The apparent high affinity of conjugation is well illustrated
by scanning electron micrographs and immunohistochemical techniques
which show an intimate relationship between the two cells. The
differences in conjugation observed with the flow cytometric assay do not
correlate with the differences in ICAM-1 expression or with the differential
susceptibility of bladder cancer cells to LAK activity. In fact the least
sensitive cell line (RT112) formed the most conjugates, suggesting events
down-stream of primary adhesion are important in LAK mediated
cytolysis. Whether or not the efficiency of target cell repair mechanisms
has significant bearing on the sensitivity to LAK activity remains to be
investigated. During situations of intimate contact signalling may occur
between effector and target cells and visa versa. It is possible that cell
lines which are less sensitive to LAK activity inactivate the effector cells
thus inhibiting cytolysis. One explanation for the disparity between
techniques lies in the number of effector cells per target, as the flow-
cytometric method could not account for such differences whilst the
microscopic evaluation could.
If the primary interaction between cells is mediated by the LFA-
1/ICAM system then the expression of LFA-1 by LAK cells is mandatory
but not sufficient to mediate adhesion. Rather, an active form of LFA-1 is
required (Figdor et al 1990). Freshly isolated PBMC do not adhere to
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bladder cancer cell lines. However, following activation with IL-2 a
significant level of adhesion and cytotoxicity is observed. The adhesion of
LAK cells to bladder cancer cells is critically dependent upon energy and
the presence of certain divalent cations, in accordance with data for LFA-1
dependent functions (Dransfield et al 1989, 1990. Figdor et al 1990).
Depravation of divalent cations from such cells prevents their forming
stable conjugates with bladder cancer target cells. In the absence of Ca2+
a decrease in conjugation is observed whilst in the absence of all divalent
cations almost total abrogation of conjugation is noted.
The studies of Dransfield have shown a role for three divalent
cations in particular, namely calcium, magnesium and manganese
(Dransfield et al 1992b). Such studies revealed the presence of a Mg2+
dependent epitope termed 24. Divalent Ca2+ ions are able to inhibit the
expression of the 24 epitope and in parallel inhibit LFA-1 dependent T-cell
binding. In the interaction between LAK and bladder cancer cells, Ca2+,
Mg2+ and Mn2+ are able to increase the formation of conjugates.
Furthermore, in the absence of calcium ions both Mg2+ and Mn2+ increase
conjugation to much higher levels. Calcium ions are able to compete with
Mg2+ but not Mn2+ in the interaction between LAK and TCC cells. In
contrast, the work of Dransfield showed that calcium could compete with
both Mg2+ and Mn2+ for the expression of the 24 epitope and for T-cell
adhesion. Dransfield's studies also showed that low binding occurred in the
presence of Ca2+, however high levels of binding are observed between LAK
cells and TCC targets under similar conditions. These studies were found
to function in a similar concentration range of cations (0.1-10mM). It has
been suggested that Ca2+ may have a negative regulatory role in LFA-1
dependent functions (Dransfield et al 1992b). However, in the light of the
evidence presented in this thesis, Ca2+ may not always be able to serve
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such a function. Whether differences exist in the LFA-1 molecule on LAK
cells as compared to classical T-cells remains to be investigated.
The increased binding of LAK cells treated with Mn2+ to bladder
cancer cells is due to alterations in LFA-1 as both sodium azide and anti-
LFA-1 antibodies were able to inhibit such functions. It is therefore
probable that Mn2+ binds directly to one or more of the cation binding
domains on the alpha chain of LFA-1 and in doing so causes a
conformational change thereby increasing the affinity of LFA-1 for its
ligands. Alternatively it is possible that the binding of cations to LFA-1
merely mimics the binding of LFA-1 to ICAM-1, imposing a similar
conformational change.
Following binding of LAK cells to bladder cancer cells and the
delivery of a lethal hit, de-adhesion is required for the LAK cell to again
exert its cytolytic function. Presumably this would involve a
conformational change. When de-adhesion is prevented (by treatment
with mAb 24) LFA-1 dependent functions are inhibited (Dransfield et al
1992). The exact mechanisms of detachment are not known, whether
divalent cations such as Ca2+ (possibly spilling from the target cell) could
serve to switch LFA-1 to its "OFF" state remains unclear. However, a
better understanding of this process is essential for a complete
appreciation of the function of LFA-1.
4.4 The expression and function of interferon-gamma receptors
The expression of cytokine receptor is a prerequisite for the exertion
of cytokine action, but is not sufficient for such. The results from
Scatchard analysis indicate that high affinity IFNy receptors are present
in large numbers on the surface of four bladder cancer cell lines studied.
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The number and affinity of IFNy receptors on the Daudi cells in this study
was in close agreement with the values found by other workers and would
seem to verify the method of assay used here (Merlin et al 1985. Kd=0.5-5
x 10-10 and 3500-7000 receptors / cell). There were ten-fold fewer IFNy
receptors on the Daudi cells than on any of the bladder cancer cells
(p<0.01). There was no statistical difference between the concentration of
the receptors or their affinities amongst the four bladder cancer lines, and
therefore the differential biological response of these lines to IFNy could not
be accounted for by the level of receptor expression. It would therefore
seem that differences in biological response of individual tumour cell lines
(and possibly tumours) to IFNy are determined down-stream of the
receptor-ligand interaction.
This study uses a competitive binding assay for the assessment of
IFNy expression. The results show a wide range of affinities and surface
receptor numbers for the individual cell lines which has been the
experience of other investigators using noncompetitive assay systems
(Ucer et al 1985 and 1986). Ucer and colleagues found that receptor
affinities on cells of the same line differed by a factor of ten at different
times. Such differences have several possible explanations, both
experimental and biological and could account for the large standard
deviation of the results for IFNy receptor expression on bladder cancer
cells. The source and specific activities of the labelled IFNy, as well as the
labelling methods and the types ofbinding assays performed are important
factors. The possible biological explanations for such variability, include
tumour heterogeneity, alterations in receptor expression with cell cycle,
the effect of increased cell density of receptor expression (Alexandrov et al
manuscript submitted) and the presence of known modulating cytokines
such as TNFoc (Raitano 1990) and Granulocyte-Macrophage Colony
258
Stimulating factor (Fischer et al 1990).
Grups and Bange (1990) have examined the expression of
Interferon-alpha receptors on three human bladder cancer cell lines (RT4,
SD and 637V) and found no correlation between affinity and sensitivity to
this cytokine. Jakse and colleagues (1988) have measured the expression
of IFNy receptors on two other human bladder cancer cell lines, 647V and
J82, and found affinities of the same order ofmagnitude as those described
here (0.6-1.lxlO"10M). However, receptor numbers on the 647V and J82
cells were an order ofmagnitude lower (870-3000 receptors per cell). It
would seem from this data that the expression of IFNy receptors is not a
useful parameter for predicting the response of bladder tumour cell lines to
this cytokine and therefore would have no clinical use for determining
response or prognosis.
It would appear that IFNy binds to its receptor very rapidly, this
event not being energy dependent as the kinetics of surface binding were
similar at 37 °C and 4°C. These results are substantiated by the earlier
observations that only brief exposure of bladder cancer cells (<10 seconds)
to IFNy is required to generate significant biological response in terms of
ICAM-1 expression. It is interesting that this is not the case for MHC
class II expression by the same cells, suggesting that a higher threshold
exists for biological effect (Hawkyard, personal communication). Following
receptor binding IFNy is internalized by the cell and here degraded,
presumably after transportation into lysozomes. Although it is usual for
the biological actions of IFNy to be receptor mediated this need not
necessarily be the case. Transfection studies have shown that
cytoplasmic IFNy can exert a variety of biological effects (Sanceau et al
1987). Whether internalized IFNy can affect gene regulation via
interaction with a potential nuclear receptor or whether alternative modes
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of signal transduction exist inside the cytoplasm remains to be determined
(Kushnaryov et al 1985). Nuclear receptors for IFN(3 have been identified
in various cells (Kushnaryov et al 1985 and 1986). Such nuclear receptors
had a seven fold higher affinity for ligand than those in the plasma
membrane. Microinjection studies have also elegantly demonstrated a
possible intracellular role for IFNy (Smith et al 1990b). In these studies
human IFNy was seen to induce la expression by murine macrophages, a
phenomenon which was not due to membrane receptor binding as the
actions of IFNy are species specific (Raziuddin et al 1984). Other
cytokines such as TNFa may also have intracellular actions (Smith et al
1990c). The function of intracellular IFNy in the case of bladder cancer
cells remains to be investigated, however it may account for the
differential susceptibility of tumour cells to IFNy.
4.5 The signal transduction ofthe interferon-gamma receptor
The exact mechanisms involved in signal transduction via the IFNy
receptor are unknown however, several investigators have attempted to
delineate the primary events (Koide et al 1988. Dumont et al 1990.
Nobukazu et al 1990. Celada et al 1991). It has been shown that PKC
and calmodulin play crucial roles in the intracellular signalling of a large
number of cytokines and growth factors (Isakov et al 1986. Means et al
1988). Earlier investigations have suggested that PKC and calmodulin
were mediating the action of IFNy in macrophages (Hamilton et al 1985.
Celada et al 1986). The investigations within this thesis use bladder
cancer cell lines and their response to IFNy as a model for investigating the
signal transduction pathway for this important cytokine. Three different
cell lines were employed and the studies concentrated on two discrete
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effects of IFNy, namely the induction of MHC class II and ICAM-1
molecules.
Firstly the question of a role for PKC was addressed using PMA to
activate PKC and the specific inhibitors H-7 and staurosporine.
Differences are apparent between the cell lines in that PMA induces MHC
class II expression on RT4 but not other cells and induces ICAM-1
expression on MGH-U1 but not on the other cell lines. The situation is
further complicated by the lack of inhibition with H-7 and staurosporine.
H7 inhibits PKC by competing with ATP, whilst staurosporine interacts
directly with the catalytic domain of PKC specifically inhibiting its
function. Furthermore, inhibition of this enzyme failed to prevent the
induction of either MHC class II or ICAM-1 molecules on three cell lines
indicating a lack of PKC in signal transduction. Activated PKC
phosphorylates a range of cellular proteins by which a signal is transduced
to the next steps (Nishizuka et al 1988). Therefore, in the case of PMA
stimulation of RT4 and MGH-U1 it is possible that PKC activation
mimicked a signal other than IFNy. It is well known that phorbol esters,
such as PMA, can activate PKC in a similar manner to diacylglycerol
(DAG) (Nishizuka 1984). In order for PKC to become activated a rise in
the concentration of intracellular calcium leads to binding of membrane
associated PKC to Ca2+ (Huang 1989). No such increase in the levels of
intracellular calcium is observed in bladder cancer cells following
stimulation with IFNy.
As initial studies suggested the involvement of a PKC independent
pathway, the role of the Ca2+/calmodulin pathway was investigated. The
activation of the Ca/calmodulin-dependent protein kinase can be achieved
by the use of calcium ionophores (Klee et al 1980). In contrast with other
studies the calcium ionophores A23187 and ionomycin do not induce
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ICAM-1 and MHC class II expression (with the exception of RT4)
(Nobukazu et al 1990). Using the specific inhibitor of calmodulin, W7, the
induction of class II molecules on RT112 is inhibited. However, the induced
expression of MHC class II molecules on RT4 and MGH-U1 and the
expression of ICAM-1 on any of the cell lines is not inhibited by W7.
Removal of extracellular Ca2+ using EGTA resulted in a decreased MHC
class II response of RT112 but failed to reduce the response in terms of
ICAM-1 induction further suggesting differential usage of calcium ions for
signal transduction pathways within the same cell type. The inhibition of
intracellular calcium mobilization in RT112 also prevents the induction of
class II antigens, this is not the case for RT4. Calcium channel blockade
of RT112 also partially prevents the cell from expressing ICAM-1, similar
blockade having no effect on either RT4 or MGH-U1 cells. In fact, the
removal of extracellular calcium ions from these cells results in increased
ICAM-1 expression. The reason for this remains unclear however, it is
possible that calcium is in some way negatively regulating ICAM-1
expression in these cells.
The information from this area of investigation fails to provide a
simplistic view of the signal transduction mechanisms for IFNy in bladder
tumour cell lines. Various lines of evidence implying a role for both PKC
and Ca2+/calmodulin dependent kinase. It would appear that different
mechanisms are employed by the various cell lines and that the expression
ofMHC class II and ICAM-1 genes are further differentially regulated. It
would be of interest to investigate the contribution of activated oncogenes
to the signal transduction of the MHC and ICAM-1 gene products. It has
been postulated that such effects due to oncogenes may occur at the level
ofMHC induction by interference with signal transduction (Morris 1990).
Unfortunately the picture is further complicated by the work of others
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suggesting signal transduction through cAMP (Gariglio et al 1988),
calmodulin (Celada et al 1991), and PKC (Hamilton et al 1985. Yap et al
1986. Ostrowski et al 1988). Whether cells such as MGH-U1 express
increased levels of oncogenes (such as ras) which inturn lead to decreased
responsiveness in terms of MHC class II induction by IFNy remains to be
determined (Maudsley and Morris 1989).
4.6 The relationship of in vitro studies to the situation in vivo
In clinical immunology it is important for in vitro studies to have
direct bearing and reference to the in vivo situation. For this reason
several attempts have been made to link the in vitro findings and
observations to the disease of superficial bladder cancer.
Previous workers have identified the presence of various cytokines
in the urine following BCG therapy (Prescott et al 1990. Bohle et al 1990).
In order to dissect the role of such molecules, the effects of recombinant
versions have been investigated in vitro (Hawkyard et al 1991 and 1992).
However, in vivo it is unlikely that a single cytokine is produced, in fact a
cocktail of cytokines is usually active at any one instant. When urine from
BCG treated patients is incubated with bladder cancer cells, phenotypic
changes take place. The cells express MHC class II molecules and ICAM-
1 molecules on their surface in much the same way as when treated with
recombinant cytokines. These changes are not induced by urine from all
instillations, the general trend being that with repeated instillation
increased levels of potential biological activity are produced. The
expression of MHC class II molecules occurs in vivo following repeated
instillations of BCG (Prescott et al 1991). Therefore, it is possible that the
same mediators in urine which induce phenotypic changes in vitro also do
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so in vivo. Neutralizing antibody experiments demonstrate that a large
proportion of the ICAM-1 inducing ability from patients urine is due to
IFNy. Using immunoassay techniques the presence of IFNy in the urine
samples was confirmed. As already mentioned, this is a point of debate.
The work of de Boer (1991) does not confirm the presence of this cytokine
in urine. One possible reason for this lies in methodological differences. In
the study of de Boer urine samples were taken and immediately frozen.
Prior to assay they were thawed, the cellular debris removed and dialyzed
prior to re-freezing. The data presented in this thesis is derived from urine
which was centrifuged and dialyzed to pH7.2 immediately, then frozen prior
to determination of the cytokine content. Several problems exist within
the method of de Boer. Firstly, the urine is stored at acidic pH. Studies
from our group demonstrate that under such conditions IFNy cannot be
detected in urine as it is acid labile (S. Prescott, personal communication).
Secondly, it would appear that repeated freeze-thaw cycles were used for
urine. It is a generally held belief that cytokines are destroyed by such
practices (A. Meager, personal communication). However, the same group
have employed the methods recommended in this thesis and are still
unable to confirm the presence of IFNy (E de Boer, personal
communication). Until independent workers confirm the existence of IFNy
in urine it will remain the subject of debate.
The cytokine TNFa is also produced following BCG treatment.
However, it would not seem to have a major biological role in the induction
of ICAM-1 expression. In fact, the synergy observed with recombinant
cytokines is not observed between these cytokines in urine. One
explanation could be that the TNFa in urine is immunoreactive but not
bioactive. A further explanation for this could be due to the presence of
soluble TNF-binding proteins. Such proteins are produced in normal
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physiological urine, however their presence in the urine of BCG treated
patients remains to be investigated (Englemann et al 1989). Therefore, for
a clinical response to occur it may be that not only the level of cytokine
produced is important but also the level of the soluble form of its receptor.
Other soluble receptors are also produced under normal physiological
conditions and secreted into urine including IL-2, IL-6 and IFNy (Marcon
et al 1988. Novivk et al 1989). In addition, the urine of patients receiving
intravesical BCG therapy also contains elevated levels of soluble IL-2R (I.
Milne, personal communication). The function of such receptors in normal
urine is unclear. However, they may have an immunoregulatory role,
either by participation in the process of eliminating cytokines via the
kidney, or by modulating the availability of cytokines. Whether bladder
cells or bladder tumour cells secrete soluble cytokine receptors also
remains to be determined, however preliminary data suggests that in
vitro, bladder cancer cell lines may secrete a soluble IFNy binding protein
of molecular weight approximately 75kDa (unpublished personal
observation).
In addition to cytokines and cytokine binding proteins, soluble
ICAM-1 is detected in the urine following BCG therapy, but not in normal
urine. The levels of sICAM-1 increase with repeated instillation and can be
detected within 12 hours of treatment. If the kinetics of ICAM-1
expression by cells in vivo are similar to those observed in vitro then
maximal expression will not occur until 24 hours. Furthermore, the
subsequent production of sICAM-1 molecules would not be maximal until
after 72 hours. The source and function of such molecules is unclear.
Studies have demonstrated that sICAM-1 molecules can exert powerful
effects by inhibiting LFA-1 dependent functions in vitro (Becker et al
1991). Furthermore, in addition to its role as a cell adhesion molecule,
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ICAM-1 has been identified as the receptor for rhinoviruses (Greve et al
1989. Staunton et al 1989). Furthermore, a soluble form of ICAM-1
inhibits rhinovirus infection (Marlin et al 1990). Whether other viral
particles can be inhibited by this means provides an interesting avenue of
research with potentially fruitful rewards. In bladder cancer patients,
sICAM-1 could compete with membrane ICAM-1 for LFA-1 molecules on
leucocytes, thus preventing immune recognition. Alternatively, sICAM-1
could act to promote transmembrane signalling via LFA-1 to the leucocyte
as has been demonstrated (Van Seventer et al 1990. Wacholtz et al
1989).
In clinical practice, what is required is an accurate indicator of the
tumour response to treatment. Failure to respond would allow a different
modality to be employed. Whether sICAM-1 production by patients has
any correlation with clinical response remains to be determined, however,
unlike the presence of IL-1, IL-2, TNFoc and IFNy in the urine (which
indicate an activated immune infiltrate) the presence of sICAM-1 may
indicate a response of the tumour cells to these cytokines. This would
seem to be the desired reaction. As shown in vitro, not all TCC cell lines
respond to IFNy in the same way, and in vivo a heterogeneous response is
observed in terms of cytokine production and the secretion of sICAM-1.
4.7 A model for the action of intravesical BCG therapy for the treatment of
superficial bladder cancer
The work presented in this thesis and that of other workers (namely
Hawkyard, Prescott, Bohle and de Boer) combine together to give a picture
of the immune response in BCG therapy (Figure 85). BCG organisms
adhere to the tumour cells and are eventually endocytosed (Hawkyard,
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personal observation). Whether various shock proteins such as heat
shock protein (either human or bacterial) are released remains to be
investigated, however such molecules could serve to activate the resident
macrophages within the tumour. Following repeated instillation of BCG
organisms a marked cellular infiltrate into the bladder wall and tumour
occurs. This infiltrate contains immunologically active T-cells (both helper
and cytotoxic), polymorphonuclear cells and macrophages. Such cells are
the likely source of the cytokines which are transiently secreted in the
urine of patients (IL-1, IL-2, IL-6, TNFa, IFNy). These cytokines may
serve two functions. Firstly they may further activate infiltrating cells
and attract further circulating immunologically relevant cells to the site of
inflammation. Such cells could then mediate the destruction of tumour
cells by nonspecific cytotoxic mechanisms, as observed in the case of LAK
cells killing bladder cancer cells in vitro. Secondly, the cytokines can exert
direct effects on the tumour cells, inducing changes in the cell surface
phenotype (increased MHC class I, class II, ICAM-1, and decreased EGF
receptor as demonstrated by A. Alexandrov (manuscript in preparation))
and dramatically modify the growth rate of tumour cells (both cytostatic
and cytotoxic mechanism being involved). Such phenotypic changes could
alter the susceptibility of tumour cells to cytolysis be infiltrating cells, thus
increasing the anti-tumour activity. Cells other than macrophages have
been shown to act in an antigen presenting fashion. Whether tumour cells
which express MHC class II can process mycobacterial antigen and
express it in the context of class II molecules remains to be determined.
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Figure 85. The possible mechanism of action of intravesical BCG
Shown is a possible series of events (1-7) in the successful adjuvant
immunotherapy of superficial high grade bladder cancer using intravesically
administered BCG organisms. This model is based on the studies of Prescott,
Hawkyard, De Boer and on observations obtained from this thesis.
1. A high grade superficial bladder cancer.
2. BCG organisms are instilled into the bladder and allowed to interact with
the bladder wall for 2 hours. Some organisms adhere to the bladder wall and
tumour and are eventually endocytosed.
3. The interaction of BCG organisms with tumour cells, normal cells and
resident macrophages leads to the release of heat shock proteins or chemotactic
factors which activate the macrophages to produce inflammatory cytokines.
4. In response to the chemotactic and inflammatory signals, a large infiltrate
of immunologically active cells occurs. These cells may be attracted to the site by
changes in adhesion molecule expression in the local vasculature. Such
infiltrating cells produce a variety of cytokines which are readily detected in the
urine within 12 hours.
5. The cytokines produced by the infiltrate induce and augment the expression
ofMHC class I and II antigens and of ICAM-1 on the tumour cells. Such
immunologically relevant molecules allow the interaction of tumour infiltrating
lymphocytes (TIL) with tumour cells expressing ICAM-1. Furthermore, there is
a possible role for specific BCG related antigen which may be presented by
macrophages or tumour cells expressing MHC class I and II molecules to
infiltrating T cells. In addition, IFNymay exert direct cytostatic and cytotoxic
effects on bladder cancer cells.
6. The tumour cells are sloughed off the urothelium into the urine and voided.
7. After 3 months the patient is examined and found to be disease free
(approximately 80% of patients disease free at this stage).
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These investigations have attempted to more fully understand the
actions of LAK cells and BCG as used in the immunotherapy of bladder
cancer. Although the findings, together with those of other workers, have
gone some way to explaining the mechanisms of action, several key
questions remain to be answered.
The source of cytokines and soluble ICAM-1 molecules in urine
requires clarification. Although it is likely that helper T-cells are producing
IFNy, such speculation requires substantiation, possibly with the aid of in
situ hybridization techniques. Preliminary investigations are now
underway in our laboratory.
The function of increased ICAM-1 and MHC class II expression in
vivo remains unclear. We are currently attempting to establish bladder
cancer cell lines and autologous T-cell clones for use in antigen presenting
studies. With such tools we aim to investigate the role ofMHC class II
molecules in possible antigen presentation to infiltrating T-cells. Such
presentation would require specific antigen, the source of which could be
either human (self heat shock proteins) or bacterial. The possibility of an
auto-immune type response has been raised as the presence of auto¬
antibodies has been noted (Dr. A. Clarke, personal communication).
Recently a report has emerged showing that murine bladder cancer cells
are able to present antigen to BCG-specific CD4+ T-cells (Lattime et al
1992).
If the source of soluble ICAM-1 is tumour cells then studies of
sICAM-1 production could provide a useful, easy-to-measure indicator of
tumour response. Detailed studies into this possibility are already
underway. Only with clinical response correlation can this parameter be
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attributed with anymerit.
The treatment regimen with BCG has been determined empirically,
in Edinburgh six weekly instillations are given (complete response rate 70-
80% at 3 months), in other groups instillations consisting ofmore frequent
higher doses are given, yielding complete response rates in excess of 90%
(D. Lamm, personal communication). If ICAM-1 expression has similar
consequences in vivo as it does in vitro and behaves in a similar manner
then the more frequent instillation protocols could prove more effective.
The mechanism of activation and adhesion of LFA-1 to its known
ligands has been the subject of energetic investigations. Although not fully
understood, a great deal is now known. Whether divalent cations actually
bind to LFA-1 in vivo or simply mimic the interaction with ICAM-1
remains to be determined. However, little is known about the process of
de-adhesion ie the detachment of LFA-1 from its ligand and its subsequent
transformation to the "OFF" state. A more complete appreciation of the
intricacies of LFA-1 function would be of great interest and could have
clinical applications in chronic inflammatory disorders.
The clinical use of LAK cells has not yielded the results expected
from initial studies in vitro. Furthermore, their use against bladder cancer
has to date proved unsuccessful. It would appear that what is required is
localized administration of high activated LAK cells. Ease of access to the
bladder provides an opportunity to investigate such protocols for the
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